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Abstract
Calcium silicate ceramics are amongst a group of ceramic materials currently utilised as
bone graft materials. However, current calcium silicate grafts offer little therapeutic
potential and poor mechanical properties. The objective of this project was to examine
the composition-structure-property relationships arising from the incorporation of
therapeutic ions of strontium (Sr) and zinc (Zn) into calcium silicate glass-ceramics (GC)
in order to allow for healthy bone regeneration and antibacterial efficacy. Five
compositions were studied with varying mole fractions of Sr and Zn. The GC’s were
characterised using differential scanning calorimetry (DSC), x-ray diffraction (XRD) at
room and ascending temperatures, x-ray tomography (XRT) and dilatometry. The
evolution of crystalline phases for each GC was investigated up to the materials’ first
temperature of crystallisation, where it was established that BTl 10, BTl 11 and BTl 12
comprised of biocompatible materials, namely sodium calcium silicate in the case of
BTl 10, calcium silicate in BTl 11, and calcium silicate and sodium silicate in BTl 12.
BTl 11 and BTl 12 also contained a Sr rich glass phase within the glass ceramic. Based
on the characterisation data, GC foams were fabricated with structures permissive for
osseous integration and vascularisation. The foams had an average porosity of 94% and
Sr^^ and Zn^^ release was quantified over 1, 7 and 30 days, under normal (NPC) and
extreme physiological conditions (EPC) for each GC. The Zn^^ release results at pH 7.4
ranged from lppm-30ppm and indicated that under NPC, all examined Zn-containing
GC’s have potential as therapeutic bone grafts, but, under EPC, the high Zn^"^ levels
(74ppm-600ppm) may produce cytotoxic effects. Sr-containing GC’s demonstrated Sr
release in the range 6ppm-318ppm at pH 7.4 and 138ppm-582ppm at pH 3, and indicated
that all GC’s s may have therapeutic potential under both physiological conditions.
BTl 10, BTl 11 and BTl 12 sintered disks were found to have biaxial flexural strengths
(BFS) in excess of both hydroxyapatite and p-tricalcium phosphate, following incubation
in simulated physiological conditions with average maximum values of 120MPa, 149Mpa
and 121 Mpa, respectively. The antibacterial activity of BTl 10, BTl 11, and BTl 12 was
then assessed by the zone of inhibition test using three bacterial strains commonly

associated with orthopaedic implant infections. BTl 12 exhibited a zone of inhibition for
all three bacteria used. The radii of the zones of inhibition were as follows - E.faecalis 13
mm ±0.2 mm, MRSA 6.5 mm ±0.2 mm and P. aeruginosa 16 mm±0.2 mm. Also shown
in Figure 7(C), BTl 10 demonstrates an inhibitory effect on P. aeruginosa with a halo of
inhibition present whose radius was measured at 3.8 mm±0.2 mm. The results of the
work carried out indicate that the glass ceramics investigated have excellent potential in
both load bearing and non-load bearing application, whilst providing therapeutic benefit
at a local level.
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IV

Aim and Rational of work program

The objective of this research was to synthesize and evaluate synthetic bone grafts based
on calcium silicate bioactive glass ceramics comprising zinc (Zn), strontium (Sr) and to
establish the potential therapeutic benefit these bone grafts may possess.

In order to

achieve this objective a rational and systematic approach was adopted. The research has
been carried out as follows:

1. Synthesis and Characterisation of glass ceramic compositions Five compositions will be synthesised, based on incremental additions of Na for Zn in
groups separated by variable Sr content. To evaluate the composition-structure
relationships of these materials and the crystalline structures evolved as a result of
thermal processing up to the first crystallisation temperature, each glass ceramic will be
characterised using DSC (Differential Scanning Calorimetry) and subjected to high
temperature x-ray diffraction to establish the crystalline phase evolution.

2. Quantification of Therapeutic Ion release
Based on the characterisation results, an investigation into the Sr^^ and Zn^^ release from
five, three dimensional (3D) glass ceramics foams, BTl 10-BTl 14, using A AS (Atomic
Absorption Spectroscopy) will be carried out. This will allow for the evaluation of best in
class materials with respect to potential therapeutic applications in structures conducive
to osseous integration and vascularisation. Therapeutic ion release profiles will be
monitored as a function of incubation of three dimensional fully articulated glass
ceramics under normal and extreme physiological conditions over a period of 1, 7 and 30
days to evaluate which material exhibit the optimum ion release profiles. The porosity of
the foams will be established by x-ray tomography.

3. Mechanical properties
The optimum sintering conditions for the best in class materials will be evaluated by
dilatometry in order to optimise the glass ceramics mechanical properties and crystalline
phases present identified by XRD. The biaxial flexural strength of each best in class glass
ceramic will then be evaluated following incubation in simulated physical conditions for
0, 1,7, 30 and days This will identify the glass ceramics, and their crystalline structure,
capable of producing the strongest materials.

4. Evaluation of Antibacterial Efficacy
The antibacterial properties of the best in class glass ceramics will be examined using the
popular ‘zone of inhibition’ test. Three of the most prevalent bacteria found at the site of
implantation will be used, namely Enterococcus faecalis (E. faecalis). Pseudomonas
aeruginosa (P. aeruginosa) standard stocks along with a clinical methicillin resistant
Staphylococcus aureus (MRSA) isolate. This should allow for the establishment of the
materials with the greatest antibacterial efficacy against bacteria known to cause post
operative infection.
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Literature Review
1. Anatomy of bone
Bone is a highly specialised hierarchically structured composite material comprising a
unique structure and mechanical properties. The skeleton, which comprises bone and
cartilage provides structural support, enables movement and protects internal organs. It is
also of importance in haematopoesis, and mineral homeostasis; bone being the principal
reservoir of calcium, phosphorous, sodium, magnesium and carbonate in the body [1-3].
Bone undergoes renewal and repair throughout life as a result of bone remodelling and
the interactions of support cells such as osteoblasts and osteocytes. The following chapter
will briefly outline the structure of bone, its remodelling cycle, and its mechanical
properties.

1.1 Macroscopic organisation
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Figure 1.1. Typical macrostructure of a long bone [4].

Bones are classified into four types: (a) flat bones, e.g. bones of the skull; (b) long bones,
e.g. major limb bones; (c) short bones, e.g. carpus and tarsus; and (d) pneumatic bones,
i.e. bones containing air sinuses. There is a fifth type, called irregular bone which
combines features of two or more of the other four [2].

The long bone (Figure 1.1) consists of a tubular shaft called the diaphysis. The diaphysis
is a hollow cylinder with walls consisting of thick cortical bone tissue. The cortical tissue
is calcified, and in the centre of the cylinder is the medullary cavity, which houses the
hematopoietic bone marrow. At each end of the bone is a roughly spherical epiphysis of
spongy bone also known as cancellous or trabecular bone. The epiphysis is usually wider
than the diaphysis and the Joint surface is covered by articular cartilage that does not
calcify.
Separating these two main sections at either end of the bone is the metaphysis. It is made
up of the epiphyseal plate and adjacent trabeculae of spongy bone tissue on the
diaphyseal side of the long bone. The epiphyseal plate is a thick plate of hyaline cartilage
that provides the framework for the synthesis of cancellous bone tissue within the
metaphysis. The epiphyseal plates are the only places where long bones continue to grow
in length after birth [5]. Toward the metaphysis and the epiphysis the cortex becomes
progressively thinner, and the internal space is filled with network of thin, calcified
trabeculae. [6]. The medullary cavity running through the length of the diaphysis contains
yellow marrow, which mostly comprises adipose tissue. The porous latticework of the
spongy epiphysis is filled with red bone marrow. The red bone marrow, also known as
myeloid tissue, manufactures red blood cells, which give the marrow its colour [5].
Covering the outer surface of the bone (except in the joint) is the periosteum, a fibrous
membrane that has the potential to form bone during growth periods and in fracture
healing. The periosteum is often attached to the underlying bone by collagenous fibres
called periosteal perorating fibres. These fibres penetrate the inner layer of the periosteum
and become embedded in the matrix of the bone. The periosteum contains nerves,
lymphatic vessels and many capillaries that provide nutrients to the bone and give living
bone its distinctive pinkish colour. Nutrients reach the marrow and spongy bone tissue
through small openings called ‘nutrient foramen’ [5]. A thin membrane, similar to that of
2

the periosteum, lines the interior surface of compact bone tissue and covers the trabeculae
of spongy bone is the endosteum [5]. Cortical and trabecular bone are constituted of the
same cells and the same matrix elements, but there are structural and functional
differences.

The primary structural difference is quantative: 80-90% of the volume of compact bone is
calcified, whereas only 15-25% of the trabecular bone is calcified (the reminder being
occupied by bone marrow, blood vessels, and the connective tissue) [6]. Trabecular bone
is between 50-95% porous, it is typically found in cuboidal flat bones, and at the end of
long bones. Cortical bone possesses 5-10% porosity containing various pore diameters
the largest being vascular (c.50pm) [7]. Short bones have a structure analogous to that of
the epiphysis of long bones, with cortical bone surfaces surrounding a cancellous bone
centre with small spaces that are usually filled with marrow. Flat bones possess no
diaphysis or epiphysis; they consist of an internal framework of cancellous bone which is
sandwiched between two layers of cortical bone (Figure 1.2).

Cortical bone
Cancellous bone

Figure 1.2. The structure of flat bones in the human body, cancellous bone sandwiched in-between sheets
of cortical bone [8].

1.2 Microscopic histology of bone

Bone is a dynamic tissue, being continually formed and destroyed under the control of
hormonal and physical factors. This constant activity permits the process of modelling. In

an adult bone, turnover can increase from its normal basal level to meet increased
demands such as increasing bone density to cope with physical activity or the repair of
bone after trauma. Increased bone turnover and remodelling may also be the result of
pathological processes such as excessive secretion of parathyroid hormone by an
overactive parathyroid gland [9].

As in most connective tissues, the matrix of bone occupies a greater volume than the
cells. In addition to water, which accounts for about 20% of the weight of bone matrix,
the matrix has four major components; three organic and one inorganic. The organic part
of the matrix is 30-40% of the dry weight. By far the most abundant organic component
of bone (90-95%) is type I collagen. In addition, non-collagenous proteins and non
protein components such as complex saccharides and lipids [2] account for the remaining
organic components of bone.

Collagen - the main organic component of the bone matrix is a fibrillar protein
comprising two collagen a 1(1) peptide chains and one a2(I) chain, wound together in a
triple helix. Collagen is synthesized as a propeptide, but following its secretion from
osteoblasts, the amino and carboxyl terminal fragments are cleaved by proteolytic
enzymes in the extracellular space; the triple helical domains that remain then selfassemble in a staggered configuration, forming collagen fibrils. Subsequently, individual
collagen molecules within these fibrils become linked at each end by specialized covalent
bonds called pyridinium cross-links, which contribute to the tensile strength of bone.
When bone is broken down, these cross-links are released into the extracellular fluid;
their levels can be measured in serum and urine to provide biochemical markers of bone
resorption [10].

In addition to collagen, the main organic component of bone matrix, an inorganic
component comprised of calcium phosphate Ca3(P04)2 accounts for around two thirds of
the weight of bone [11]. The calcium phosphate interacts with calcium hydroxide
[Ca(OH)2] to form crystals of Hydroxyapatite (HA) Caio(P04)6(OH)2. Mineral crystals of
bone form within the collagen template after a fast primary and a protracted secondary
4

mineralization stage [12, 13]. The longer c-axes of HA crystals are aligned along the
longer axis of collagen fibers [14]. Mineral crystals are reported to be plate- [14] or
needle-shaped [15] and exhibit relatively poor crystallinity due to the presence of
impurities; the average dimensions of crystals are small, around 5x5x20 nm, rendering
non-stoichiometric substitutions of ions like carbonate, fluoride and chloride easier [15].
Contribution of the mineral phase to the mechanics of bone is investigated in great detail
in terms of its amount, i.e. the so called degree of mineraliz^ation [16]. Studies examining
a variety or vertebrates including human bones have repeatedly demonstrated that
increased degree of mineralization imparts strength and stiffness to bone tissue, yet,
excessive mineralization has a negative effect on tissue [17]. Hydroxyapatite gives bone
its weight bearing capacity, compressive strength, while the collagen fibres contribute to
properties such as tensile strength and toughness of bone.

1.3 Cortical and Cancellous bone

There are two types of osseous tissue: compact bone, or dense bone and spongy bone [1
also known as cancellous bone.

1.3.1 Cortical bone

The basic functional unit of mature compact bone (Figure 1.3 and 1.4) is the osteon or
Haversian system [11]. In the centre of the osteons are central canals (Haversian canals),
longitudinal canals that contain blood vessels, nerves, and lymphatic vessels [5]. Central
canals usually run parallel to the surface of the bone. Other passageways, known as
perforating canals, or canals of Volkmann, extend roughly perpendicular to the surface.
Blood vessels in the perforating canals deliver blood to the osteons deeper in the bone
and supply the interior marrow cavity [11]. Unlike central canals, perforating canals are
not enclosed by concentric lamellae [5]. Interstitial lamellae fill in the spaces between the
osteons in compact bone, and circumferential lamellae lie beneath the periosteum and
5

endosteum. Interstitial lamellae are remnants of osteons whose matrix components have
been recycled by osteoclasts. Circumferential lamellae are produced during the growth of
the bone [11]. Lamellae contain lacunae, which house the osteocytes, or bone cells.
Radiating like spokes from each lacuna are tiny canaliculi that contain the slender
extensions of the osteocytes. Nutrients and waste products can pass to and from the blood
vessels in the central canal [5].

Figure 1.3 Osteon showing Haversian canal, canaliculi and lacunae [18].
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Figure 1.4: Typical structure of cortical and cancellous (spongy) bone [8],

1.3.2 Cancellous bone

In contrast to compact bone, spongy bone usually does not contain true osteons. It
consists of an irregular latticework of thin plates of bone called trabeculae [19]. These
trabeculae are tiny spikes of bone tissue surrounded by bone matrix that has calcified, or
become hardened by the deposition of calcium salts. The trabeculae form along the lines
of greatest pressure or stress. This arrangement provides the greatest strength with the
least weight [5]. The spaces between the trabeculae of some bones are filled with red
marrow. Within the trabeculae lie lacunae, which contain osteocytes. Blood vessels from
the periosteum penetrate through to the spongy bone, and osteocytes in the trabeculae are
nourished directly from the blood circulating through the marrow cavities.

1.4 Bone cellular structure

There are three classical bone cells which may be classified according to their structure
and function. The following section provides summary details for osteoblasts, osteocytes
and osteoclasts before elucidating their interdependent roles in bone metabolism.
1.4.1

Osteoblasts

Osteoblast cells (Figure 1.5) are differentiated mesenchymal cells that are responsible for
the synthesis of collagen and the non-collagenous proteins of bone, the orderly
organization of collagen and the non-collagenous proteins of bone, and the mineralization
of osteoid. These cells are characterized by the expression of genes required for the
synthesis of alkaline phosphatase, type 1 collagen, osteocalcin, osteonectin, osteopontin
and many cytokines [2]. Typical osteoblasts are transient cells that work focally on bone
surfaces. They function as part of a short-lived consortium with other neighbouring
osteoblasts, manufacturing seams of osteoid characteristically many times longer than the
diameter of individual cells. These cells will only deposit osteoid on pre-existing
mineralized surfaces [2, 6, 7]. In the adult skeleton, osteoblasts will deposit bone matrix
at a rate of about 1pm per day. Mineralisation however, lags behind matrix formation,
leaving a layer of unmineralised bone (osteoid) at that active formation site [1].
Mineralization will occur only if there are adequate supplies of calcium and phosphate in
the extracellular fluid and these in turn are dependent upon the presence of parathyroid
hormone and 1,25 dihydroxy vitamin D3 (vitamin D). It is believed that osteoblasts
entrapped in osteoid produce intracellular membrane bound structures called matrix
vesicles. Rich in sulphate and sodium, these vesicles are ejected from the cell, but, just as
they leave there is a rapid exchange of calcium and phosphate for the sodium and
sulphate. The extracellular matrix vesicles thus act as discrete foci about which the
crystal lattice of bone is established by inorganic chemical reactions [2].

Figure 1.5 SEM image of osteoblasts in bone matrix [20]

1.4.2 Osteocytes

During osteoid formation osteoblasts may become embedded in calcified bone matrix [5];
the entrapped cells are known as osteocytes. Osteocytes are linked to one another by fine
processes contained within the canaliculi. The osteocytes themselves lie in holes known
as osteocytic lacunae. Within lacunae and canaliculi, osteocytes are surrounded by
extracellular fluid. Ion exchange occurs between the crystal lattice of the bone matrix and
the extracellular fluid (ECF) around osteocytes, enabling the maintenance of mineral
homeostasis [26]. The morphology of the osteocytes varies according to their age and
functional activity. A young osteocyte possesses most of the ultrastructural characteristics
of the osteoblast from which it was derived, apart from a decrease in cell volume and
number of organelles involved in protein synthesis [6]. An older osteocyte, located
deeper within the calcified bone, shows these decreases further accentuated and there is
an accumulation of glycogen in the cytoplasm. Osteocytes are phagocytized and digested,
together with other components of bone, during osteoclastic bone resorption. These cells
may also play a role in local activation of bone turnover by acting as mechanoreceptor.

capable of sensing microdistortions in bone matrix, or changes in shearing microforces
between the osteocyte and its ECF (extracellular fluid), and translating these directly, or
via passage of information from one osteocyte to another, into signals that influence the
activity of bone surface cells [2] .

1.4.3 Osteoclasts

Osteoclasts (Figure 1.6) are the bone lining cell responsible for bone resorption. These
cells are giant multinucleated cells, originating from the bone marrow [7] and formed by
the fusion of mononuclear progenitors of the monocyte/macrophage family [1]. They
contain four to twenty nuclei which are responsible for the resorption of bone [6].
Characteristic ultrastructural features of this cell are the abundant Golgi complexes
characteristically disposed around the nucleus, the mitochondria, and the transport
vesicles loaded with lysosomal enzymes.

Figure 1.6 SEM image of osteoclasts in bone matrix [20]
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Bone resorption is facilitated by a unique cell specialization called the “ruffled border”.
The ruffled border is a highly invaginated and physically active membrane specialization
and is the site of enzyme and acid release to facilitate the degradation of the matrix and
dissolution of mineral. The ruffled border and resorption area is surrounded by a
filamentous adhesion zone termed the “sealing zone”, which appears to form a barrier
around the resorption area [21]. In the resorption area the osteoblast secretes proteolytic
enzymes which lower the pH of the microenvironment at the bone surface and decalcify
the bone [22, 23], coupled with the digestion of the collagen framework matrix [2].
Through the decalcification and breakdown of osteoid, osteoclasts are able to excavate
resorption pits on the surface of trabecular, subcortical and periosteal bone, and produce
tunnels in cortical bone [24]. The concerted effort of several osteoclasts either side by
side or acting sequentially at the same site leads to excavation of larger quantities of
bone. Removal of bone in this way serves several purposes; first, it allows bone
modelling and remodelling to occur, it liberates calcium from the bone to add to the
calcium pool within the extracellular fluid and also allows fracture healing to occur by
allowing the invasion of blood vessels which in turn promotes osteogenic cells to develop
into osteoblasts [2, 25]. Following degradation / dissolution osteoclasts may return to an
inactive state or die via apoptosis [ 1 ].

1.5 Bone remodelling

A general change in bone shape or architecture is termed bone “modelling”, while an
internal change and replacement is termed “remodelling” [1]. It has been estimated that
approximately 10% of the adult skeleton is being remodelled at any one time [27]. The
remodelling process is not performed individually by each cell, but by groups of cells
functioning as organized units, known as “basic multicellular units” (BMUs) [28]. The
BMUs always follow a well-defined sequence of processes, normally known as the A-RF sequence: activation-resorption-formation [7]. Bone remodelling, as outlined in Figure
1.7, commences with attraction of osteoclast precursors in peripheral blood to the site
which is to be resorbed. The mechanisms which trigger this process are unclear, but it has
11

been speculated that chemotactic factors released from areas of skeletal microdamage
may play a role [1, 27]. Once present in the bone microenvironment, osteoclast
precursors start to differentiate and fuse together to form multinucleated osteoclasts in
response to activation of a receptor on the cell surface called RANK (receptor activator of
nuclear factor kappa B) by the RANK ligand (RANKL), which is expressed on
osteoblasts and bone marrow stromal cells. This interaction is inhibited by a soluble
protein with homology to RANK called osteoprotegerin (OPG). OPG acts as a ‘decoy’
receptor which inhibits osteoclast activity by binding RANKL. The RANK and OPG
molecules belong to the TNF (tumour necrosis factor) receptor superfamily of molecules
whereas RANKL is a member of the TNF superfamily [27]. Osteoclasts resorb bone by
secreting hydrochloric acid and proteolytic enzymes into the space underneath the sealing
zone through a specialized membrane, the ruffled border. The osteoclast contains
specialized proton and chloride pumps, which are responsible for secretion of
hydrochloric acid into the extracellular space [27]. Under normal circumstances, the acid
dissolves hydroxyapatite and allows proteolytic enzymes access to degrade components
of bone matrix. One of the most important proteolytic enzymes expressed by osteoclasts
is cathepsin K, which is largely responsible for degradation of bone collagen. When bone
resorption is complete, osteoclasts move away from the bone surface and undergo
programmed cell death (apoptosis) in the so-called reversal phase, which heralds the start
of bone formation [6, 27].

Pre-

Osteocytcs

Mineralization

Figure 1.7: Bone remodelling cycle [29].
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Bone formation begins with the attraction of osteoblast precursors to the site which has
undergone resorption. These cells are derived from mesenchymal precursors in bone
marrow stroma. Osteoblast precursors differentiate into mature osteoblasts in response to
the transcription factors Cbfal (Core-Binding Factor, Runt Domain, Alpha Subunit 1)
and osterix (Osx), which binds to the promoter of several osteoblast specific genes such
as osteocalcin, type i collagen and alkaline phosphatase, causing the cells to assume an
osteoblast like phenotype [27]. Other growth factors, including bone morphogenic
proteins, are also thought to promote bone formation by encouraging proliferation and
differentiation of osteoblast precursors to form mature osteoblasts [27j. Lipoproteinreceptorrelated protein 5 (LRP5) is another key regulator of bone formation which acts
downstream of Cbfal and Osx to stimulate bone formation when activated by the Wnt
protein family. The stimulator effects of Wnt proteins on bone formation are antagonized
by a protein called sclerostin (SOST), which is produced by osteocytes and inhibits bone
formation [30]. Mature osteoblasts lay down uncalcified bone matrix (osteoid) onto the
bone surface and this subsequently calcifies after a period of about 10 days to form
mature mineralized bone [6, 27]. The enzyme alkaline phosphatase, which is produced by
osteoblasts, plays an important role in promoting mineralization by degrading
pyrophosphate, which is a naturally occurring inhibitor of mineralization that is present in
extracellular fluid. Alkaline phosphatase is released from normal osteoblasts and used
clinically as a biochemical marker of bone formation. Osteocytes are the most abundant
cells in bone and are thought to be responsible for sensing the effects of mechanical strain
on the skeleton [27]. They produce various signalling molecules such as prostaglandins
and nitric oxide in response to mechanical loading. They also produce SOST, which is a
negative regulator of bone formation, DMPl (Dentin matrix acidic phosphoprotein),
which regulates mineralization of bone, and FGF23 (Fibroblast growth factor), which is
involved in phosphate homeostasis [27]. In adult humans, the time required for a
complete remodelling cycle and formation of a complete osteon is about 120 days [1].

1.6 Mechanical properties of bone
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The composite structure of bone allows it to withstand compressive and tensile stresses,
as well as bending and tensional movements [6]. Compositional features such as mineral
density and collagen content as well as age, gender and disease influence the material
properties of bone [7]. The inorganic phase of bone with hydroxyapatite crystals arranged
in a protein matrix provides the ability to resist compression. However hydroxyapatite
possesses a poor ability to withstand tensile loads. In the case of bone this tensile strength
arises from collagen fibrils organized into lamellae [6, 31]. The collagen orientation
between adjacent lamellae can rotate by as much as 90° permitting the tissue to resist
forces and moments acting from several different directions; directed deposition of
collagen adds to the anisotropy of bone [6]. Table 1.1 illustrates some selected physical
properties of bone from the literature.

Table 1.1: Selected mechanical properties of various bones.

Type of bone

Cortical (midfemoral)

Direction and type of
load

Modulus of
elasticity (GPa)

Reference

Longitudinal tension

133

17

[32]

Longitudinal
compression

193

17

[32]

Longitudinal shear

68

3

[32]

Transverse tension

51

11.5

[32]

Transverse
compression

33

11.5

[32]

5.3

0.445

[33]

6.8

0.441

[34]

Trabecular (proximal
tibia)
Trabecular (proximal
femoral)

Ultimate strengh
(MPa)

Axial

In general, values for mechanical properties of bone at the macrostructural level vary
from one bone to another as well as within different regions of the same bone [35]. For a
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number of human bones including the femur, tibia, humerus, mandible, lumbar vertebrae,
and patella, the site-specific orthotropic mechanical properties have been studied as a
function of position. A feature of this data is the huge variation in modulus and strength
reported for trabecular bone [36]. These variations have been shown to be a function of
anatomic position, loading direction, methods of storage and testing conditions. For
instance Goldstein et al. [37] measured the modulus of the proximal tibia to be between 4
and 430MPa, whereas Ciarelli et al. [38] found it to be 5-552 MPa, and Lindahl et al.
[39] to be 1.4-79MPa. Of the three examples given two different storage methods for the
specimens were used as well as three different specimen dimensions 7mm (diameter),
8mm (diameter) and 14x9 mm respectively. Vertebral bodies, as studied by McElhaney et
al. [40] under uniaxial stress, were found to have an average strength of 4.13 MPa and
average modulus of 151.7 MPa, whereas those studied by Lindahl et al. [39] were found
to have strength ranging from 0.3-7.0 MPa and a modulus ranging from l.l-139MPa
under uniaxial stress. Again both authors used specimens of differing size and
preparation, fresh of 10mm length and dried, defatted and 10x9x14 mm respectively. The
most significant result from these studies was the correlation between the variation in
material properties and the function of the bony region tested. These findings support the
generally accepted hypothesis that function directly influences the structure and strength
of metaphyseal bone, a relationship known as Wolffs Law [36]. In human cancellous
bone, by contrast, there is no difference in the mechanical properties of the humerus, the
proximal tibia, and the lumbar spine. The stiffness and strength of cancellous bone from
these bones were found to be lower than those of the patella, and the distal and proximal
femur (patellar cancellous bone had the highest values overall) [41]. In human cancellous
bone, mechanical properties vary significantly around the periphery and along the length
and they also show significant inter-subject differences [41]. This could suggest that
experiments performed on a large number of samples from one subject are not enough to
draw conclusions. It can be seen from the cases presented above and others in the
literature [36] that any potential load bearing bone graft must be designed with a range of
mechanical properties in mind and a graft which may be appropiate for one site of
implantation may not necessarily mean that it will function as required in another.
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1.7

Clinical Need & Principles of Bone Grafting

Bone is limited in the size of fracture or defect it is able to restore to healthy tissue.
Furthermore, bone can suffer from pathological conditions, (e.g. cancer) and is subject to
degeneration as a result of age and disease (i.e. osteoporosis). In these cases, patient
comfort and bone function can often only be restored by surgical reconstruction [42].
Sites and indications for bone grafting (Figure 1.8, 1.9 and 1.10) include fractures with
bone loss, comminution, metaphyseal defects, delayed unions and non-union’s, bone
lesions, osseous voids, and arthrodesis, their aim being to provide timely healing of
musculosketal injuries [43-47]. Bone grafting techniques have been used by medical
specialists dating back 300 years when Job van Meekeren performed the first bone graft
using canine xenograft to repair a cranial defect [48]. In 1879 Macewen successfully
replaced the proximal two thirds of a humerus in a four year old child with allograft bone
[49], and in 1892 the first documented use of synthetic bone grafts was reported, where
large-bone defects were treated with calcium sulfate [50]. Bone grafting became critical
during World War II, prompting the US navy to establish bone banks in order to better
treat fractures sustained in battle [48]. Currently more than 500,000 bone grafting
procedures are carried out annually in the United States [43-45, 49] and 2.2 million
worldwide in order to repair bone defects in orthopaedics, neurosurgery and dentistry
[45]. In the USA there are an estimated, 280,000 hip fractures, 700,000 vertebral, and
250,000 wrist fractures each year at a cost of $10 billion, with joint diseases account for
half of all chronic conditions in people over 65 and this number is set to rise in the future
[51, 52]. Demand for bone grafts has risen without a corresponding increase in supply.
For example, in Scotland, the Scottish National Blood Transfusion Service performs
Bone Banking. They collect and distribute all the bone that is used in revision total hip
arthroplasty in Scotland. In 1993, they collected 1559 femoral heads and issued 1061. In
1995, they collected 1778 heads and issued 1567. This represents a 13% increase in
supply, against a 50% increase in demand over a 2-year period. Between 1993 and 1995,
the number of primary total hip arthroplasties performed increased by approximately
1.8%, whilst the number of revision arthroplasties increased by approximately 20% [53].
The requirement for bone replacement is further demonstrated by the fact that delayed
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healing or non-union occurs in 5 per cent of all fractures, and 20 per cent of high-impact
fractures [54], such defects may exceed the body’s regenerative capabilities unless
surgeons intervene to bridge the skeletal defect [51]. There are a number of options
currently available to orthopaedic surgeons when it comes to bone grafts; these include
those that are of either biological or synthetic origin.
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Figure 1.8: Sites where bone grafts are typically implanted [55].
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Resection of
Bone Tumor

Figure 1.9; Bone tumor defect requiring bone graft [55].

Figure 1.10: Non union of femur following trauma [52].

Bone formation as a natural process or one that involves bone grafting occurs via the
process of bone morphogenesis. The bone morphogenesis cascade is a triphase sequential
cascade: chemotaxis and mitosis of mesenchymal cells, differentiation of the
mesenchymal cells initially into cartilage, and replacement of the cartilage by
remodelling [56, 57]. The innate repair mechanism of bone utilizes bone-forming cells
such as osteoblasts, a cartilaginous scaffold upon which the new woven bone is formed,
and bioactive molecules to direct the repair process. The main processes of bone repair
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and regeneration comprise of osteoinduction, osteoconduction, and osseointegration,
which results in new bone formation, bone union, and incorporation of the graft with
bone. In addition to the characteristics of the implanted material, the speed and degree of
graft incorporation into host skeletal tissue is dependent on local and systemic factors,
including local tissue integrity and the systemic physiological state of the host [57]. The
cellular events occurring at the graft-tissue interface and graft material itself during its
incorporation

involve

six phases,

namely haematoma formation,

inflammation,

vascularisation, resorption, regeneration, and remodelling [58]. Haematoma formation
occurs on trauma to host-site, preparation and graft implantation, which also triggers the
release of cytokines and growth factors. The inflammatory process involves proliferation,
differentiation, and migration of mesenchymal stem cells [25, 59]. Neutrophils,
lymphocytes, and monocytes are also attracted and recruited to the zone of trauma,
migrating to the site where they organize haematoma formation. This process also
involves platelet adherence and deregulation with the release of several growth factors
(e.g. FGF-2, PDGF, TGF-P) into a fibrin meshwork. Fibroblasts produce collagen in
response to various stimulatory factors (e.g. TGF-p). Fibroblasts and macrophages also
produce matrix metalloproteinases which degrade collagen [60]. The vascularisation
process involves the development of fibrovascular tissue within the graft and in the
immediate tissue periphery. There also occurs vascular invasion into the graft, which may
also originate from pre-existing Haversian and Volkmann canal systems. This phase is
essential for provision of the graft environment with nutrients and cell populations [58].
The resorptive process involves focal osteoclasts acting on graft surfaces before bone
regeneration

is

intramembranous

achieved
or

by

highly

endochondral

active

ossification.

osteoblasts
Once

producing

mechanically

bone

via

stable,

the

remodelling process occurs to optimize functionality. The rate of skeletal remodelling, is
dependent on age, ethnicity, genetics, and metabolic and pathological conditions, and will
influence the long-term graft turnover and integrity [58]. The ideal bone void filler should
provide a three dimensional (3D) matrix to support osteoblasts and pre-cursor cell
attachment, migration, proliferation, interact actively with cells and tissues and stimulate
repair and regeneration [43, 61] produce non-toxic degradation products [62, 63], and
bond to the host bone, creating a stable interface without the formation of scar/fibrous
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tissue [64], in order for this to occur the bone graft must be osteoconductive,
osteoinductive, orthogenetic, allow osseointegration be biocompatible and possess
structural integrity [43, 44].

1.7.1

Osteoconduction

Osteoconduction is defined as the process of bony growth from local osseous tissue onto
surfaces [58, 65], where an osteoconductive material is one where bone formation is
promoted to appose and conform to its surface, when the material is placed into bone, by
virtue of its composition, shape, or surface texture [58]. Bone growth on an implant
surface depends on the action of differentiated bone cells. The source of these may be
pre-existing surviving preosteoblasts or osteoblasts activated by trauma, but more often
primitive MSC’s recruited by osteoinduction. In order for osteoconduction to take place
and the extent to which it occurs, is dependent on whether osteoinduction has already
happened [65]. Bone growth, including bone conduction, does not occur without a proper
vascular supply and bone growth factors [65, 66], where the principal action of many
growth factors is both mitogenic and angiogenic [67]. In terms of biomaterial
implantation, bone conduction is dependent on optimal environmental conditions as well
as the osteoconductive potential of the biomaterial itself [58].

1.7.2

Osteoinduction

Osteoinduction

is

defined

as

the

stimulation,

by

osteogenesis,

of primitive

undifferentiated and pluripotent cells to develop into bone forming cells i.e. osteoblasts or
preosteoblasts [65]. The original definition of osteoinductive materials by Marshal Urist
states that the biomaterials are capable of inducing bone to form when placed into an
extraskeletal site [58]. Osteoinductive materials including autografts, blood-borne
proteins, cytokines that naturally form bone within the skeleton as well as extraskeletally
such as demineralized bone matrix (DBM), and specific BMPs, and peptides provide this
stimulation [44, 58].
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1.7.3 Osteogenesis

Osteogenesis is the process of direct bone formation and is only present in cells
(osteoblasts and osteoblast precursors). The only material, to date, that possesses inherent
osteogenic properties is autograft [44]. Ontogenetic properties have been instilled in
synthetic grafts through the seeding of scaffolds before implantation with cells such as
such as osteoblasts and mesenchymal cells that have the potential to establish new centres
for bone formation [68].

1.7.4

Osseointegration

Osseointegration is the process of achieving stable direct anchorage and contact between
bone and implant during functional loading without the growth of fibrous tissue at the
bone implant interface

[45, 58]. The bone anchorage process may be enhanced or

accelerated by variable surface modifications such as bioactive coatings, however
secondary failure of osseointegration may be caused by poor contact factors such
inadvisable surface enhancements such as excessive topographical roughness and
overloading [58].

1.7.5

Biocompatibility

The widely accepted definition of biocompatibility is the ability of a material to perform
with an appropriate host response in a specific application [69, 70]. The reaction of the
body to different materials differs in that the body may reacts to materials that are called
biocompatible and walls them off in an avascular, collagenous bag (fibrous
encapsulation), c.50-200 pm thick. This reaction is referred to as the foreign body
reaction [69]. When taking biocompatibility into account it is important to avoid any
toxic or immunological reaction caused by the graft which can lead to graft failure or
tissue necrosis [71].
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1.7.6

Structure of porous grafts

When designing bone grafts along with the biochemical factors that make an ideal bone
graft, there must also be an optimum physical structure to that bone graft so as to enhance
its effectiveness. Bone grafts which do not mimic bone in their architecture can only ever
be of limited use and have limited applications as the living tissue has certain
requirements such as surfaces which allow three dimensional healing, tissue integration
and mechanical support. Grafts which are in powder or sold form can neither allow for
mechanical support nor tissue integration, therefore an open porous three dimensional
scaffold whose architecture mimics that of natural bone appears to be an improvement if
indeed that scaffold possesses a combination of the properties outlined above. Scaffolds
should

show an internal structure which is highly porous, permissive for osseous

invasion [72], allowing proper vascularisation [72, 73] and provide structural support for
the newly formed bone [62]. The porous structure should be highly interconnected with
pore sizes in the range of 100-500pm [62, 73, 74] and with a porosity higher than 90%
[63], it must also degrade at the rate at which new tissue forms [75]. Some studies have
demonstrated that direct interaction with the intrinsic chemistry of the graft material may
be responsible for osteoinduction through the dissolution and release of specific key ions
that act directly on local cells to upregulate gene expression or influence cell
differentiation [76]. It had been demonstrated that Bioglass® glass-ceramic [77] possesses
the ability to stimulate cell cycling and subsequently enhance osteoblast turnover, in
vitro. Bioglass substrates were seeded with human primary osteoblasts and evaluated
after 2, 6, and 12 days. Flow cytometric analysis of the cell cycle suggested that the
bioactive glass-ceramic substrate induced osteoblast proliferation, as indicated by
increased cell populations in both S (DNA synthesis) and G2/M (mitosis) phases of the
cell cycle. Biochemical analysis of the osteoblast differentiation markers alkaline
phosphatase (ALP) and osteocalcin indicated that the bioactive glass-ceramic substrate
augmented osteoblast commitment and selection of a mature osteoblastic phenotype.
Scaffolds such as Vitoss® which is based on tricalcium phosphate are currently on the
market but are not indicated for load bearing applications; therefore a new material is
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required to fill the requirements outlined above.

1.8

State of the Art Bone Grafting Materials

Based on the significant patient need, a number of biomaterials are available for clinical
use for bone grafting indications. The following section summarizes the salient features
of popular clinical materials.
1.8.1 Autograft

Autograft bone is bone which may be transplanted from one site to another within an
individual (i.e. the donor and recipient are the same patient) [78]. Autograft is considered
the “gold standard” bone grafting material as it combines all properties required in an
ideal bone graft material: osteoinduction, osteogenesis, osteoconduction, structural
support, within a materials that is non-immunogenic and fully histocompatible for the
patient [78, 79]. Iliac crest bone graft, as shown in Figure 1.11, is by far the most
commonly used autologous bone graft compared to other alternative donor sites, such as
the proximal tibia, distal femur, fibula, ribs and distal radius. It can be harvested from the
anterior or the posterior iliac crest. Its main advantages include the availability of an
increased bone quantity of bone graft (cancellous, cortico-cancellous or vascularised)
with progenitor cells and growth factors, and structural support when tricortical graft is
used [80]. In craniofacial surgery, bone grafts are frequently taken from the skull, at the
tabula externa, or so-called split thickness, calvarial grafts. The use of rib grafts in the
treatment of bone defects of the skull was described as early as the beginning of the 20th
century; today rib grafts are primarily used in nasal reconstruction. In dentoalveolar
surgery and implantology, bone grafts are frequently harvested from the jaw (chin,
retromolar region) [81]. However, the amount of bone that may be obtained from the sites
mentioned is very limited. To harvest larger amounts of autologous bone, the iliac crest is
the most common donor site [81, 82].
Cortical autografts are often used in scenarios where the structural integrity of bone is
compromised. However despite its initial mechanical strength cortical bone may lose up
to 33% of its strength during incorporation and remodelling, and generally remodels
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over a 6 to ISmonth period [51, 82, 83]. Typically chosen autografts for osteoinduction
and osteoconduction are cancellous autografts. These grafts are most rapidly
revascularized and incorporated, and have the greatest osteogenic potential through viable
osteogenic cells and the release of bone-inducing growth factors. Cancellous grafts are
often used as void-fillers in metaphyseal fracture defects due to their moulding
characteristics. Rapid revascularization and incorporation make cancellous grafts ideal if
infection is a risk. However in comparison to cortical bone cancellous bone provides little
mechanical stability [83]. The bone segment, which contains both cancellous and cortical
bone, can also be harvested with its blood supply intact. The vascular pedicle is
anastomosed onto blood vessels at the recipient site to reduce the risk of subsequent
necrosis of the autograft [51]. In comparison to non-vascularised cortical grafts, they
have greater mechanical strength during the first six months after transplantation [83].

Figure 1.11: Harvesting of bone from the anterior iliac crest using oscillating saw [81].
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Despite their obvious benefits, autologous bone grafts do have significant disadvantages.
The harvesting procedure requires a second surgery to extract the graft from the donor
site (Figure 1.11). This can extend operation time by typically 20 minutes, increase blood
loss, leading to increased risk to patient safety [78]. Although iliac crest bone harvesting
is a frequently performed surgical procedure with relatively easy access, its complications
have been well documented in the literature; high morbidity rates as well as infection,
haematoma/seroma, fracture, nerve and vascular injuries, chronic donor site pain, hernias,
and unsightly scars are all cited as disadvantages to the use of autograft [80]. Differences
in the incidence and severity of complications have been described according to the
location of the iliac crest donor site and the harvesting techniques used [81]. The success
rate of the bone graft procedure itself is highly dependent on the repair site and technique
[78]. Limited volumes and supply are another major disadvantage of autografts. It has
been estimated that an iliac crest donor site requires approximately 24 months to
regenerate, before it could be reutilized to supply adequate tissue for further
autotransplantation [84]. As stated earlier joint diseases accounts for half of all chronic
conditions in people over 65, such diseases include osteoporosis which limits further the
amount of autologous bone available for donation [84].
1.8.2

Allograft

Allograft bone refers to bone, which has been harvested form, an individual other than
the recipient; the donor may be living or deceased [51, 85]. Allograft bone has many
benefits compared with autografts, including the absence the need for an additional
surgery in the patient leading to shorter operating times and a quicker recovery. Also in
elderly patients with osteoporosis in whom the supply of autografts of good quality is
limited [86], allografts may provide a superior substitute. Fresh-frozen bone is at present
the most popular, but freeze-dried, autoclaved, boiled, ethylene oxide-treated, irradiated,
defatted, detergent-treated, and decalcified bone may be prepared [85]. Fresh and frozen
allograft material, possess stronger mechanical properties but greater infection and
rejection potential. Freeze-dried allograft may mitigate such compatibility issues.
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however such processing leads to compromised mechanical properties. Corticocancellous
allograft is classically used for tumours, large defects from nonunions such as the
humerus, and areas of large defects. Cancellous allograft chips are used more commonly
for smaller nonunions and metaphyseal voids, either as autograft extender or as
replacement [44]. The frozen and freeze-dried types are osteoconductive through the
release of osteogenic bone-inducing proteins but are considered, at best, to be only
weakly osteoinductive and undergo slower incorporation than autografts. Hence, they are
less effective at stimulating repair than equivalent quantities of autograft [83, 86]. The
method of preparation is designed to minimise the immune response of the host and
therefore in most allografts there are no viable cells to confer osteogenic properties [86].
Despite the obvious advantages of allografts, allografts present themselves with some
inherent drawbacks. The FDA has recalled over 59,000 musculoskeletal allografts over
the period 1994 to 2007, for reasons such as improper donor evaluation, contamination,
recipient infection, positive serology and improper/invalid testing [87]. Regarding
immunogenicity, allograft tissues can elicit immune responses in the hosts. This is
normally mediated via class I and II major histocompatibility complex (MHC) antigens.
However, because cell death occurs with tissue processing, whether this is performed
after aseptic procurement or during terminal sterilization, with ethylene oxide or gamma
sterilization for example, the magnitude of a possible immune reaction is considerably
diminished but not eliminated [88]. The harsh terminal sterilization processes carried out
on the allograft material, can alter the demineralised bone matrix’s (DBM’s) natural
proteins, decreasing its osteoinductivity, and ultimately rendering the resulting DBM
inactive and non-functional [89]. Although the risk of transmission of disease is much
lower than with blood and blood products, it has occurred.
In particular, transmission of HIV (human immunodeficiency virus) and hepatitis C has
been described [86]. The estimated risk of HIV transmission with allograft bone
transplantation from screened donors is 1 in 1.6 million procedures, with no new reported
cases since 1985. Cases have originated from a cadaveric donor with viral titres below the
limit of detection of the assay in use at the time, and as such have been used to reinforce
the argument that irradiation improves safety. Similarly, 5 patients have become infected
with hepatitis C in 2002 secondary to subclinical viral titres in the donor. However, the
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usual upper limit of y irradiation exposure to bone allograft in the US is 25 kGy, and it
has been reported that up to 50 kGy is required to inactivate HIV [90]. This therefore
brings into question whether an increase in the standard level of y irradiation would have
altered the outcome in these cases however it must be emphasized that irradiation with
25 kGy is already known to reduce osteoblast differentiation [90] and higher doses are
likely to amplify this effect. Due to the general increase in life span, the eligible donor
population is decreasing as is the case for autografting. This is due to that fact that
increasingly more people suffer from conditions such as osteoporosis which effects
mechanical properties of bone rendering them unsuitable for donation [91].

1.8.3

Demineralised Bone Matrix and Bone Morphogenic Protein

Demineralised bone matrix (DBM) are allograft-derived products, in which the mineral
phase of bone undergoes acid extraction, with retention of proteins, growth factors and
collagen [83]. DBM has been termed an osteoinductive material based on its ability to
induce endochondral bone formation when implanted in mesenchymal tissues that would
otherwise not form bone [92]. Reddi et al [93] demonstrated that, when rat DBM is
implanted subcutaneously in rats, a series of events is initiated that follows a well defined
time course, beginning with chondrogenesis and resulting in the formation of one or more
ossicles consisting of a lamellar bone cortex with trabeculae extending into a marrow
cavity. It has since been shown that the active components of DBM are a series of
glycoproteins, which belong to a group commonly referred to as the transforming growth
factor (TGF-p) superfamily. The members of this family are responsible for
morphogenetic events involved in the development of tissues and organs. These proteins
are found widely in many different species in a closely similar molecular form and are
not species-specific. Of particular interest in this group of compounds are the BMPs
(Bone Morphogenic Proteins) , Figures 1.12 and 1.13, of which BMP-2 to BMP-6 and
BMP-7 to BMP-9 have osteoinductive properties [86]. Demineralization “unmasks” the
BMPs within DBM, increasing their bioavailability for interaction with mesenchymal
stem cells and rendering demineralized bone matrix (DBM) osteoinductive [94]. The
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collagen matrix which also remains post demineralisation also imparts osteoconductive
behaviour to DBM [94]. Bone induction produced by BMPs occurs in a specific
sequence. The proteins induce chemotaxis of progenitor cells, differentiation of
chondrocytes, calcification of the cartilaginous matrix, angiogenesis and vascular
invasion, differentiation of bone, mineralisation and remodelling [86].

Figure 1.12: BMP on collagen graft: ready to be applied to femoral non-union [95].
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Figure 1.13: Local inflammation at site of BMP application [95].

DBM as stated earlier is osteoinductive but the degree of osteoinductivity may vary
considerably for a number of reasons including donor age, as well as DBM processing
and sterilization. Host physiology can also affect the osteoinduction response to DBM. A
number of studies have shown that aging can negatively impact the ability of DBM to
induce bone formation. Others have shown that treatment with pulsed electromagnetic
fields can increase the amount of new bone produced in response to DBM [96]. Similar to
allograft bone, DBM undergoes processing before implantation including washing,
demineralization with organic solvents, drying and sterilization [97]. Procedures used
can vary greatly with differing factors such as temperature and solvent concentration
during demineralization, ethylene oxide or gamma irradiation sterilization, and frozen
storage or lyophilization and room temperature storage [97].

Processing significantly

decreases the risk of transmitting infection but can simultaneously decrease the graft’s
osteoinductive capacity [98].
Once extracted from bone, DBM exists as a particulate powder. For ease of handling and
use, DBM is often combined with various carriers to form a putty or paste- including
glycerol, poloxamer, gelatin, calcium sulfate, lecithin and hyaluronic acid [97]. Glycerol
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is found in Grafton (Osteotech). It is highly soluble in water, but studies have shown
toxic reactions when high doses were used in rats [99]. Grafton-DBM has been
demonstrated to have both osteoinductive and osteoconductive properties [100].
Poloxamer is found in Dynagraft/Orthoblast (Iso Tis). It is a polymer gel containing
water which becomes more rigid with an increase in temperature. Gelatin is denatured,
fragmented collagen which is mixed with water to form a gel. The properties of this
carrier are dependent on temperature [99]. When DBM, with its small amounts of
osteoinductive proteins, is combined with a carrier, a significant portion of the complex is
the carrier (^85% carrier and -^15% DBM). Current preparations of DBM which are
mixed with a glycerol carrier (Grafton) are very acidic. The low pH may have detrimental
effects on host cells if it is used in large quantities. Other preparations containing
hyaluronic acid (DBX) have a more neutral pH and thus may be less harmful to host
tissues. As a result, the amount of DBM used does not correlate with efficacy because the
different methods of processing and sterilization can affect its osteoinductivity [99].
Currently, only two BMP products, rhBMP-2 (INFUSE, Medtronic) and rhBMP-7 (OP-1,
Stryker), are available for commercial clinical use. Although originally extracted from
cadaveric specimens, to increase yields, these companies now produce BMP from
recombinant gene technology. This has paved the way for companies to produce large
quantities of specific BMPs that isolate the proteins believed to have the greatest potential
for clinical use. Both commercially available options come with a collagen carrier. This
delivery system both provides a scaffolding system that allows bony in-growth, as well as
keeping the liquid-BMP media concentrated at the appropriate anatomical location.
Although the process of healing is dynamic, as the collagen carrier dissolves, the BMP
similarly decreases in concentration over a period of weeks. This allows sufficient time
for the chemotaxis of bone-forming mesenchymal stems cells (MSCs) to be recruited to
the area of healing, however these graft offer no mechanical strength [95]. Although
BMPs are naturally occurring proteins, the concentration delivered for bone formation in
spine fusion surgery is significantly greater than normal physiological levels. This high
dose and concentration of BMP can result in inflammation leading to soft tissue swelling,
radiculitis and unwanted ectopic bone formation (abundant ectopic bone formation may
theoretically cause neural compression). Animal studies on the behaviour of BMP in the
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spinal canal have shown ectopic bone formation and subclinical, histological evidence of
spinal cord compression with demyelination and axonal loss [101]. With several
complications now identified with the use of BMP in spinal arthrodesis, reports are now
being recognised in fracture literature. Boraiah et al. evaluated complications associated
with the use of BMP-2 in complex tibial plateau fractures. In this study, 10 of 17 patients
developed heterotrophic ossification, and four of these patients required additional
operative interventions for ectopic bone removal [102].
This development of heterotopic ossification has also been found with use of BMP-7 [95,
103]. Another factor to take into account when considering BMP is their relative high
cost. Costs of commercially available BMP are volume-dependant, but large volumes can
cost $US 5000 [95].
Despite the fact that natural bone grafts are the gold standard for bone grafting
procedures they are associated

with several inherent drawbacks including the need of

second surgical site, increased surgical times, donor pain, disease transfer risk,
procurement morbidity, immunogenic and limited availability. Clearly an alternative is
required in order to satisfy an ever increasing demand for bone graft material. A synthetic
bone graft substitute provides an alternative to autograft and allograft bone and would
intrinsically ameliorate the primary complications associated with such materials.
Synthetic bone grafts offer advantages over natural bone graft. For instance, such
materials would be non immunogenic, reduce the risk of disease transmission, eliminate
the second surgical site, decrease operation reduce morbidity, offer limitless supply and
ease of fabrication in to various forms, sizes and shapes. An ideal graft would possess the
following inherent qualities- an osteoconductive matrix that provides a nonviable threedimensional framework similar to that of bone, which is amenable to the ingrowth of
blood vessels and osteoprogenitor cells required for bone formation. The ideal graft
candidate should release non toxic dissolution products, possess osteoinductive properties
that aid in the recruitment of the recipient's mesenchymal cells through chemotaxis and
then induce or modulate bone formation, possess osteogenic qualities with the potential to
differentiate cells into osteoblasts. Succinctly the graft should oseointegrate with host
tissue and possess structural integrity that provides mechanical support during healing.
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Currently a number of synthetic bone grafts exist which are discussed below.

1.9

1.9.1

Synthetic bone grafts

Calcium Phosphates

Calcium phosphate (CaP) based bioceramics have received much attention as bone
substitutes due to their chemical similarity to natural bone, their bioactivity and
promising

application

for

less

invasive

orthopaedic

surgeries

[104].

Different

configurations of CaP ceramics are currently available on the market Including,
hydroxyapatite (HA), alpha-tricalcium phosphate (a-TCP), beta-tricalcium phosphate (PTCP) and biphasic calcium phosphate (BCP) [105, 106]; the salient features of each shall
follow respectively.

1.9.2

Hydroxyapatite (HA)

The most used calcium phosphate in implant fabrication is (HA), Caio(P04)6(OH)2, since
it is similar to the mineral component of bone [106-108]. HA exhibits advantageous
properties as a biomaterial, such as biocompatibility, bioactivity, osteoconductivity and
osseointegration the ability to bond directly to bone [108]. HA implants do not appear to
elicit foreign body responses which has been attributed to their close chemical and crystal
resemblance to bone mineral and also posses good bone apposition and the ability to
bond directly to bone [109-112]. Synthetic HA powder can be prepared by numerous
methods including wet chemical procedures, solid-state diffusion and hydrothermal
processes [113]. Synthetic HA, Figure 1.14, can similarly be produced in dense, sintered
or porous forms. The Ca/P ratio of a calcium phosphate plays a key role in determining
the solubility of the material and the acidity of the environment created, the lower the
Ca/P ratio, the larger the acidity of solution and solubility of the material. As the Ca/P
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ratio is increased towards 1.67, which is the value of stoichiometric HA, the solubility of
the material decreases [104, 106, 108]. A potential limitation of HA bone graft substitutes
is their low solubility and slow in vivo resorption profiles [61, 105], where calcined HA
implants have been retrieved from bone defect sites many years post implantation [114].

k. w...

Figure 1.14: Cerabone® in block and particulate form [127]

It also appears that the morphology of the HA implant plays a role in the rate of
bioactivity and resorption, with porous implants appearing more bioactive than larger
blocks of HA. It has also been suggested that the long term presence of the material can
potentially limit bone formation and make accurate radiological assessments of new bone
or healing difficult [61]. Other disadvantages include limited osteoinductive properties
[72], and certain mechanical properties preventing use in load bearing applications [115],
for example the fracture toughness of HA has a value of ~ 1.0 MPa m

, compared to

human bone whose value is measured at 2-12 MPa m'^^ [114]. Generally, fracture
toughness increases with decreasing grain size. However, in some materials, especially
noncubic ceramics, the fracture toughness reaches a maximum and rapidly drops with
decreasing grain size. For example, Halouani et al. investigated the fracture toughness of
pure hot-pressed HA with grain sizes between 0.2 and 1.2 pm [116]. There appeared to
be two distinct trends, where fracture toughness increased with decreasing grain size
above -0.4 pm and subsequently decreased with decreasing grain size. The maximum
fracture toughness measured was 1.20 +/- 0.05 MPa m

at 0.4 pm [116]. Fracture energy
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of HA bioceramics is in the range of 2.3-20 J/m , while the Weibull modulus is low (~512) in wet environments. This indicates that HA behaves as a typical brittle ceramic and
indicates a low reliability of HA implants [117]. Even though

HA does show some

excellent mechanical properties such as bending, compressive and tensile strengths in
dense HA bioceramics (38-250 MPa, 120-900 MPa and 38-300 MPa, respectively
[117]) to that of bone, load bearing applications are still contraindicated due to its fracture
toughness. Similar values for porous HA bioceramics are in the ranges of 2-11 MPa, 2100 MPa and ~3 MPa, respectively [117]. Strength was found to increase with increasing
Ca/P ratio, reaching the maximum value around Ca/P ~1.67 (stoichiometric HA) and
decreases suddenly when Ca/P > 1.67 [117]. Furthermore, the strength decreases almost
exponentially with porosity increasing [118,

119], where porous materials are

considerably less fatigue resistant than dense ones [120]. Young’s modulus of dense HA
bioceramics is in the range of 35-120 GPa, which more or less similar to those of the
most resistant components of the natural calcified tissues (dental enamel:~74 GPa,
dentine:~21 GPa, compact bone:~18-22 GPa), however the mechanical strengths above
are dramatically diminished in the case of porous bulk compacts [121], whilst Vickers
hardness of dense HA bioceramics has been measured to be within 3-7 GPa [117]. HA
grafts do not exhibit osteoinductive properties and in an effort to counteract this, work is
currently underway to increase osteoinduction by the seeding of cells such as human
mesenchymal stem cells, and recombinant human osteogenic protein-1 (BMP-7) [122].
HA bone grafts do not offer any antibacterial efficacy and site infections have been noted
when Endobon®was used as a bone defect filler in contraindicated sites [123]. Currently
work is underway to induce the anti-bacterial efficacy of HA by incorporating ions such
as silver, zinc and copper or by the addition of antibiotics [124, 125]. Examples of
commercially available HA bone grafts are listed in Table 1.21.
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Table 1.2: Commercially available bone grafts based on HA with attributes [44, 126].

Product

Cerabone

Company

Origin

Pore size
(pm)

Osteoconductive

Biodegradable

(%)

Porosity

Fame
Medical
Products
BV

Bovine

No data

100-1500

Yes

No data

Endobon®

Biomet

Bovine

60-80

390-1360

Yes

No

Ostim®

Heraeus

Synthetic
60%
HA/40%
H2O

No data

No data

Yes

Yes

Pro
Osteon
500®

Biomet.

Coral

No data

280-770

Yes

Yes

®

Summary

advantages:

Biocompatible,

bioactive,

osteoconductive

and

shows

osseointegration.
Summary disadvantages: Low solubility, slow in vivo resorption profile, poor
osteoinductive properties, non load bearing and no therapeutic properties.

1.9.3

Tricalcium Phosphate

Tricalcium phosphate (TCP) is classified as a biodegradable bioceramic with the
chemical formula Ca3(P04)2 [128]. TCP consists of four polymorphs, the most common
being a and p [129], where both phases have an identical chemical composition but differ
in crystallographic structure [129]. p-Tricalcium phosphate can be obtained by a thermal
treatment above at least 650°C and below 1125°C [129, 130]. Several routes are possible,
for example: (a) mixture of an equimolar amount of Dicalcium phosphate and
precipitated HA (PHA) (Ca:P ratio = 1.67) and subsequent calcination; (b) calcination of
PHA (Ca:P ratio 1.50). P-TCP has an apatite structure and corresponds to a PHA with a
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Ca:P molar ratio of 1.50. It has been extensively used as bone substitute, either as
granules or as blocks. a-TCP is normally obtained by heating j3-TCP above 1125°C or
1166°C, and quenching it to prevent the reverse transformation. a-TCP is readily
transformed into PHA (Ca:P molar ratio of 1.50) in an aqueous solution. This property is
used to make apatite CPC. a-TCP bone substitutes are sold in the forms of granules,
blocks and powders. The literature contains conflicting information regarding the
solubility and degradation rates of both phases. Horch et al [131] state that in contrast to
a-TCP, p-TCP is thermodynamically stable in a biological environment and within a
normal temperature range, despite a similar degree of solubility, biodegradation of p-TCP
is faster than that of a-TCP because the latter form hydrolyses either partially or
completely to hydroxyapatite Ca5[0H(P04)3]. The resulting crystals have a nonphysiological morphology, are not resorbed due to their very low level of solubility and
may enter the lymphatic system by phagocytosis. In contrast, Bohner et al., [129] state
that due to the difference in crystallographic structure a-TCP is much more soluble and
biodegradable than P-TCP. However, based on the evidence reported in the literature it is
widely accepted that a-TCP is much more soluble due to its crystallography and
hydrolyses partially or completely into hydroxyapatite in a biological environment [129,
132-134]. The literature is also conflicted with respect to the mechanisms of material
degradation, where degradation is said to occur by osteoclastic activity [129] and also
claims that osteoclasts are thought to play only a minor role in the degradation of both
forms [135]. Owing to a lower Ca:P ratio in TCP (Ca:P 1.5), to that of HA (Ca:P 1.67),
TCP is theoretically more soluble than HA [104, 106, 108]. TCP with Ca/P ratio of 1.5 is
more rapidly resorbed than HA. Mixtures of HA and TCP, known as biphasic calcium
phosphate (BCP), have been investigated as bone substitutes and the higher the TCP
content in BCP, the higher the dissolution rate [128, 129]. Most commercial products,
e.g. Triosite (Zimmer, USA) and BCP (Sofamor Danek, France), contain 60% HA and
40% P-TCP [129]. The biocompatibility of P-TCP has been demonstrated in several
studies. Kondo et al., found that highly purified p-TCP provided early bone conduction
post implantation in rat femoral condyle, followed by bioresorption of p-TCP and the
replacement of large parts of the p-TCP with newly formed bone. The authors further
showed that osteoblasts, osteoclasts, and mononuclear macrophages adhered to p-TCP
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[136] . Von Doernberg et al implanted p-TCP blocks of four macropore diameters (150,
260, 510, and 1220 pm) in metaphysial or epiphysial defects in sheep. All implants were
said to have been tolerated very well as evidenced by the low amount of inflammatory
cells and the absence of macroscopic signs of inflammation. All grafts were found to be
biocompatible and osteoconductive [137]. Walsh et al., using a bilateral tibial defect in
rabbits, demonstrated p-TCP to be osteoconductive and support new bone formation [61].
The biocompatibility of a-TCP has been demonstrated and its capability of supporting the
in vitro growth and differentiation of human-osteoblast like cells [138]. In vivo studies
have indicated that a-TCP supports new bone growth in tibial head defects in minipigs,
however a mild inflammatory reaction was noted [139]. An in vitro study by dos Santos
et al. [140] on the cytotoxic effect of calcium phosphate cement based on a-tricalcium
phosphate, immersed for different lengths of time in simulated body fluid (SBF), showed
that the extracts were cytotoxic to Chinese hamster ovary (CHO) cells, however the
cytotoxicity was determined to be related to the pH of the environment, and further in
vivo work would be required. TCP is not believed to possess the ability to treat conditions
such as osteoporosis, given that TCP does not show excellent osteoinductive qualities.
Studies by Otsuka et al. and Ito et al. [141-143] where zinc was substituted for calcium in
an a pZnTCP and injected into female Wistar rats, indicated that pZnTCP has the
potential for use in the local treatment of zinc deficiency diseases such as zincdeficiency-type osteopenia, or other bone mineral density related disease such as
osteoporosis. Another inherent drawback of TCP is the lack of antibacterial efficacy of its
degradation products. Bacterial infection at implant sites has a significant impact in terms
of morbidity, mortality and medical cost [144]; and implant infections are frequently a
cause of implant failure [145]. HA and P-tricalcium phosphate (p-TCP) have induced
anti-bacterial efficacy by incorporating ions such as silver, zinc and copper or by the
addition of antibiotics [124, 146]. Any antibacterial promise shown by TCP is due to the
inclusion of the stimulatory ions. Figure 1.15 shows the various forms of the p-TCP
based Cerasorb® available.
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Table 1.3: Commercially available bone grafts based on TCP with attributes [44, 126].

Product

Company

Porosity
(%)

Pore
size
(pm)

Osteo-

Bio-

conductive

degradable

Synthes
(USA) and
Mathys
(Europe

60-75

100400

Yes

Yes

Vitoss®

Orthovita

88-92

1-1000

Yes

Yes

Cerasorb
M®

Curasao
(Europe)

65

5-500

Yes

Yes

ChronO
Stm

Figure 1.15: Cerasorb® in particulate and block form [147]

Summary advantages: Osteoconductive, biocompatible, quicker resorption that HA.
Summary disadvantages:

Poor

osteoinductive

properties,

poor

osteoconductive

properties, non-load bearing, degradation products shown to be mildly inflammatory and
no therapeutic properties.

1.9.4

Calcium Sulphate

Calcium sulfate (CaS04), better known as plaster of Paris, results from the calcination of
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gypsum (CaS04-2H20), which partially dehydrates to produce a hemihydrate (CaS04'l/2
H2O) [126, 148]. It is a non physiological salt which has been used as a bone void filler
since the late 1800’s [44, 126]. Since the clinical use of calcium sulfate predated the
existence of the FDA, it was designated a class 11 “special controls” device in 1998,
requiring institution of voluntary consensus standards for its use [148]. The consensus
findings designate “surgical grade” CaS04 as reflecting purity and consistency of the
material. The first calcium sulfate marketed was Osteoset (Wright Medical Technology,
Inc, Arlington, TN), available in pellet form, and more recently as an injectable
(Minimally Invasive Injectable Graft, MUG). Other marketed calcium sulfate products
include Calceon (Synthes USA) in pellet form, and BonePlast (InterporeCross), available
in pellet, block, and injectable forms [44]. Calcium sulphates appear to function as a
resorbable osteoconductive scaffold that provides the structural framework necessary for
angiogenesis and osteogenesis while preventing soft tissue invasion by acting as a void
filler; however, they lack not only osteogenic but also osteoinductive properties [126,
149]. Calcium sulphate is considered biocompatible, eliciting little or no macrophagic
reaction, and has a rapid rate of dissolution where it is fully dissolved within 6-12 weeks,
the rate of resorption is however dependant on formulation and configuration of the
material, as well as the size and local environment of the host defect [126, 148, 150].
Whereas fast resorption occurs by dissolution and arguably renders no advantage to bone
healing, replacement with trabecular bone has been shown [151]. It is currently approved
for filling metaphyseal defects. Calcium sulfate potentially renders immediate stability,
but requires augmented fixation, given its insufficient persistence as a scaffold [44].
Kelly and Wilkins [152] used MUG® X3 to graft bone defects of the distal tibia, patella,
calcaneus, ileum, femur and humerus. But MUG® may also be used to treat both proximal
[153, 154] and distal tibia fractures [154]. Twenty-one tibia plateau fractures were treated
with MUG® X3 and internal fixation, resulting in complete fracture healing and graft
resorption after 12 weeks [153]. OsteoSet® fills defects of the humerus, radius, ulna,
femur, tibia, fibula and calcaneus [126]. However, OsteoSet® may not provide sufficient
biomechanical support as several stress fractures after grafting have been reported [151,
155, 156], and a self-limiting local sterile inflammatory reaction occurred in 4-20% of
graft sites [126]. In one case convulsions, and a complication of elevated calcium, were
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reported after the use of OsteoSet® in a lumbar fracture [126]. Also Bone Plast® may be
indicated as it has been used in pelvic, humerus, calcaneus and femoral bone after
aspiration of recurrent aneurysmal bone cysts [157]. The compressive strengths of
OsteoSet® and MUG® X3 were attained in similar experiments, using in vivo samples
which were implanted for 26 weeks in the humerus of dogs. The compressive strength of
OsteoSet® was 0.6-0.9 MPa [154, 158, 159] and of MIIG® X3 0.6 MPa [154]. Young’s
modulus of OsteoSet® was 59 MPa [158].

Summary advantages: Biocompatible.
Summary disadvantages: Quickly resorbed, non load bearing, poor osteoconductivity,
poor osseointegration and no therapeutic effects

1.9.5

Wollastonite

Wollastonite is a calcium silicate ceramic with the chemical formula CaSi03.
Wollastonite has been studied for its biocompatibility and bone bonding ability. Several
studies have shown wollastonite’s ability to form an apatite layer on its surface both in

vitro in SBF (simulated body ftuid) and in vivo which is an indication of its bioactivity.
Figure 1.16 shows histological morphologies of the interface between wollastonite
coatings and bone tissue after implantation in cortical bone. Liu et al. [160] demonstrated
wollastonite’s ability to form an apatite layer when the calcium silicate was deposited
onto Ti-6A1-4V substrate by plasma spraying. Following immersion into SBF solution
bone-like apatite formed on the surface of the soaked plasma-sprayed wollastonite
coatings, however this must be clarified as the samples were initially soaked in lactic acid
for 1,3 and 7 days followed by immersion in SBF for 4 days. However another study
carried out on wollastonite coated on a Ti-6A1-4V substrates, where post coating the
coated coupons were immersed directly in SBF and an apatite layer was found to form
[161]. The potential of wollastonite to exhibit biocompatibility was demonstrated by

Risbud et al. [162] in vitro. A wollastonite/poly(butylene terepthalate) composite was
placed in direct cell contact with NIH3T3 fibroblast. The test did not show deleterious
effects on the cells morphology and DNA integrity indicating its potential compatibility.
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The bone bonding ability of Wollastonite has been shown in vivo, where Ti-6AI-4V rods
plasma sprayed in wollastonite were implanted in six adult dogs weighing 12-15 kg’s.
Following harvest it was found that a Ca-P layer was formed on the surface of the
coating. The EDS analysis demonstrates that this newly formed layer was not a
biologically equivalent HA, but is a precursor phase with Ca/P ratio (about 1.43) similar
to that of bone apatite. A silica-rich intermediate layer was observed between apatite and
the wollastonite coating, which was suggested, was the result of the surface reaction of
wollastonite with surrounding body fluids. New bone growth was also observed. It is also
noted that there were no inflammatory cells or acute inflammation processes at the
interface and no indication of fibrous tissue development around the implant, which
points to the biocompatibility of wollastonite [163]. Another study where an
intamedullary plug fabricated form an apatite wollastonite glass ceramic was implanted in
22 adult beagle dogs demonstrated no inflammatory response to the implants. At 12
months, the walls of the AW-GC pores had been partially resorbed and at 24 months they
were almost fully replaced by newly-formed bone. In the 24-month specimens, backscattered SEM of the interface between the bone and AW-GC showed a Ca-P-rich layer
10 pm thick.
Three dimensional scaffolds have also been fabricated from wollastonite. In one study Ni
and co-workers [164] investigated bioactive porous CaSiOs scaffolds and examined their
effects on proliferation and differentiation of osteoblast-like cells. Osteoblast-like cells
were seeded into the CaSiOs scaffolds. Results show that the proliferation rate and
alkaline phosphatase (ALP) activity of the cells in the scaffolds were improved as
compared to the p-tri calcium phosphate (beta-TCP) control scaffold, however other
studies have shown that the mechanical strength of wollastonite scaffolds at just over 48
MPa in compression at a porosity of 53% [74] is far short of what is required for a load
bearing indication. The shortcomings of wollastonite regarding its antibacterial efficacy
has been noted in the literature [165]. Efforts have been made to improve the antibacterial
properties of biocompatible wollastonite by the incorporation of ions such as silver and
titanium [165, 166], and while wollastonite does demonstrate biocompatibility and
bioactivity, its mechanical properties and in particular low fracture toughness limit its
clinical applications [167]. Lacking to date in the available literature are examples of the
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efficacy of wollastonite in the regeneration of healthy bone in osteopenic states, or the
demonstration of any therapeutic benefits.

Bone'

Figure 1.16: Histological morphologies of the interface between wollastonite coatings and bone tissue after
implantation in cortical bone for: (a) 1 and (b) 3 months. WC-wollastonite coating, NB^newly formed
bone [163]

Summary advantages: Biocompatible, osteoconductive and osseointegration properties.
Summary disadvantages: Non load bearing and no therapeutic effects.

1.10 Glass formation
Various definitions of glass have been proposed such as “glass is an inorganic product of
fusion which has cooled to a rigid condition without crystallising”, however this
definition excludes organic substances which can form supercooled materials without
crystallising and also amorphous materials prepared by methods other than cooling.
Another definition states that “an amorphous substance is one that in which, long range
order in the atomic arrangement does not exist over distances greater than that of lOnm”
which does not take into account polycrystalline materials with a long range order less
than 10 nm [209]. The current accepted definition of a glass is “an amorphous solid
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completely lacking in long range, periodic atomic structure, and exhibiting a region of
glass transformation behaviour”, therefore any material, inorganic, organic or metallic,
formed by any technique, which exhibits glass transformation behaviour is a glass [210].
As our understanding of glass technology progressed over time so too did the theories to
explain how or why glasses formed. Classical nucleation theory was developed where the
theory consists of two parts: 1) a thermodynamic expression for the free energy of
formation of a liquid droplet, and 2) a kinetic part which governs the size evolution of a
droplet. The first part leads to concept of critical radius and the definition of the nucleus,
while the second leads to an expression for the nucleation rate. The first part of this
theory been named as the “Structural theories of glass formation” and the other as the
“Kinetic theory of glass formation” [210]. Additional information can be found in
Appendix D.

1.11 Glass-Ceramics
Glass-ceramics are polycrystalline solids prepared by the controlled crystallisation of
glasses. Crystallisation is accomplished by subjecting suitable glasses to a carefully
regulated heat treatment schedule which results in the nucleation and growth of crystal
phases within the glass. It has been suggested by certain authors [223] that the
crystallisation of bioactive glasses is widely regarded as being undesirable since
crystallisation inherently reduces bioactivity since crystal phases are in a lower energy
state, the structure will be more tightly packed and the bonding will be stronger than the
equivalent glass composition, however it has also been shown by Boccaccini et al. [63]
that the bioactivity of Bioglass® is not compromised by crystallisation as crystalline
Bioglass has been shown to transform into a bioactive and biodegradable amorphous
calcium phosphate upon immersion in SBF. In many cases the crystallisation process can
be taken almost to completion, however residual glass may remain [209, 220]. Without
controlled crystallisation, glass ceramics with the desired characteristics could not be
produced [224], for example it is especially important in order to achieve an optimum
mechanical strength, to produce a fine grained microstructure, containing crystal of small
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dimensions which are closely interlocked [209]. As stated earlier the precursor to
crystallisation in a glass is nucleation, nucleation may occur spontaneously or it may be
induced artificially. Nucleation can be induced by different methods such as agitation,
mechanical shock, and extreme pressures within solutions [225]. Two methods of
nucleation exist which may lead to crystallisation of glasses, the terms used are Primary
and Secondary nucleation. If a solution contains no foreign particles or crystals of its own
type, a nucleus can only be formed by homogeneous nucleation. If foreign surfaces
(particles) are present in the system, it is possible for a liquid to form on those surfaces
nuclei at less supersaturation compared to the case of homogeneous nucleation. This
process is called heterogeneous nucleation. It has been observed that nuclei occur even at
very low supersaturations [225]. This is the case when crystals of the same material exist
and act as attrition agents or seed crystals. Such nuclei are known as secondary nuclei.
Fig. 4.3.1 outlines the flow mentioned.

NUCLEATION

i

I

PRIMARY

SECONDARY
(induced by crystals)

I

r
IfOVIOGENEOUS
(spontaneous)

HETEROGENEOUS
(induced by foreign
particles)

Fig 4.7 : Mechanisms of nucleation [226].

Additional information can be found in Appendix D.
1.11.1 Sintering of glass-ceramics

One of the main disadvantages of current bone grafts which have been alluded to in
previous sections is that of mechanical strength. Many grafts come in the forms of
particulates, injectable cements and porous blocks but none have been indicated for load
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bearing applications [114, 151, 155, 156]. Powders do not fill space efficiently as there is
typically porosity between particles, powder structures pre-sintering are termed green
bodies [231]. Mechanical properties are important in many applications; pores reduce the
effective cross-sectional area and affect strength negatively. The elimination of pores is
an obvious requirement to obtain high mechanical strength [228] A method which has
been employed in order to increase the mechanical strength of glass and glass-ceramic
grafts is that of sintering [232-234]. Sintering is a thermal treatment for bonding particles
into a coherent, predominantly solid structure via mass transport events that often occur
on the atomic scale. The bonding leads to improved mechanical strength and a lower
system energy [228]. Sintering of packed powders generally occurs when heated to
temperatures in excess of approximately half of the absolute melting temperature of the
material concerned [231]. Sintering can occur in two forms, solid state sintering and
liquid phase sintering [228]. Additional information can be found in Appendix E.

1.12 Strontium and Zinc Doping in Bone Graft Materials

Research into incorporating zinc and strontium into glass structures for their therapeutic
benefit has steadily increased over the past number of years. Several studies including
those by Lotfibakhshaiesh et ai, [235], Fredholm et al, [236] and Wu et al, [237] have
been carried out where successful inclusion of strontium into the glass matrix has
occurred. Other studies including those by Ito et al, [142], Bandyopadhyay et al, [238]
and Haimi et al., [239] demonstrate that zinc can be incorporated into both glass and
ceramic systems with positive effects. Recently calcium silicate based glasses have been
developed which incorporate both zinc and strontium in its structure, giving a synergistic
effect to the glass. These glasses have been found to bond to bone in vivo [240], and
studies by Murphy et al, [241]have demonstrated their efficacy against bacteria such as
Pseudomonas aeruginosa and Staphylococcus epidermidis which are known to occur at
sites of orthopaedic implantation. Murphy at al., [242] further demonstrated the potential
therapeutic effect these glasses may impart on bone strength. In an in vitro study it was
shown that the level of strontium divalent ions release from the glasses as they
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degraded in physiologically simulated conditions was within levels known to have
therapeutic effects on osteoporotic bone. It has clearly been demonstrated that these
glasses have the potential as a therapeutic bone graft which inhibits infection and
promotes bone growth. However the Sr-doped zinc-silicate glasses, which have
demonstrated exceptional potential as bioactive bone substitutes, have limitations. The
studies by Murphy and Boyd were carried out with particulate glass particles. Particulates
are suitable for numerous indications but are contraindicated where the implant may be
required to bear loads. Additionally, the glass particulates do not offer a three
dimensional structure to support tissue regeneration and integration. Thus, the
investigation of a load bearing, reticulated construct based on the calcium-strontium-zincsilicate composition is warranted and may provide for an advance toward the ideal tissue
engineering graft.

1.12.1 Zinc

1.12.1.1

Biological role of zinc

Zinc (Zn) is a trace element essential for cell proliferation and differentiation. It is a
structural constituent of many enzymes and proteins, including metabolic enzymes,
transcription factors, and cellular signalling proteins, and has a total body content of 2-4
grams [243]. It is found in all body tissues with 85% of the whole body zinc in muscle
and bone, 11% in the skin and the liver and the remaining in all the other tissues. In
multicellular organisms, virtually all zinc is intracellular, 30-40% is located in the
nucleus, 50% in the cytoplasm, organelles and specialized vesicles (for digestive enzymes
or hormone storage) and the remainder in the cell membrane. Human zinc requirement is
estimated at 15 mg/day [244]. Zinc is required for the biological function of more than
300 enzymes. In particular, Zn is essential and directly involved in catalysis and co
catalysis by the enzymes, which control many cell processes including DNA synthesis,
normal

growth,

brain

development,

behavioural

response,

reproduction,

fetal
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development, membrane stability, bone formation and wound healing [245]. Zinc, due to
its physico-chemical properties, plays structural and functional roles in several proteins
involved in DNA replication and reverse transcription and it is critical for the function of
a number of metalloproteins [245]. Zinc ions are hydrophilic and do not cross cell
membranes by passive diffusion. In general, transport has been described having both
saturable and non-saturable components, depending on the zinc concentrations present.
Zinc ions exist in the expression of genetic information, in storage, synthesis and action
of peptide hormones and structure maintenance of chromatin and biomembranes [244].
Zinc is considered crucial for immune responses. It influences and interacts specifically
with components of the immune system, a highly proliferative system [246]. Zinc is
relevant for immunocompetence, because it bounds to enzymes, proteins and peptides
with different binding affinity [247]. Zinc is transported to cells bound to proteins,
predominantly albumin, a2-macroglobulin (large plasma protein) and transferrine
(protein of the beta globulin group), but only free zinc ions seem to be biologically active
[248].The function of a2-macroglobulin is regulated by zinc itself Zinc alters the
structure of a2-macroglobulin and enhances its interaction with cytokines and proteases,
thus indirectly influencing immune function. Impairment of immune function has been
attributed to zinc deficiency and may be the most common cause of secondary
immunodeficiency states in

humans [244]. Zinc deficiency produces

impaired

haemostasis due to defective platelet aggregation, a decrease in T-cell number and the
response of T-lymphocytes to phytomitogens. In fact, Zn is the only naturally occurring
lymphocytic mitogen [244, 249]. Zinc release in vivo has been shown to be effective
against bacteria which cause infection

[250]

such as

Staphylococcus aureus,

Streptococcus pyogenes, Escherichia coli, and Streptococcus viridans. The antibacterial
action of zinc is further demonstrated by the intra-prostatic injection of zinc in a rat
model [251]. Adult male Wister rats were made to develop chronic bacterial prostatitis by
the instillation of Escherichia coli bacterial suspension into the prostatic urethra, however
the average infection rates of the zinc treated animals was noted to be significantly lower
that control animals receiving no zinc injections. The decreased rate of infection was
ascribed to increased prostatic zinc level. Deficiencies in Zn also accompany many
diseases such as gastrointestinal disorders, renal disease, sickle cell anaemia, alcoholism,
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some cancer types, AIDS, burns and others [249, 252-256]. The beneficial effect of zinc
supplementation on the immune system is also documented in both minor and severe
infections, including the common cold and cough, and in some pathologies, including
acrodermatitis enteropathica and sickle-cell anaemia, that are characterized by increased
incidence of infection [245].

1.12.1.2

Zinc in bone

Zinc has been demonstrated to be essential for normal growth of the human and animal
skeleton and to play an important role in bone metabolism [257-259]. The mean zinc
content in bone has been quantified as 110-300 pg/kg [260]. Zinc can influence bone
mineralization either directly, as a divalent cation acting on nucleation and mineral
growth, or indirectly, as a cofactor of enzymes like alkaline phosphatase or other
metalloenzymes involved in the process [260]. O'Dell et al. [261] reported defective
hypertrophic chondrocyte proliferation related to low dietary zinc, providing additional
evidence for an osteogenic zinc requirement. Bone formation in zinc-deficient animals is
characterized by retarded growth plate activity [262] and is associated with reduced
cancellous and trabecular volume [263]. Zinc is known to increase the synthesis and the
effect on target tissues of growth factors such as insulin-like growth factor 1 (IGF-I)
[264]. It stimulates the proliferation and the differentiation of osteoblasts regulates the
activity of the calcium-regulating hormones 1-25 vitamin D and parathormone (PTH),
which increases calcemia [265], alkaline phosphatase and osteocalcin, which decreases
calcemia [259]. Studies also suggest that vitamins (vitamin A and vitamin D) play a role
in the metabolism of bone under the regulation of zinc ions [266]. Yamaguchi et al.,
demonstrated that Zn has a stimulatory effect on the mRNA expression of Runx2 - a
transcription factor involved in osteoblastic cell differentiation [267]. This effect was
completely blocked by the presence of cycloheximide - an inhibitor of protein synthesis
at the transcriptional level [267, 268], suggesting that the zinc-induced gene expression
was as a result of newly synthesised proteins [269]. Zinc has also been demonstrated to
have a positive effect on the mechanical properties of bone. Ovesen et al [266]
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demonstrated that zinc supplementation in male induced an increase of bone strength in
both the femoral neck and the femoral diaphysis. Thus it is evident that zinc leads to the
up-regulation of osteoblastic activity and is essential for healthy bone formation. As well
as demonstrating a pro osteoblastic function, zinc is also known to have an inhibitory
effect on bone resorption [270]. Osteoclasts are the principal resorptive cells of bone that
are derived from the monocyte-macrophage lineage [271]. Most adult bone diseases, such
as osteoporosis and periodontal disease, are due to an imbalance in bone remodelling,
which favours resorption and loss of bone mass. Zinc has been shown to have a positive
effect on skeletal growth by favouring bone formation [272]. Depletion of zinc in bone
cells has been shown in 30 week old rats, versus those which were 3 weeks old [273], and
this decrease has been associated with the development of bone loss with increasing age
[274]. Osteoporotic patients have been shown to have decreased levels of skeletal zinc in
comparison to healthy individuals [275, 276], and women with osteoporosis have been
shown to excrete larger amounts of zinc in their urine [277]. Zinc has been well
established to act as an inhibitor of osteoclast formation and activity. Hadley et al. [278]
demonstrated that

femur osteoclastic resorption

potential,

indicated

by matrix

metalloproteinases (MMP-2 and MMP-9) and carbonic anhydrase-2 activities decreased
with increasing dietary zinc in growing rats, whilst Yamaguchi et al. examined the effect
of zinc on the gene expression of molecules related to bone resorption - tartrate resistant
acid phosphatase (TRAP) and cathepsin K [276]. The results of the aforementioned
studies indicate the suppressed expression of enzymes associated with the degradation of
the bone matrix, showing zinc to have a positive effect on skeletal growth by stimulation
of osteogenesis, accompanied by a parallel inhibition of osteoclastogenesis. Zinc is
known to stimulate the gene expression and release of osteoprotegerin (OPG) in
osteoblast cells which is a natural antagonist of RANKL thus down regulating its activity
in pre-osteoclastic cells [279]. It has also been suggested that a possible mechanism by
which zinc inhibits osteoclast function is stimulation of an increase in intracellular
calcium concentration [280]. Calcium, though not as potent as zinc, has been shown to
inhibit resorption [280]. Zinc has also shown the ability to block the proton channel in
osteoclasts, which in turn inhibits proton secretion [281]. Similar to osteoblasts, zinc
effects on osteoclasts appear multi-facetted, culminating in the down regulation of the
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cells.

1.12.1.3

Zinc in biomaterials

Due to the desired physiological effects zinc has demonstrated such as gene regulation,
anti-inflammatory effects and bone growth stimulation etc, a logical next step is to
introduce those zinc induced benefits in an orthopaedic role for bone augmentation.
Ramaswamya et al. [282] studied a calcium silicate which incorporated zinc to form
hardystonite. The results showed that the zinc doped calcium silicate supported HOB
(human osteoblast-like cells) attachment with a well-organized cytoskeleton structure,
and significantly increased cellular proliferation and differentiation compared to calcium
silicate. In addition, hardystonite showed increased expression levels of osteoblast-related
mRNAs (alkaline phosphatase, collagen type I, osteocalcin, receptor activator of NFkB
ligand and osteoprotegerin) compared to calcium silicate, this was attributed to the slower
rate of degradation due to the addition of zinc, which also lead to increased bending
strength and fracture toughness. Wang et al. [283] showed that zinc-containing apatite
layers precipitated on the Ti external fixation rods caused a significant increase in
fibroblastic proliferation, osteoblastic proliferation and differentiation in vitro using
MC3T3-E1 cells. Ito et al. [142] incorporated zinc into tricalcium phosphate (pTCP)/hydroxyapatite (HA) composites leading to enhanced osteoblastic cell proliferation
and differentiation in vitro and demonstrated that the level of zinc did not inhibit the
formation of a calcium phosphate layer in vivo demonstrating the ability to bond to bone.
Lusvardi et al. [284] studied zinc-doped phosphosilicate glasses in vitro and in vivo, the
results showing good bioactivity and osteogenic potential and again demonstrated that the
addition of zinc did not compromise on apatite layer formation. Aina et al. highlighted
the reduction in the overall leaching activity of zinc-containing glasses leading to a
decrease in solution pH, suggesting this may have a beneficial effect on cytocompatibility
[285]. In a subsequent paper, Aina et al. demonstrated that the levels of zinc released
from their glass compositions induced cytotoxicity in vitro [285], suggesting the cell
damage was via oxidative stress. This emphasizes the need to control zinc release from
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bioactive glasses in order to impart beneficial and therapeutic effects in vitro and in vivo.
Yamada et al. [286] demonstrated a zinc doped TCP inhibited osteoclast activity on
mature osteoclasts isolated from rabbit bone marrow, with the zinc release attributed with
the inhibitory effect. Zinc has been shown to be toxic to a broad range of pathogenic
bacteria, including Staphylococci, the most commonly found genus in infected hip joints
[287, 288]. Boyd et al. demonstrated good antibacterial efficacy against Streptococcus
mutans and Actinomyces viscosus in glass polyalkenoate cements by incorporating zinc
[289]. Similarly, Chung et al. produced zinc-doped HA, resulting in good antibacterial
effects against Streptococcus strains [290]. Thus, incorporating zinc into an orthopaedic
biomaterial at the appropriate concentration may not only aid in stimulating bone
regeneration and repair, but may have the added effect of imparting antibacterial
properties.

1.12.2 Strontium

1.12.2.1

Biological role of Strontium

Strontium (Sr) is a trace element which has not been demonstrated to be essential in
humans [291]. The average body content of Sr is approximately 0.32g/70 kg body weight
[291] and under normal physiological conditions, 99.1% of this Sr is distributed in bone
[292] . The gastrointestinal tract represents the main route of entry of strontium into the
body. The gastrointestinal absorption of strontium largely depends on age and may vary
from 90% of the element's dietary intake in infants to only 10% in the elderly [293].
Discrimination in favour of calcium absorption develops over time in rats and has been
suggested as an explanation for the age-related differences in Sr absorption [294]. Several
mechanisms for strontium transport through the intestinal wall have been postulated.
Some authors suggested that in contrast to calcium, strontium is absorbed entirely via
passive diffusion, i.e., paracellular transport [295, 296]. However, Papworth et al. [297]
proposed two routes of entry for the element: carrier-mediated and diffusion-mediated.
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With the exception of infants, it can generally be stated that strontium is absorbed to a
lower extent than calcium, the amount of Sr in the skeleton being only 3.5% of the
calcium molar content [291, 292]. Strontium is excreted in urine, sharing common renal
tubular transport paths with calcium [291], and to a lesser extent in faeces and sweat. In
healthy adults, the total clearance varies between 9.4 ml/minute and 11.7 ml/minute,
while the renal clearance appears to vary between 4.0 ml/minute and 5.4 ml/minute [298].
Sr is excreted by the kidney at a much higher rate than calcium and this is thought to be
related to its larger atomic size [291, 299]. Toxic symptoms due to Sr overdose have not
been reported in man [291]. However, in rats with renal failure Schrooten et al., reported
that high Sr levels lead to bone mineralization defects [300]. Similarly, Morohashi et al,
demonstrated that high Sr doses of 875pmol/day disturbed calcium metabolism leading to
hypocalcaemia [301].

In endocrinological systems, Sr tends to mimic the actions of

calcium, but to a weaker extent [291]. The role of strontium in the body is not yet fully
understood, however its role in bone is better appreciated and will be discussed further.
1.12.2.2

Strontium in bone

Strontium is chemically and physically closely related to calcium (Ca), it is a natural
bone-seeking trace element that accumulates in the skeleton [302]. Strontium is
incorporated into bone at the same rate as calcium [303]. The distribution of strontium in
the skeleton is directly proportional to plasma levels [66]. In monkeys receiving
strontium ranelate, bone strontium content increases dose-dependently, as shown by Xray microanalysis [304]. However, bone strontium content depends on the duration of
exposure, gender, and skeletal site, and is preferably incorporated into trabecular bone
[299]. A study by Raffalt et al., in which dogs were treated with various concentrations of
Sr malonate, demonstrated Sr uptake by bone to be dose-dependent, but at high doses
showed saturation tendencies [305]. MacDonald et al. [306] observed a rapid decrease in
the Ca^VSr^^ ratio in rat and mouse femur during the first day of oral administration of
strontium, followed by a much slower decrease in ratios during 6-8 weeks. The
investigators postulated that Sr

is taken up into bone by two different mechanisms: (1)

an initial rapid mode, depending on osteoblastic activity, which is eventually saturated,
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and whereby

is taken up by ionic exchange with bone

binding of

to

preosteoid proteins, or combinations of these; and (2) a second slower mechanism
involving the incorporation of Sr^^ into the crystal lattice of the bone mineral. The
concept of two different phases involved in the uptake of strontium into bone has since
been generally accepted — that is, a relatively rapid uptake into new bone and long-term
exchange processes in old bone [307]. More recently, similar results were obtained in a
human trial, also showing cancellous bone to contain a higher proportion of Sr than
cortical bone [308].

This is thought to be related to the higher remodelling rate of

cancellous bone, thus being proportionally richer in newly formed tissue or the greater
surface-to-volume ratio [308].

1.12.2.3

Role of strontium in normal bone

Strontium is known to exert both a metabolic and an anabolic effect on bone in vivo
which affects osteoblasts and osteoclasts [303, 309]. In vitro studies have shown that
strontium enhances the replication of preosteoblastic cells, and stimulates bone formation
in cell and calvarial cultures in vitro [309]. In experimental studies using rats with normal
renal function, histologic examination of bone samples revealed the oral administration of
low strontium doses (Sr content in diet <4/gl) to increase both the bone formation rate
and trabecular bone density. This observation was found to be due to a strontium-induced
stimulation of the osteoblastic activity evidenced by an increase in the amount of osteoid,
which was noted in the absence of any mineralization defect or any change in osteoclastic
surface or in the number of active bone-resorbing cells [310, 311]. The fact that the
increased osteoblastic activity was not accompanied by increased bone resorption was
suggested to be due to covering of the endosteal bone surface with osteoid, by which
bone resorption was prevented [312]. Treatment with low doses of strontium (316-634
mg/kg per day Sr^^), administered as strontium chloride or strontium ranelate for 9-26
weeks, stimulates bone formation and decreases bone resorption in rodents and humans,
resulting in increased cancellous bone volume, while mineralization remains normal
[313]. Marie et al. [314] reported that following four weeks of oral strontium
supplementation an increased in the osteoid surface and reduction in the number of acid
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phosphatase-stained osteoclasts that occurred. Brennan et al. indicated similar stimulatory
effects on human osteoblast-like (HOB) cell replication and also demonstrated enhanced
cell differentiation as indicated by increased Runx2/cbfal expression of strontium
ranulate [315]. Sr

concentrations as small as 0.1 mM have been shown to increase the

expression of ALP, bone sialoprotein (BSP) and osteocalcin (OCN) in murine osteoblasts
all indicating enhanced osteoblastic activity [316]. Data has signified that the Sr induced
stimulatory effect on pre-osteoblasts is in part mediated through the calcium-sensing
receptor (CaSR) [317]. However, another cation-sensing receptor is also thought to be
involved as strontium similarly promotes replication in osteoblasts from CaSR knockout
mice [318].

Chondhary et al., indicated that induction of cyclooxgenase-2 (COX-2)

enzyme expression and subsequent increase in prostaglandin E2 (PGE2) production may
also play a role in Sr induced osteoblastogenesis [319]. Strontium administration in
normal rats (as strontium ranelate, 2.4 mmol Sr/kg/day Sr for 104 weeks) by Ammann et
al. was also found to increase the humeral shaft diameter, suggesting a stimulatory effect
on periosteal bone formation [320]. This was associated with increased mechanical
properties of both the axial (lumbar vertebrae) and appendicular (midshaft humerus)
skeleton. Both ultimate strength and energy were increased in a dose-dependant manner
with no difference in stiffness, suggesting no alteration of the bone quality [320].
Bonnelye et al. by quantification of TRAP (Tartrate-resistant acid phosphatase or acid
phosphatase 5) activity, demonstrated that Sr ranelate induced a significant dosedependent inhibition of osteoclast differentiation starting at 0.1 mM concentration [316].
Barbara et al. [321]demonstrated strontium ranulate’s ability to inhibit osteoclasts in
MC3T3-E1 cells, whist several other studies also claim that strontium inhibited osteoclast
activity [309, 322, 323]. The demonstrated combined stimulatory effect of strontium has
on bone formation and an inhibitory effect on bone resorption, leads to beneficial effects
on bone mass and bone mineral in vivo and in vitro, indicating its potential in a fracture
healing role.
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1.12.2.4

Strontium in osteoporotic bone

Postmenopausal osteoporosis is a condition caused primarily by the absence of
oestrogen after cessation of ovarian function leading to bone loss due to an increase in
bone turnover and a negative bone-remodelling balance [316]. Osteoporosis is a systemic
skeletal disease characterized by low bone mass and micro-architectural deterioration,
with a consequent increase in bone fragility and susceptibility to fracture. These fractures
include the vertebral body, distal forearm and proximal femur, and are particularly
common in postmenopausal women. A more practical definition of osteoporosis is based
on bone mineral density (BMD). BMD that is less than 2.5 standard deviations below the
mean for young people may be considered osteoporosis, or established osteoporosis if the
patient has sustained an osteoporosis-related fracture [324]. The fractures that result from
osteoporosis cause considerable morbidity and mortality. The incidence of these fractures
is increasing in developed countries, as a result of both an increase in the proportion of
elderly people in the population, and a trend towards increased fracture rates within the
elderly population that could result from a more sedentary lifestyle [324]. Bone
undergoes a continual process of resorption and formation in discrete bone remodelling
units. About 10% of the adult skeleton is remodelled each year; this turnover prevents
fatigue damage and is important in maintaining calcium homeostasis. Bone loss results
from an imbalance between rates of resorption and formation. The human skeleton
comprises about 80% cortical bone and 20% trabecular bone, which is more
metabolically active. Osteoporotic fractures tend to occur at sites comprising more than
50% trabecular bone [324]. Bone loss leads to thinning, and sometimes perforation, of the
trabecular plates. Trabecular perforation occurs where there is increased bone turnover;
the resulting change in architecture leads to a disproportionate loss of strength for the
amount of bone lost [324]. The dual mode of action displayed by Sr leading to increased
bone mass and quality suggested that strontium may have potential benefits in the
treatment of osteopenic disorders such as osteoporosis - disorders characterised by
increased bone turnover and bone loss [325]. A therapeutic trial of strontium ranelate for
the treatment of postmenopausal osteoporosis called STRATOS (STrontium RAnelate for
Treatment of OSteoporosis), was a dose-fmding study in which bone mineral density was
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the primary evaluation criterion. The secondary objectives were to evaluate femoral bone
mineral density, the incidence of new vertebral fractures, and markers for bone turnover.
STRATOS included 153 women with postmenopausal osteoporosis, as defined by a Tscore lower than -2.4 and at least one prevalent vertebral fracture. A randomized double
blind design was used to compare 0.5 g, 1 g, or 2 g of strontium ranelate and a placebo
taken daily for 2 years. Supplemental calcium (500 mg/d) and vitamin D (800 lU/d) were
given to all the study patients [326]. The study demonstrated that strontium ranelate at a
concentration of 2g/day decreased the risk of vertebral fracture by 41% after 3 years
compared to the placebo group. Lumbar spine and femur BMD were also significantly
increased in Sr treated groups [327, 328]. The SRATOS study similarly demonstrated a
dose dependent increase in lumbar BMD, and the proportion of patients experiencing an
incident fracture during year 2 was decreased by 44% in the strontium 2g/day group
versus the placebo group [329]. The PREVOS study was based on examining the efficacy
of strontium ranelate in a preventative rather than curative role. Early postmenopausal
women were administered strontium ranelate concentrations ranging 125-lOOOmg/day for
2 years. The Ig/day group showed significant increases in lumbar, femoral neck and total
hip BMD versus a placebo group which demonstrated decreases [329].

Overall, the

results of these clinical trials have supported other in vitro and in vivo findings, indicating
the effectiveness of Sr in an anti-osteoporotic role.

1.12.2.5

Strontium in biomaterials

An advantage of strontium doped biomaterials is that it is possible to deliver a
local and controlled release of strontium ion, which has been demonstrated previously to
impart desirable effects on bone. Zhang et al studied strontium (Sr) doped HA, calcium
silicates (CS) and borosilicates (BS). In each case the released Sr affected osteoblast
proliferation and alkaline phosphatase activity increasing bioactivity, with clear evidence
that an optimum Sr dose exists [330]. Landi et al., using Sr-substituted HA produced a
porous structure with a compressive strength of 4.52 ± 1.4 MPa - within range of that of
the human femur and proximal tibia [302]. Introduction of Sr into the apatitic structure
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is thought to cause lattice distortions and crystal expansion, due to its larger atomic size
than calcium. Consequently, solubility and ion release is altered and bone-bonding may
be enhanced as shown by Ni et al. [331]. Towler et al. [240] showed that a series of
strontium doped glass polyalkenoate cements induced new bone growth in vivo with no
inflammation noted. Wu et al. [332] examined a mesoporous Si02 glass which suffered
from less than optimum bioactivity and doped it with Sr. The prepared mesoporous Sr-Si
glass was found to have an excellent release profile of bioactive Sr

ions, and the

incorporation of Sr^^ improved structural properties, such as mesopore size, pore volume
and specific surface area, as well as rate of dissolution and. The mesoporous Sr-Si glass
had no cytotoxic effects and its release of Sr

ions enhanced alkaline phosphatase

activity - a marker of osteogenic cell differentiation - in human bone mesenchymal stem
cells. Wren et al. illustrated Sr cements to have compressive and biaxial flexural strengths
of 75MPa and 34Mpa respectively, indicating their potential in load bearing applications
[333]. Boyd et al. have demonstrated Sr-doped silicate glass compositions to induce bone
growth in an ovariectomized rat femur healing model [334]. With an understanding of the
biological effects of Zn and Sr, their dual incorporation into a bone graft can be
envisaged to provide synergistic effects facilitating localized treatment of diseased or
damaged bone tissue, while simultaneously offering protection against implant site
infection.
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Abstract
Bone grafts are required in many clinical situations. Autografts are the traditional gold
standard for treating conditions requiring bone grafts. However autografts have inherent
drawbacks such as donor site morbidity, pain and increased operative time. An alternative
for autografts are synthetic grafts. A series of strontium doped zinc silicate glasses were
developed which were investigated using high temperature X-ray diffraction (HT- XRD)
in order to establish phase transformations, which occur up to the first crystallization
temperature, (Tpl), thus identifying the composition-structure relationships which arise
during this thermal processing. In analysing BTl 10 it was observ'ed that all glass material
crystallised into 4 phases including strontium zinc silicate, sodium calcium silicate,
calcium silicate and strontium silicate, leaving no residual glass phase. BTl 11 and BTl 12
were shown to contain a residual glassy phase alongside for BTl 11, sodium zinc silicate,
Lamite and silicon oxide and for BTl 12 strontium silicate, calcium silicate, sodium
silicate and silicon oxide. In the case of BTl 11 the residual glass phase appears to be rich
in strontium. The residual glass phase being Sr enriched with respect to the glass-ceramic
may offer increased release of Sr^"^ from the material; important for the regulation of
osteoblastic and osteoclastic activity. BTl 13 crystallized to form strontium silicate,
sodium silicate, and strontium zinc silicate. BTl 14 crystallized to form strontium silicate
and sodium silicate. The biocompatibility of phases formed in BTl 13 and BTl 14 is as yet
unknown. Further knowledge will be generated by later work examining the
biocompatibility of these phases identified in this research. However, on the basis of
these results, the materials (BTl 10-BTl 12) exhibit potential as a bone graft substitutes,
whilst BTl 13-BTl 14 give rise to phases with unknown biocompatibility and so warrant
further investigation.
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2.1

Introduction
Bone grafts are frequently required due to trauma, bone neoplasia, stabilisation of

spinal segments and more generally in orthopaedics, dental, maxillofacial and
craniofacial surgeries [1, 2]. Autografts or allografts can be used as bone substitutes.
Autograft is still considered the gold standard due to its ability to support osteoinduction
and osteogenesis [1]. However, autografts have a number of inherent drawbacks
including limited volumes and supply; it has been estimated that an iliac crest donor site
requires approximately 24 months to regenerate, before it could be reutilized to supply
adequate tissue for further autotransplantation [2]. Furthermore the need for a second
surgery, associated donor site morbidity, neurologic injury, vascular injury and pain are
all heavily cited disadvantages associated with the use of autograft tissue [1, 3]. An
alternative to autograft bone, is allograft bone, [4]. Allograft bone has been employed in
fresh, frozen or freeze-dried forms [4]. Fresh allografts are rarely used because of the
immune response and the risk of transmission of disease [4, 5]. However, the frozen and
freeze-dried categories are common, and offer an osteoconductive framework for
regeneration but are considered, at best, to be only weakly osteoinductive [4]. The
method of preparing allograft bone is designed to minimise the immune response of the
host and therefore most allografts contain no viable cells to confer osteogenic properties.
The harsh terminal sterilization processes carried out on the allograft material, can alter
the

demineralised

bone

matrix’s

(DBM’s)

natural

proteins,

decreasing

its

osteoinductivity, and ultimately rendering the resulting DBM inactive and non-functional
[6]. Furthermore, allograft has the potential for disease transmission. Whilst transmission
is limited the literature notes the transmission of HIV and hepatitis C from donated tissue
to otherwise healthy individuals [4, 5]
The limitations of autograft and allograft materials, has driven the need for
artificial bone substitute materials which do not damage healthy tissue, require a second
operative site nor pose a viral or bacterial threat to patients [7]. Various types of glass and
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glass-ceramics have been developed over the past few decades. Some of the most
successful of these systems, include Bioglass® (in the Na20-Ca0-Si02-P205 system)
[8], Na20-Ca0-B203-Al203-Si02-P205 [9], Ceravital® (Si02-Ca0-Na20-P205, MgO,
K2O)

[10],

glass-ceramic A-W [11], Bioverit® [12], Apatite/p-tricalcium phosphate

biphasic [13], and Calcium Sulfate [14], all of which have been shown to bond to bone
in-vivo through the formation of an apatite or calcium phosphate layer [15]. Among these,
the main bioactive ceramics used clinically are: the Bioglasss in the Na20-Ca0-Si02P2O5 system , sintered Hydroxyapatite (HA) (Caio(P04)6(OH)2, sintered (3-tricalcium
phosphate (TCP) (Ca3(P04)2, HA/TCP bi-phase ceramic, and glass-ceramic A-W
containing crystalline oxyfluoroapatite (Caio(P04)6(0, F2)) and (3-Wollastonite (CaOSi02) in an MgO-CaO- Si02 glassy m.atrix [16-20]. The above have been developed in
the forms of bulks and particulates with dense and porous structures [16-20]. Kokubo and
Ohtsuki et. al. [21-24] noted that the Ca0Si02 components, which are contained within
the aforementioned systems, contributed mainly to the bioactivity of those materials.
However, the introduction of synergistic compositional elements to mediate beneficial
responses in vivo are actively being considered in the literature.
In recent years calcium-silicate based ceramics have shown potential as a
bioactive materials for bone tissue regeneration and implant coating due to their excellent
bioactivity and degradability [25, 26]. Concurrently,

and Sr^\ have been shown to,

in the case of Zn^"^, stimulate fracture healing by enhancing osteoblast differentiation
[27], increasing osteoblast DNA content [7] and inhibiting osteoclastic bone resorption in
vitro [28]. Zn^"^ ion release from biomaterials has also been shown to be an effective
antibacterial agent, killing many bacterial strains commonly associated with infection
post orthopaedic surgery [7]. Synergistically, Sr^^ has been shown to have a dual mode of
action increasing bone formation enhancing osteoblast activity and differentiation, while
inhibiting osteoclast production and proliferation [29], and is currently in use as an
osteoporosis treatment in the form of Strontium Ranelate [29]. Strontium ranelate has
been shown to depress bone resorption and maintain bone formation in vivo under certain
circumstances; Strontium ranelate has demonstrated increased vertebral bone volume
without inducing a mineralisation defect, and enhanced bone cell replication and bone
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formation in vitro. It has also been shown to significantly reduce the risk of vertebral and
non-vertebral fractures, including those of the hip, in postmenopausal women with
osteoporosis [30].
Research into incorporating strontium into glass structures, due to its positive therapeutic
effects has increased. Several studies including those by Lotfibakhshaiesh et al [31] and
Fredholm et al [32] have been carried out where successful inclusion of strontium into the
glass matrix has occurred. Recently, calcium-strontium-zinc-silicate glasses, which are
based on the Ca0-Zn0-Si02 ternary phase diagram [33], coupled with ionic substitution,
have been shown to release controlled amounts of therapeutic Zn^^ and Sr“^ ions when
placed in normal and extreme physiological conditions. The levels of synergistic ion
release from these materials correlates well with the levels of Sr^"^ and Zn^^ions typically
associated with clinical benefits (Osteoblastic differentiation and impaired osteoclastic
resorption) [7, 28]. However, in addition these materials have also demonstrated
antibacterial efficacy along with enhanced

cell

viability;

indicating that such

compositions may be ideally suited to utilize as a bone replacement material [7]. Boyd et.
al. previously demonstrated, that grafts from the glass system comprising of CalciumStrontium-Zinc-Silicate, exhibited superior in vitro cell viability over Novabone®
(Novabone products, FL, USA) [34], and demonstrated the ability of the glass grafts to
integrate into host bone tissue and induce bone growth in close apposition to the
implanted particles [35]. However the Sr-doped zinc-silicate glasses, which have
demonstrated exceptional potential as bioactive bone substitutes, have limitations. In
particular, the research work to date has emphasised the use of glass particles (90710|am). Particulates in this range are suitable for numerous indications but are
contraindicated where the implant may be required to bear loads. Additionally, the glass
particulates do not offer a three dimensional structure to support tissue regeneration and
integration. Thus, the investigation of a load bearing, reticulated constructs based on the
calcium-strontium-zinc-silicate composition is warranted and may provide for an advance
toward the ideal tissue engineering graft [36]. However, in order to control bioactivity
and mechanical properties a full knowledge of phase transformations during thermal
treatments of these materials is required. The aim of this work is to investigate the phase
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transformations, which occur in Sr-doped zinc silicate materials up to the first
crystallization

temperature,

(Tpl),

thus

identifying

the

composition-structure

relationships which arise during thermal processing.

2.2 Materials and Methods
2.2.1 Glass Synthesis

Five glass formulations (Table 1) were synthesised. Glasses were prepared by weighing
out the appropriate amounts of analytical grade reagents (Sigma Aldrich, Wicklow,
Ireland); silicon dioxide, zinc oxide, calcium carbonate, strontium carbonate and sodium
carbonate into a plastic container. Each formulation was thoroughly mixed in the closed
container for 30min. Compositions were then fired (1480°C for 1 h) in platinum crucibles
and the glass melts shock quenched into water. The resulting frit was dried in an oven at
120‘’C for 1 day.

Table 1: Glass composition (mol. fraction).

Glass

Si02

ZnO

CaO

SrO

NaiO

BTllO

0.4

0.2

0.1

0.2

0.1

BTlll

0.4

0.1

0.1

0.2

0.2

BT112

0.4

0

0.1

0.2

0.3

BT113

0.4

0.2

0

0.3

0.1

BT114

0.4

0.1

0

0.3

0.2
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2.2.2 Attrition Milling

The dried frit was ground in an attrition mill (NETZSCH, Lebenschauerschmierung,
Germany) using iso-propanol and Zirconia beads. The frit was processed in 15g batches,
which were placed in a ceramic crucible, zirconia beads with a diameter ranging 2-4 mm
were placed in the crucible, and iso-propanol was added to the level of the beads. The frit
was milled by means of two shaft mounted blades rotating at a speed of 1500 rpm for one
hour. The resulting ground powder was placed in a sieve and washed with iso-propanol in
order to separate it from the Zirconia beads and to capture any glass particles attached to
the beads. The resulting slurry was placed in a round bottomed flask, dried in a water
bath at 100°C, and stored in a dessicator for subsequent use.

2.2.3 Particle size

A MALVERN MS 2000 LF particle size analyzer, with the ability to detect particles in
the range of 0.02pm - 2000pm, equipped with a Hydro 2000 wet dispersion module was
used to determine the particle size distribution using the ISO 13320-1 protocol (fixed
wavelength >.=0.63, result accuracy ± 1%). The glass was prepared for particle size
analysis by the following means. 0.5g of the attrition milled glass powder was placed into
a 40ml beaker and 30 ml of a 0.1% Sodium Pyrophosphate, which acts as a dispersant
was added, as the MALVERN MS 2000 LF uses a wet technique. The beaker was placed
on a magnetic stirrer and stirred for a minimum of 1 minute to ensure that the powder and
dispersant formed a suspension. Following a debubbling step, 20 ml of the suspension
was taken, by means of a pipette, from between the middle of the vortex and edge of the
glass at half the depth of the liquid. The suspension was placed in the MS2000 sample
tank and ultrasonic vibrations applied for two minutes.

94

2.2.4 Thermal Characterization

2.2.4.1 Differential scanning calorimetry

In order to identify the first crystallization temperature (Tpi), differential scanning
calorimetry (DSC) was performed using a Labsys 1600 (SETARAM Instruments,
Caluire, France). Samples were heated in a platinum crucible from room temperature to
950°C at a heating rate of 10 °/min to determine the glass transition and first
crystallisation temperatures. The tolerance of the DSC is listed as 2%. Intrinsic
characteristics of the glass networks for BT110-BT114 have previously been reported
(glass transition onset (Tg)) [7] . Data are presented in table 3.

2.2.4.2 High temperature X-ray Diffraction

The high temperature in situ X-ray diffraction patterns of the samples were recorded
using a PANalytical X’pert MPD Pro 3040/60 X-ray Diffractometer (PANalylical B.V.
Almelo. The Netherlands) unit fitted with an Anton Parr HTK1200 (Anton Paar, Graz,
Austria) high temperature oven chamber with a Pt/PtRh thermocouple. The temperature
was controlled with an accuracy of ±1 K using a Eurotherm temperature controller. An
alumina sample holders is used for scanning samples (Cu k-alpha radiation at 40 kV and
35 mA). The XRD patterns (15°<20<8O°, scan time 10 sec), with a scan step size 0.0083°
were recorded at various temperatures in the range of room temperature to Tpi at various
intervals after holding the sample for 10 min at each desired temperature. Where
significant crystalline activity occurred above the glass transition temperature the phases
present were identified using JCPDS (Joint Committee for Powder Diffraction Studies)
standard diffraction patterns using X’pert Highscore Plus software (PANalytical) and
graphed using Origin lab 8 version 8.1.

95

2.3 Results
2.3.1

Attrition milling and Particle Size analysis

The particle size analysis carried out shows that attrition milling the glass powders
produced a multimodal particle size distribution including sub micron particles (Table 2).
Particle size distribution ranges from a d90 of 5.53pm to 18.23 pm.

Table 2; Particle size distribution for each glass (post-attrition milling).

Particle Size Distribution (pm)
Glass

dlO

dSO

d90

BTllO

0.35

0.61

5.48

BTlll

0.42

6.71

7.41

BT112

2.98

5.59

18.23

BT113

0.32

0.47

5.53

BT114

0.40

3.09

17.68

2.3.2 Differential scanning calorimetry

The results of the differential scanning calorimetry are shown in table 3. The glass
transition temperatures recorded range from 522°C to 623°C, and the first crystallization
temperatures range from 525°C to 713 °C.
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Table 3: Glass transition temperature (Tg) and first crystallization peak (Tpi) for each glass.

Glass:

Tg(°C)[71:

Tp, fC):

BTllO

603

713

BTlll

546

577

BT112

522

525

BT113

598

668

BT114

542

567

2.3.3 High Temperature X-ray diffraction
The following diffraction patterns (Figure 1 to Figure 4) illustrate the phase evolution for
each glass from commencement of crystallisation up to Tpi. Table 4, which precedes the
figures, identifies diffraction peak positions for each of the 6 crystal systems identified
during analysis. Table 4 is designed to guide the interpretation of Figures 1-4.
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Table 4; Detailed Legend for Figures 1-5.

Peak Identifier

JCPDS card no.

Phase Identifier.

Chemical
Composition

A

00-039-0235

Strontium-zinc-silicate

Sr2ZnSi207

B

00-024-1069

Sodium-calcium-silicate

Na2CaSi04

C

00-031-0299/

Calcium-silicate

Ca2Si04/

D

00-031-0301/

CasSiOs/

00-051-0092

CaSj205

00-038-0271/

Strontium-silicate

Sr2Si04

00-039-1256

E

00-037-0407

Sodium-zinc-silicate

Na2ZnSi04

F

00-033-0302

Lamite

Ca2Si04

G

00-051-1380

Silicon oxide

Si02

H

00-016-0818

Sodium silicate

Na2Si03
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BT 110

580“C

680“C
(/>

c

(U

700°C

720°C

BT 111

520°C

540“C

560°C

580‘’C

Figure 2; High temperature XRD phase evolution for BTl 11.

99

BT 112

470“C

490°C

510”C

530°C

Figure 3; High temperature XRD phase evolution for BTl 12.

BT 113

eio^c
630“C

650°C

eyo^c

Figure 4: High temperature XRD phase evolution for BTl 13.

100

BT 114

Figure 5: High temperature XRD phase evolution for BTl 14.
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2.4 Discussion
The inclusion of particle sizes in the sub micron range and larger is preferred for the
fabrication of reticulated glass-ceramic foams utilizing the replication technique [37].
This technique will be utilized in later work to synthesise and evaluate biocompatibility
of reticulated foams based on crystal phases identified in this paper. The thermal
characteristics of such glass system have previously been reported [30, 35]. However the
Tpl data for the powders in this study were required to be evaluated using DSC in order
to mitigate against the effects of bulk versus surface nucleation as a function of the
particle size distribution considered in this work. Table 3 illustrates Tg (intrinsic property,
previously reported [35]) and Tpi for each glass composition; it was observed, as one
would expect, that both Tg and Tpi decrease with increasing Na to Zn ratio. The atomic
radii of Zn^"^ and of Na^ are 74 pm and 95 pm respectively [38], thus as Na20 content
increases, the glass network is expanded resulting in a reduction of both glass density and
glass oxygen density [39] accounting for the reduction of Tpi as Na20 content is
increased [39]. Another factor in the reduction of Tg is the Sr to Ca ratio. A substitution
of 0.1 mole fraction of strontium for calcium, where all calcium has been substituted in
BT113 and BT114 shows a marked reduction in Tg. Sr

is slightly bigger that the

Ca^'^cation, (113 and 99 pm respectively [38]) again resulting in the expansion of the
network and a reduced glass density. In order to achieve a dense material sintering of the
glass powder compact must take place prior to crystallization. [31]. A large window
between Tg and Tpl is required to ensure that the glass sinters without crystallizing [31,
39]. The Tpl temperatures reported for our system overlap closely with respective Tg’s
[7], in particular BTlll, BT112 and BT114, where the maximum difference in
temperature, taking into account the 2% machine accuracy, may be as little as 19°C;
indicating an unsuitable processing window. However, we are concerned with the
examination of phase evolution in this paper and evaluating if the by-products of
crystallisation may be biocompatible phases in their own right. Further analysis
compromising dilatometry and hot stage microscopy will be reported in future work in
order to establish the optimal sintering temperature for the glass-ceramic system.
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Each BT glass-ceramic reflects specific crystalline phases depending on the composition
of the parent BT glass and heat treatment applied. For BTl 10, it was observed that two
dominant phases pervade the temperature range; strontium zinc silicate (Sr2ZnSi07)
(tetragonal) and sodium calcium silicate (Na2CaSi04) (cubic). Orthorhombic calcium
silicate (Ca2Si04) is found at temperatures 580°C and 680°C; however this structure is
replaced with, strontium silicate (Sr2Si04) upon heating to 700°C. Upon heating to Tpi the
Monoclinic strontium silicate (Sr2Si04) is replaced with the dominant crystalline phases
of strontium zinc silicate (Sr2ZnSi07) and sodium calcium silicate (Na2CaSi04). Analysis
of Figure 1 also indicates that all glass material has been crystallised, leaving no residual
glass phase. BTl 11 is found to comprise of sodium zinc silicate (Na2ZnSi04) and
calcium silicate (Ca2Si04) in the form of Larnite at each temperature examined, where
the respective crystal structures are orthorhombic and monoclinic. BTl 11 shows no
transitional evolution from one phase to another, rather the dual crystal system exists
from onset of crystallization up to Tpi. In fact at only one temperature was an additional
crystal structure detected, which was silicon oxide (Si02) at 520 °C. No crystalline phase
is identified which contains strontium even though the levels of strontium present for
BTl 11 glass are comparable to that of BTl 10 and BTl 12, consequently it is most likely
that the strontium remains within a residual glassy phase which is evident as a typical
amorphous diffraction pattern in Figure 2. The presence of a residual glass phase is
interesting as in indicates incongruent behaviour within the system. A residual glass
phase contained within a biocompatible glass-ceramic matrix is very advantageous when
relating to bioactive glass ceramics as its reactivity is likely to be substantially different
to the bulk glass-ceramic. It is likely that the residual glass phase will exert a marked
influence on a number of important properties of the glass-ceramic including its chemical
stability and durability which are closely related to bioactivity [40]. The residual glass
phase being Sr enriched with respect to the glass-ceramic will enhance the release of Sr

9+

which may be important for the regulation of osteoblastic and osteoclastic activity by
stimulating bone formation and reducing bone resorption [41]. The use of glass for load
bearing applications is relatively low due to intrinsic properties of glass [40], however the
inclusion of a glass phase within a glass-ceramic matrix which itself is believed to be
bioactive and bioresorbable [25, 26, 41] may lead to an improvement in the mechanical
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properties whilst maintaining a desired level of bioactivity. In respect of BTl 12, it was
observed that the Tpi occurs at 525°C where a four phase system evolves. Two of these
crystal structures consist of calcium silicate with one formed with an anorthic (CajSiOs)
structure and the other with an orthorhombic (Ca2Si04) structure. The other two phases
identified are strontium silicate (Sr2Si04) and

sodium

silicate (Na2Si03) with

orthorhombic and hexagonal structures respectively. Moving from Tpi to the lower
temperatures it is evident that calcium silicate (CasSiOs), strontium silicate (Sr2Si04) and
sodium silicate (Na2Si03) occur at each temperature point apart from 470 °C, where
sodium silicate has not yet precipitated and only strontium silicate (Sr2Si04) and calcium
silicate (CaSi205)are identified. At 490°C silicon oxide (Si02) forms with a monoclinic
crystal structure. A residual glass phase may be present at all temperatures shown in
figure 3 for BTl 12. As all oxides which are incorporated into the glass-ceramic have
crystallised at each temperature point apart from those at 470‘^C, where sodium has not
been identified, it is difficult to establish what the residual glass phase may consist of and
requires further analysis. BTl 13 appears to be the most stable glass-ceramic from the
point of view of crystal phase changes as a function of temperature. Throughout the
temperatures up to and including Tpi only three crystal phases are formed, strontium
silicate (Sr2Si04), sodium zinc silicate (Na2ZnSi04) and strontium zinc silicate
(Sr2ZnSi07). Interestingly BTl 13 contains the highest level of zinc and strontium oxides
with no calcium oxide present. BTl 14 like BTl 13 contains no calcium oxide and again
presents a stable biphasic system. At all temperature points both strontium silicate
(Sr2Si04) and sodium zinc silicate (Na2ZnSi04) are formed with both crystals having an
orthorhombic structure. BTl 14 also comprises of the highest levels of strontium and
second highest levels of sodium oxides in the system. From examining figures 4 and 5 it
is not apparent that a significant residual glass phase remains in BTl 13 and BTl 14
respectively.
When analysing a system which is being proposed as possessing therapeutic benefits to
host

tissue,

the

biocompatibility

of the

materials

must

be

considered.

The

biocompatibility of calcium silicate polymorphs such as Ca3Si05 [42] and Ca2Si04 [43],
has been established in previous in vitro studies, hence if the compounds formed in the
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BT system are examined, it may be seen that BTl 10, BTl 11 and BTl 12 systems contain
these calcium polymorphs, which is an indication of their potential biocompatibility.
Additionally BTl 10 and BTl 12 have been shown to comprise of sodium calcium silicate
and sodium silicate respectively where the bioactivity of both crystalline materials has
been demonstrated previously [44, 45]. In fact BTl 10, BTl 11 and BTl 12 exhibit at least
one crystalline phase at each temperature point investigated, where the biocompatibility
of phases has been clearly demonstrated [42-45]. The biocompatibility of the crystalline
phases found in BTl 13 and BTl 14 is as yet unknown and because of this further
investigation is required into the biocompatibility of the phases present. These same
phases are also found in BTl 10, BTl 11 and BTl 12 across the temperature points. It is
likely that glass that preferentially precipitate into biocompatible phases may afford
improved biocompatibility.

2.4.1 Limitations of the study and future analysis

The identification of crystal phases is challenging where multiple phases occur together
and their Bragg Diffraction lines overlap and in particular where residual stresses in a
glass-ceramic can impose significant changes to the lattice parameters. Whilst this work
has leveraged JCPDS standards, strontium and calcium ions have similar ionic sizes and
identical charges and can form solid solution crystal phases readily. As such an
examination of solid solution substitutions would be of additional benefit to the literature.
Based on the potential for such substitutions to occur, the literature would benefit from an
elemental and structural evaluation of the residual glass phases reported herein.

2.5

Conclusion

The objective of this work was to investigate the phase transformations, which occur in
Sr-doped zinc silicate materials up to the first crystallization temperature, (Tpl), thus
identifying the composition-structure relationships which arise during thermal processing,
by the creation and analysis of high temperature X-ray diffraction patterns. The X-ray
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diffraction patterns generated indicate all glasses were successfully converted to glass
ceramics, where BTllO, BTlll and BT112 were shown to comprise of biocompatible
crystalline materials. Furthermore BTlll and BT112 appear to demonstrate a residual
glassy phase at Tpl. It is likely that the residual glass phase will exert a marked influence
on a number of important properties of the glass-ceramic including its chemical stability
and durability which are closely related to bioactivity, due to its differing properties from
the bulk glass-ceramic. The biocompatibility of all crystalline phases found in BTl 13 and
BTl 14 and which also occur in combination with the biocompatible phases in BTl 10,
BTlll and BTl 12 is as yet unknown and because of this further investigation is required
into their biocompatibility. On the basis of these results, the materials examined exhibit
sufficient potential as a bone graft substitutes to warrant further investigation.

Acknowledgements: The work in this paper was funded by Enterprise Ireland under the
technology development fund (Grant number CFTD/2007/119B).
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Abstract
Bioactive and degradable porous bioceramics play an important role in many
clinical situations. Porosity is essential to the performance of a material which is
proposed to be used as an implantable osseous scaffold. Scaffolds provide a three
dimensional support and template to osseous integration and vascularisation. Combining
the porosity of a scaffold with the ability of the scaffold material to deliver therapeutic
ions to the site of implantation goes some way towards developing an ideal bone graft. A
series of strontium doped zinc silicate (Ca-Sr-Na-Zn-Si) glass ceramics scaffolds, whose
porosity was measured to be between 93 and 96%, which is advantageous in terms of
osseous integration and vascularisation were developed. The levels of Zn^"^ and Sr^^
detected as a result of degradation of the crystalline phases were found to be 1.4-600 ppm
(parts per million) and 0-583 ppm, respectively. The levels detected correlate well with
the levels of Sr

and Zn ions typically associated with clinical benefits including

antibacterial efficacy, osteoblastic differentiation and impaired osteoclastic resorption.

113

3.1

Introduction

Loss of bone tissue as a result of injury or disease necessitates the use of bone
grafts to improve patient’s quality of life [1, 2]. At present difficulties exist in respect of
the repair of large or critical size defects via unaided bone regeneration [2]. Autograft is
considered the gold standard [2, 3] graft material to facilitate regeneration and repair of
larger defects; however autograft tissue has inherent drawbacks such as limited volumes,
limited supply and donor site morbidity [2, 4]. Allograft bone is an alternative to
autograft but also comes with its complicating factors, even though it does provide an
osteoconductive framework for regeneration it is considered weakly osteoinductive [5]
and carries a risk of disease transmission [5, 6]. Consequently, there is an increasing
demand for synthetic bone-graft substitutes which do not damage healthy tissue, require a
second operative site, pose a viral or bacterial threat to patients and, in addition,
overcome the problem of an inadequate supply of material [1,2, 4-7]. Bioactive ceramics,
currently used in clinical applications are available in bulk and particulate forms with
dense and porous structures [8-12]. The ideal bone void filler should provide a three
dimensional (3D) matrix to support osteoblasts and pre-cursor cell attachment, migration,
proliferation, interact actively with cells and tissues and stimulate repair and regeneration
[13, 14] produce non-toxic degradation products [15, 16], and bond to the host bone,
creating a stable interface without the formation of scar/fibrous tissue [17]. Another
factor which should be considered in the definition of the ideal bone graft is the
antibacterial efficacy of the bone graft or its degradation products. The use of implants is
associated with an increased risk of bacterial infection, often leading to implant failure
and revision surgery where Staphylococcus aureus and Staphylococcus epidermidis
combined account for two out of three biomaterial-associated infections [18]. A bone
graft which reduces or eliminates the occurrence of wound infection would prove very
advantageous. Three dimensional scaffolds should show an internal structure which is
highly porous, permissive for osseous invasion [19], allowing proper vascularisation as
well as a flow of nutrients and waste products through the scaffold [2, 19] and provide
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structural support for the newly formed bone [15]. The porous structure should be highly
interconnected with pore sizes in the range of 100-500pm [2, 15, 20] and with a porosity
higher than 90% [16]. Some studies have demonstrated that direct interaction with the
intrinsic chemistry of the graft material may be responsible for osteoinduction through
the dissolution and release of specific key ions that act directly on local cells to
upregulate gene expression or influence cell differentiation [21]. A number of studies
purport that various materials by their chemical make up promote osteoinduction when
placed in simulated physiological conditions. It had been demonstrated that Bioglass®
glass-ceramic [22] possesses the ability to stimulate cell cycling and subsequently
enhance osteoblast turnover, however studies relating to the antibacterial efficacies of
Bioglass® mainly concern oral bacteria namely Streptococcus sanguis, Streptococcus
mutans and Actinomyces viscosus [23] and not those found at the site of orthopaedic
implantation. Other systems, namely Hydroxyapatite (HA) and P-tricalcium phosphate
(p-TCP) have induced anti-bacterial efficacy by incorporating ions such as silver, zinc
and copper or by the addition of antibiotics [24, 25]. The use of HA and p-TCP in porous
forms is presently limited due to their mechanical properties [26], and their limited
osteoinductive properties have also been documented [19]. Efforts have been made to
improve the antibacterial properties of biocompatible wollastonite by the incorporation of
ions such as silver [27], and while wollastonite does demonstrate some osteoinductive
properties, its mechanical properties and particular low fracture toughness limit its
clinical applications [28]. What can clearly be seen from the above examples is a pressing
need to design a system which inherently possesses all the qualities of an ideal bone graft.
Recently a series of strontium doped zinc silicate glasses were developed [7, 29-32]. Zn

2"b

and Sr^^ have been shown to, in the case of Zn^^, stimulate fracture healing by enhancing
osteoblast differentiation [33], increasing osteoblast DNA content [34] and inhibiting
osteoclastic bone resorption in vitro [35]. Zn^"^ ion release from biomaterials has also
been shown to be an effective antibacterial agent, killing many bacterial strains
commonly associated with infection post orthopaedic surgery [29]. Synergistically, Sr
has been shown to have a dual mode of action increasing bone formation enhancing
osteoblast activity and differentiation, while inhibiting osteoclast production and
proliferation [36, 37], and is currently in use as an osteoporosis treatment in the form of
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Strontium Ranelate [38]. These strontium doped zinc silicate glasses have been shown to
release controlled amounts of therapeutic Zn^"^ and Sr^^ ions when placed in normal and
extreme physiological conditions. The levels of synergistic ion release from these
materials correlates well with the levels of

and Zn^’^ions typically associated with

clinical benefits (Osteoblastic differentiation and impaired osteoclastic resorption) [7, 29,
35, 39]. The glass system mentioned has recently been studied in relation to phase
transformations during thermal treatments up to the first crystallization temperature, (Tpi)
[40]. The study enabled the authors to better understand the composition-structure
relationships of the material during heat treatment, establishing the crystalline phases
formed. This information provides a mechanism to control on the bioactivity and
mechanical properties of the strontium doped zinc silicate glass-ceramic. The aim of this
study is to investigate the structure and degradation of 3D scaffolds based on strontium
doped zinc silicate glass-ceramics, which have been crystallised and characterised at Tpi.
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3.2

Materials and Method

3.2.1

Glass Synthesis

Five glass formulations (Table 1) were synthesised. Glasses were prepared by weighing
out the appropriate amounts of analytical grade reagents (Sigma Aldrich, Wicklow,
Ireland); silicon dioxide, zinc oxide, calcium carbonate, strontium carbonate and sodium
carbonate into a plastic container. Each formulation was thoroughly mixed in the closed
container for 30min. Compositions were then fired (1480°C for Ih) in platinum crucibles
and the glass melts shock quenched into water. The resulting frit was dried in an oven at
120°C for 1 day.
Table 1: Glass composition (mol. fraction) with first crystallization temperatures.

Glass

SiOz ZnO

CaO

SrO NazO Tp,(®C)

'BflTo~0.4

0.2

b.T

”02

oTl

713

BTlll

0.4

0.1

0.1

0.2

0.2

577

BT112

0.4

0

0.1

0.2

0.3

525

BT113

0.4

0.2

0

0.3

0.1

668

BT114

0.4

0.1

0

0.3

0.2

567

3.2.2 Attrition Milling

The dried frit was ground in an attrition mill (NETZSCH, Lebenschauerschmierung,
Germany), using iso-propanol and Zirconia beads. The frit was processed in 15g batches,
which were placed in a ceramic crucible, zirconia beads with a diameter ranging 2-4 mm
were placed in the crucible, and iso-propanol was added to the level of the beads. The
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frit was milled by means of two shaft mounted blades rotating at a speed of 1500 rpm for
one hour. The resulting ground powder was placed in a sieve and washed with iso
propanol in order to separate it from the Zirconia beads and to capture any glass particles
attached to the beads. The resulting slurry was placed in a round bottomed flask, dried in
a water bath at 100°C, and stored in a dessicator for subsequent use.

3.2.3 Particle Size

A MALVERN MS 2000 LF particle size analyzer, with the ability to detect particles in
the range of 0.02pm - 2000pm, equipped with a Hydro 2000 wet dispersion module was
used to determine the particle size distribution using the ISO 13320-1 protocol (fixed
wavelength X,=0.63, result accuracy ± 1%). The glass was prepared for particle size
analysis by the following means. The attrition milled glass powder (0.5g ) was placed
into a 40ml beaker and 30 ml of a 0.1% Sodium Pyrophosphate, which acts as a
dispersant was added, as the MALVERN MS 2000 LF uses a wet technique. The beaker
was placed on a magnetic stirrer and stirred for a minimum of 1 minute to ensure that the
powder and dispersant formed a suspension. Following a debubbling step, 20 ml of the
suspension was taken, by means of a pipette, from between the middle of the vortex and
edge of the glass at half the depth of the liquid. The suspension was placed in the
MS2000 sample tank and ultrasonic vibrations applied for two minutes.

3.2.4 Scaffold fabrication

The slurry for the impregnation of the polyurethane foam was prepared using the
following method ; Polyvinyl alcohol (PVA) (87-89% hydrolyzed, Average Mw 13,00023,000) was dissolved in water, the ratio being 0.01 mol/L. BT glass powder was then
added to 100 ml PVA-water solution up to concentration of 40 wt%. Each procedure was
carried out under vigorous stirring using a magnetic stirrer for 1 h. The polyurethane
foams cut to shape, (5x5mm), were immersed in the above prepared slurry for 15
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minutes. The foams were manually retrieved from the suspension as quickly as possible,
and the extra slurry was completely squeezed out. The samples (called green bodies)
were then placed on a smooth surface and dried at ambient temperature for at least 12 h.
Post-forming heat treatments for the burnout of the polymer template structure were
programmed, as shown in Fig.l. The burning condition of the polymer template was
identical for all samples. The polyurethane foam exhibited both thermoplastic and
thermoset characteristics and when heated partial decomposition occurs resulting in
vaporization and the formation of a melt, which occurs at approximately 260°C. All
foams were subsequently heated to their respective Tpl values and held for 2 hours. The
identification of glass transition temperatures (Tg) and first the crystallization
temperatures (Tpi) for each glass was previously determined [40]. The first crystallization
temperatures identified will be used for the purposes of scaffold creation and can be
located in table 1.

Fig. 1 : Heat treatment program designed for burning-out the polyurethane templates and crystallizing BT
glass at Tp,
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3.2.5 X-ray Diffraction

X-ray diffraction (XRD) analysis was performed using a Philips X’pert MPD Pro
3040/60 -ray Diffraction (XRD) Unit (Philips, Netherlands). Zero background nickel
coated sample holders were used for analysis of the attrition milled glass particles with
Cu ka radiation (at 40 kV and 35 mA). Diffractograms were collected in the range
5°<0<8O°, at a scan step size 0.0083° and a step time of 10s. Where significant crystalline
activity occurred above the glass transition temperature the phases present were identified
using JCPDS (Joint Committee for Powder Diffraction Studies) standard diffraction
patterns using X’pert Highscore Plus software (PANalytical) and graphed using Origin
lab 8 version 8.1.

3.2.6 X-Ray Tomography

X-ray micro-tomography is a non-destructive analysis technique used to visualise and
characterise objects in three dimensions. The technique works by acquiring a series of Xray projection images at a known number of angular positions through 360 degrees.
Variation in the contrast of each projection image relates to how the x-rays are attenuated
as they penetrate the sample. X-ray attenuation increases proportionally to the electron
density and thickness of the sample material, thus resulting in a darker projection image.
Specialised mathematical calculations known as 'reconstruction algorithms' are used to
create a 3D image from the x-ray projections. Visualisation software then permits
numerous analysis options from creating sections through the 3D image to quantification
of size, internal porosity, surface area or segmentation based on differences in density.
The X-ray tomography examination of three samples of BTl 13 glass ceramic scaffold
was carried out using a phoenix|x-ray Nanotom (General Electric Company) with a
tungsten transmission target and a 2 megapixel high contrast flat panel digital
detector. The maximum accelerating voltage used was 50 kV. 1440 projections in 360°
views were obtained. A voxel resolution of lOp was employed to obtain a 3D image of
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the glass ceramic foam. Analysis of reconstructed 3D data sets was carried out using
Volume Graphics VGStudioMax Software.

3.2.7 Dissolution experiments

In order to simulate normal and extreme environments TRIS-HCl buffer and Citric acid
buffer solutions were prepared to have a pH of 7.4 ± 0.1 and 3.0 ± 0.2, respectively at a
temperature of 37°C ± 1°C, according to ISO 10993-14 [41]. Each glass-ceramic foam
was immersed in 10 ml of TRIS buffer (sample size = 5 for each designate) and citric
acid buffer (sample size = 5 for each designate) and maintained at 37°C in a thermally
controlled oven. Specimens were stored for 1,7 and 30 days. After each storage period,
specimens were removed via filtration and filtrates retained for ionic content analysis.
The Sr^^ and Zn^'^content of each filtrate was analysed using a SpectrAA 220 Fast
Sequential, using flame atomic absorption spectroscopy in an acetylene-air flame. Zn and
Sr hollow cathode lamps were used at wavelengths 213.9 and 460.7 nm, respectively. In
order to eliminate interferences when measuring strontium levels 0.5 g KCl was added to
each filtrate.
Results are expressed as mean of the mean of triplicate determinations. Analysis of the
results was carried out using Students’s t-test, and then one way analysis of variance
followed by Bonferroni post-hoc test for multiple comparison between different groups.
Each experiment was performed in triplicate and analysed using Graphpad prism 5
software (Graphpad software Inc.), with a significance level of P<0.05.
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3.3 Results

3.3.1

Attrition milling and Particle Size analysis

The particle size analysis carried out shows that attrition milling the glass powders
produced a multimodal particle size distribution, including sub micron particles (Table 2).
Particle size distribution ranges from a d90 of 5.53pm to 18.23 pm. The inclusion of
particle sizes in the sub micron range and larger is preferred for the fabrication of
reticulated glass-ceramic foams utilizing the replication technique [42].

Table 2: Particle size distribution for each glass (post-attrition milling).
Particle Size Distribution (pm)
Glass

dlO

dSO

d90

BTllO

0.35

0.61

5.48

BTlll

0.42

6.71

7.41

BT112

2.98

5.59

18.23

BT113

0.32

0.47

5.53

BT114

0.40

3.09

17.68

3.3.2 X-ray diffraction
The diffraction pattern evident on Figure 2, illustrates the phase for each glass-ceramic at
Tpi. Table 3, which precedes Figure 2, identifies diffraction peak positions for each of the
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crystal systems identified during analysis. Table 3 is designed to guide the interpretation
of Figure 2.
Table 3: Details of peaks shown in Figure 2
Peak Identifier

JCPDS card no.

Phase Identifier.

Chemical Composition

A

00-037-0407

Sodium Zinc Silicate

Na2ZnSi04

B

00-039-0235

Strontium Zinc Silicate

Sr2ZnSi207

C

00-033-0302

Lamite

Ca2Si04

(Calcium Silicate)
D

00-031-0299

Calcium Silicate

Ca2Si04

E

00-016-0818

Sodium Silicate

Na2Si03

F

00-039-1256

Strontium Silicate

Sr2Si04

G

00-037-1485

Zinc Silicate

Zn2Si04

H

00-038-0271

Strontium Silicate

Sr2Si04

I

00-038-1366

Strontium Silicon

SrSi2
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Figure 2: XRD trace for BTl 10-BTl 14 at Tp|. See Table 2 for details of peaks A-I
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3.3.3 X-ray tomography

Figure 3; XRT image of BTl 13 fully porous glass-ceramic scaffold, (a) superior view, (b) lateral view, (c)
medial view (d) combined view of a, b and c

An XRT image of a glass-ceramic scaffold produced from the Sr-doped zinc-silicate
glass-ceramic can be seen in Figure 3. The XRT image obtained shows an integrated
porous network. The porosity of three BTl 13 scaffolds was measured in a
250x250x250 voxel cube. The porosity of the three samples of BTl 13 scaffold was
measured at 93.6%, 96.1% and 93%.

3.3.4 Dissolution experiments

The dissolution profiles for

and Sr^^ are outlined below. Figures 4(a, b, c, d) and 5(a,

b, c, d) show the levels of Zn

detected at pH3 and pH7.4, respectively for each glass
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•^1

ceramic. Figures 6(a, b, c, d, e) and 7(a, b, c, d, e) show the levels of Sr

detected at pH3

and pH7.4, respectively for each glass ceramic. Each Figure is structured so that each
glass ceramic is independently shown over 1, 7 and 30 days, and where significant
differences have been established between the three timepoints for each glass ceramic,
this has been outlined. Figure 8 illustrates the levels of Zn^"^ (a & b) and Sr^"^ (c & d)
detected for each glass ceramic, however in Figure 8 similar timepoints have been
grouped so that each glass ceramic has been compared on the basis of incubation time
and ion of interest. Where significant differences have been established between the glass
ceramics this has been highlighted. The levels of ion quantities noted in the subsequent
sections are mean values.

3.3.5 Zinc release
The Zn^^ detection profiles at pH 3 are shown in Figure 4. Glass ceramic BTl 10, which
is shown in Figure 4(a) shows no significant differences between 1, 7 and 30 days and the
mean level appears to plateau at 7 days, with detection levels of 142 ppm (parts per
million). Figure 4(b) shows glass ceramic BTl 11 and its Zn^^ detection profiles at pH 3
over 1, 7 and 30 days. A very significant difference is seen between 1 and 7 days and
between 7 and 30 days, where the levels of Zn^"^ appear to plateau at 7 days, with
detection levels of 300 ppm. No significant difference exists between 1 and 30 days,
which IS a very interesting result. BTl 13 Zn^ detection profile at pH 3 over 1, 7 and 30
days is shown in figure 4(c). The levels of Zn

'y

I

appear to plateau at 7 days, with detection

levels of 600 ppm, which is in fact the highest level of Zn

detection throughout the

entire series. An extremely significant difference is found between day 7 and the other
two timepoints. There is also an extremely significant difference between day 1 and day
30, where day 1 has the lowest level of Zn

recorded. Figure 4(d) shows the Zn

detection profiles for glass ceramic BTl 14 at pH 3 over 1, 7 and 30 days. The level of
Zn

detected rises from 1 day to 7, where it plateaus at 184 ppm. No significant

differences between 1, 7 and 30 days are apparent.
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The Zn

detection profiles for each glass ceramic at pH 7.4 are shown m Figure 5.

BTl 10 which is shown in Figure 5(a) shows no significant differences between 1, 7 and
30 days for Zn^^at pH 7.4. The level of Zn^^ detected appears to plateau at 30 days, with
a ppm of 6.2. Figure 5(b) outlines the Zn^"^ release profile for BTl 11. The level of
divalent zinc ion released appears to increase over time, with the maximum level of
detection, 18.6 ppm, occurring at 30 days, where in fact this is the highest level of Zn
detected for the entire series at pH7.4. An extremely significant difference occurs
between days 1 and 30, a very significant difference between days 7 and 30, and no
significant differences between dayl and 7. Figure 5(c) shows glass ceramic BTl 13 and
its Zn^"^ detection profiles at pH 7.4 over 1, 7 and 30 days. An extremely significant
difference is found in BTl 13, between day 7 and 30, no other significant differences are
found within the three time points. The level of Zn

detected appeared to have reached a

plateau at 30 days, with a detection level of 14 ppm. BTl 14 Zn

detection profile at pH

7.4 over 1, 7 and 30 days is shown in figure 4(d). BTl 14 shows an increase in Zn

^ I

detection over time, with day 30 having the highest detectied level at 5 ppm. No
statistically significant differences are found within the BTl 14 grouping at pH 7.4.
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Figure 4; Zinc release at pH3 over 1, 7 and 30 days with significant differences for (a), BTl 10, (b) BTl 11,
(c) BTl 13 and (d) BTl 14
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Figure 5: Zinc release at pH7.4 over 1,7 and 30 days with significant differences for (a), BTl 10, (b)
BTlll,(c)BT113 and (d) BTl 14

3.3.6 Strontium release

The

detection profiles at pH3 are shown in Figure 6. The level of Sr^^ detected for

BTl 10 is outlined in Figure 6(a). No significant difference is seen between 1 day and the
other two time points in BTl 10. There is an extremely significant difference between 7
and 30 days, where day 30 shows the largest Sr

-ji

levels at 346 ppm. The level of Sr

‘y,

detected from BTl 11 at pH3, which is outlined in Figure 6(b), appears to plateau at 1 day
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giving a result of 180 ppm. No statistically significant differences are evident within the
glass-ceramic series. The detection of Sr^"^ is in itself an interesting result as the
crystalline structures identified in the x-ray diffraction analysis of BTl 11 appear to be
strontium deficient (Table 3, Figure 2). The significance of this result will be discussed
subsequently. For glass ceramic BTl 12, the levels of strontium divalent ion detected are
outlined in Figure 6(c). An increase in Sr^^ detection is seen over time and plateaus at day
30, giving a detection level of 582 ppm, which is also the highest level of Sr^^ detected in
the series. Within the three time points for BTl 12, an extremely significant difference is
seen between 1 and 30, and 7 and 30 days. No statistically significant difference was
identified between days 1 and 7. Following one day of incubation, as outlined in Figure
6(d), BTl 13 appears to plateau with respect to Sr^^ detected. The level of detection noted
following one day of incubation at pH3 is 434 ppm. The levels of detection subsequently
drop on day 7 and 30, where no significant difference between the two lower levels is
noted. An extremely significant difference has been identified between days 1 and 7. As
presented in Figure 6(e), BTl 14 has following one day of incubation, reached a plateau in
terms of Sr

detected at 420 ppm. There is a drop in the levels of detection at 7 and 30

days however, only at 30 days is the level significantly different to the level seen at 1 day.
No significant difference was noted between days 7 and 30.
The Sr^"^ detection profiles at pH 7.4 are shown in Figure 7. Glass ceramic BTl 10 as
shown in Figure 7(a) appears to have an almost equal Sr^"^ detection for 1 and 30 days,
resulting in measurements of 222 and 220 ppm, respectively. However, at 7 days the level
drops to where there is an extremely significant difference between day 7 and days 1 and
30. BTl 11 Sr

detection levels at pH7.4 are outlined in Figure 7 (b). It is apparent that

BTl 11 has a much lower level of Sr^"^ detection in comparison with the other glass
ceramics at pH7.4. There are no significant differences for the three time periods within
the BTl 11 grouping, where the highest level of Sr

detected was noted to occur at day

30, with 17.5 ppm. Interestingly, at day 7, no strontium divalent ion was detected. The
Sr

detection levels for BTl 12 are depicted in Figure 7(c), where the highest level of

detection was seen following 30 days of incubation, with 398 ppm of Sr

detected. This

is the largest level of Sr^^ detected in the pH7.4 series. There is an extremely significant
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difference in the level of detection between day 30 and days 1 and 7, with no statistically
significant difference established between days 1 and 7. Figure 7(d) shows the detection
profile of Sr^^ for BT113 at pH7.4. The level of ions detected appears to plateau
following one day of incubation, with 170 ppm detected. There is a drop in the levels
detected at 7 days where an extremely significant difference has been identified with one
day incubation. The levels again rise at day 30 however, no statistically significant
difference is found between days 7 and 30. An extremely significant difference is noted
between days 1 and 30. As shown in figure 7(e), BTl 14 at day 30 exhibits its highest
level of Si^^ observed for the pH7.4 environment, with 388 ppm detected. This is
followed by 1 day, where a very significant difference is seen between the two time
points. Day 7 shows the lowest level of detection within the grouping, where an
extremely significant difference is identified with day 30. There is no significant
difference between days 1 and 7.
Figure 8 demonstrates significant differences between glass ceramics at equivalent time
lines. The glass ceramics are grouped by time lines and ion of interest. It is apparent at
pH3, (Fig. 8(a)), that there are no significant differences between the glass ceramics in
terms of the level of Zn^^ detected following 1 day of incubation. However, at days 7 and
30, significant differences have been noted. Figure 8 (b) which demonstrates the level of
Zn^^ detected at pH7.4, shows that at each time point statistically significant differences
are noted between the glass ceramics. It is evident from Figures 8 (c) and (d), which
depict the level of strontium divalent ion detected at pH3 and 7.4, respectively that the
level of statistically significant differences has increased at all timepoints, in comparison
to those found for Zn . Whilst Figure 8 makes obvious the level of ion detected for each
glass ceramic and how they compare to one another, it is very difficult to perform a
detailed analysis of the presented information. In order to compare each glass ceramic
with its piers under equivalent conditions, not only is it necessary to establish the
crystalline species involved, but to also determine the percentage of each crystalline
phase and the individual elements within that phase. Additional analysis including XRD
and SEM work on each glass ceramic would be required in order to determine this
information, as such little comment can be made on the results thus found.
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Figure 6: Strontium release at pH3 over 1,7 and 30 days with significant differences for (a), BTl 10, (b)
BTl 11, (c) BTl 12, (d) BTl 13 and (e) BTl 14
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Figure 7: Strontium release at pH7.4 over 1, 7 and 30 days with significant differences for (a), BTl 10, (b)
BTl 11, (c) BTl 12, (d) BTl 13 and (e) BTl 14
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pH7.4 (d) over 1,7 and 30 days with significant differences
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3.4 Discussion
The aim of this study was to fabricate a fully integrated porous Sr-doped zinc-silicate
glass-ceramic scaffold, whose structure was permissive for osseous integration and to
investigate the ion release level with respect to the divalent ions of zinc and strontium. It
is clear from the results that a fully porous material, where the porosity is between 9396% has been created, hence providing a suitable scaffold to enhance bone ingrowth, and
to permit adequate vascularisation. We have synthesised four materials which are
designed to release zinc, namely BTl 10, BTl 11, BTl 13 and BTl 14. Each glass ceramic,
as outlined in Figure 2 and Table 3 comprise a unique grouping of crystalline species. At
pH3, all four glass ceramics show a similar release profile (Fig. 4). In all cases the level
of

detected at day 30 appears to have reduced from the levels observed at day 7,

where some differences, namely those observed in BTl 11 and BTl 13 (Fig. 4(b) and (c),
respectively), are statistically significant. Similar anomalous results have been previously
reported [43], where it was suggested that the metal ions released from the material may
be complexed with the citric acid used in the manufacture of the incubating solution.
However this phenomenon was not seen at day 7.
A possible explanation for this is that a competing complexing process may be taking
place in the solution as a result of another metal ion, released by the degrading glass
ceramic, namely silicon, calcium, strontium or sodium, being complexed by the citric
'7-F

acid in preference to the Zn , once the initial ion(s) were no longer available or less
attracted to the citric acid, Zn

was complexed up to the 30 day point. In order to

determine whether a chelating effect on the Zn^"^ or other ions released by the glass
ceramic has occurred, further investigation is required. At pH7.4, two distinct detection
profiles are apparent. Figure 5(a) and 5(c), namely BTl 10 and BTl 13, show that day 7
levels of Zn^^ detected are lower than that detected at day 1. The level of Zn^"^ detected
plateaus at day 30. The reason for the fall in Zn

levels at day 7 is not fully understood

and has not been observed in the literature.
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In glass ceramics BTl 11 and BTl 14 (Fig. 5 (b) and (c), respective!}! of Zn^"^
detected appears to increase over time as expected. All five materiiigned to
release strontium, namely BTl 10, BTl 11, BTl 12, BTl 13 and gain the
crystalline phase(s) determined for each glass ceramic are outlined innd Table
'>1

3. At pH3 it appears that each glass ceramic has its own unique Sr

file apart

from BTl 11 (fig. 6a) and BTl 13 (fig. 6d), whose release profiles are hat glass
ceramics BTl 10, BTl 11, BTl 13 and BTl 14 do have in common 1 of Sr^^
detected at day 7 which is lower than that at day 1. In some cases, naO, BTl 1
1 and BT 113 Figs. 6(a) (b) (d), respectively), the level of Sr^"^ is fourncreased
at day 30, whilst in BTl 14, the level was found to have further degain the
mechanism is not fully understood but may be similar to that as othe Zn^"^
release previously discussed. Where the level of Sr^"^ detected subsecreases at
day 30, this may indicate that the level of Sr

released may not be gthe level

of Sr^^ chelated by the citric acid. Of interest is the detection of Sr^'^l, whose
crystalline content did not show a strontium-rich phase. Similar ve been
reported in other studies [43]. The presence of an ion, the source of wot found
by in the glass ceramic by XRD, was explained by the presence of ass. Our
study shows that BTl 11 is a fully crystalline material; therehernative
explanation is required. One such explanation may be the identificaticystalline
phase itself The identification of crystal phases is challenging whe phases
occur together and their Bragg Diffraction lines overlap and, in partici residual
stresses in a glass-ceramic can impose significant changes to the ameters.
Whilst this work has leveraged JCPDS standards, strontium and ns have
similar ionic sizes and identical charges and can form solid solution cry readily
[40]. In such cases, it is possible that an unknown percentage ( silicate
(Ca2Si04) identified in BTl 11, may actually comprise of a strontium . Figure
6 (c) shows the detection profile of BTl 12 at pH3. The level of Sr^^ de appears
to increase over time, with an extremely significant difference betwc and the
other two timepoints. As to why the level of Sr^^ detected does nc as was
observed in the other glass ceramics, one possibility is that the level oldivalent
ion released may be greater than any competing reaction to completion.. At
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pH7 we observed a similar pattern to Sr

detection in all glass cera 7). In all

cases there is a decline in the level of Sr

detected from 1 to 7 dayubsequent

increase at day 30. The glass ceramics do differ in the significant^s, where
calculated, between the timepoints. A number of glass ceramics showium level
of detection at day 1, namely BTl 10 and BTl 13 (Fig. 7(a) and (d), ly) whilst,
BTl 10, BTl 12 and BTl 14 (Fig. 7 (a) (c) (e)) show the highest le' detected
occurring at day 30 for pH 7.4. The dissolution mechanism for man>imics has
been shown to be an initial attack on a residual glass phase, followeidation of
the crystalline material [44]. However, as we can see from the XRD {Figure 2,
the glass-ceramics appear to be fully crystalline with no residua)hase. In
considering the durability of glass-ceramics, the materials must be vie ltiphased
composition dependant systems, where each phase possesses ircorrosion
characteristics [45, 46]. This study is particularly interested in the d< products
Zn^"^ and Sr^^ and whether the levels released are within identified c ranges.
Figures 4(a-d) and 5(a-d) demonstrate the range of Zn

detected fromantaining

glass ceramics, where the levels were found to be in the range of 1.4)m (parts
per million) . Zn^"^ levels associated with clinical benefits on bone fonge from
2.45 to 6.5 ppm [35, 39]. Zinc deficiency has been associated with retid failure
of bone growth in animals and humans [47]. Zinc is also associaticreasing
osteoblast proliferation, osteoclast inhibition, biomineralization and btion [4850]. A range of 3-7 ppm of Zn^^ has been associated with antibacteriaigainst S.
mutans and A. viscosus, both associated with infection at orthopaedy]. It has
also been established that Zn^^ release from Tobermorites inhibitec/th of S.
aureus strains [51] and studies have also linked Zn^^ release from zinhibited
growth of MRSA [52]. As is evident from the results presented abiceramics
BTl 10 and BTl 14 fall within the range known to be of therapeu without
exhibiting cytotoxic effects, with BTl 11 and BTl 13 being marginalfhe range
at 10.2 and 8 ppm, respectively. It must be noted that the literatuie on the
release of zinc divalent ions from glass ceramics is limited and fustigation
would be beneficial. Figures 6(a-e) and 7(a-e) demonstrate the ran^ detected
from the strontium containing glass ceramics, where the levels were^e in the
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range of 0 to 583 ppm [38]. It has been established that strontices osteoblast
activity in the range of 8.7 to 87.6 ppm and, by means of inhib^oclast action,
reduce bone resorption in the range of 8.7 to 2102.8 ppm [38reatment with
strontium ranelate promotes differentiation of osteoblast pr into mature
osteoblasts and increases bone nodule number with as little as SSr^"^, which is
close to the blood active concentration in post menopausal osteopitients [38]. In
fact, it has been shown that as little as 0.1 ppm of Sr

stimulates hue derived cell

proliferation [54]. The literature would benefit from additional st^arding higher
concentrations of Sr^^ and its effects on osteoblasts, however ifcn shown that
intravenous administration of high doses of strontium induces :aemia due to
increased renal excretion of Ca

[55]. As is evident form the resented above,

glass-ceramics BTl 10 to BTl 14 fall within the range known to bepeutic benefit
and may indeed have the desired effect on bone turnover.

3.5

Limitations of the study and future analysis

The identification of crystal phases is challenging, especially vjltiple phases
occur together and their Bragg Diffraction lines overlap and, in parvhere residual
stresses in a glass-ceramic can impose significant changes to te parameters.
Whilst this work has leveraged JCPDS standards, strontium arim ions have
similar ionic sizes and identical charges and can form solid scrystal phases
readily. As such an examination of solid solution substitutions v of additional
benefit.

Currently, the level of ions released from a glass ceramic cannot 1: to any single
crystalline phase, where more than one phase exists containing of interest. In
order to quantitatively determine the level of ion release from a piphase and to
compare each glass ceramic with its peers under equivalent connot only is it
necessary to establish the crystalline species involved, but tcetermine the
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percentage of each crystalline phase and the individual elements wiise.
The use of citric acid as a buffer in the pH 3 solution is a limitaticjdy. Citric
acid has the ability to complex with metal ions such as those founcs ceramics
synthesised here. This chelating may lead to lower than expected In solution.
Evaluation of alternate media at pH3 may be valuable.

3.6 Conclusion

The objective of this work was to fabricate fully integrated porous nc-silicate
glass-ceramic scaffolds based on glasses BTl 10-BTl 14, whose stroermissive
for osseous integration, and to investigate the ion release profifect to the
divalent ions of zinc and strontium. The X-ray diffraction patterns ndicate all
glasses were successfully converted to fully crystalline fully p( ceramics,
where the porosity was found to be between 93-96%, hence providie scaffold
to enhance bone ingrowth, and to permit adequate vascularisatioise results
pertaining to Zn^^ and Sr^^ following incubation in pH levels mitreme and
normal physiological conditions indicate that the glass ceramics fafe potential
as therapeutic bone grafts. A stronger degradation was observed citric acid
buffered solution compared to the normal physiological, pH7.4. Reli elements
at appropriate levels from bone grafts may be advantageous with ngmenting
bone turnover and antibacterial efficacy. On the basis of ts, further
investigation is warranted in order to assess the level of antibicacy and
cytotoxicity demonstrated by the glass ceramics.
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Abstract

The use of artificial bone grafts has increased, in ordr to satisfy a growing demand for
bone replacement materials. Initial mechanical stabily of synthetic bone grafts is very
advantageous for certain clinical applications. Couplet with the advantage of mechanical
strength, a material with inherent antibacterial propcties would be very beneficial. A
series of strontium doped zinc silicate (Ca-Sr-Na-m-Si) glass ceramics have been
characterised in terms of their crystalline structure, »iaxial flexural strength and anti
bacterial efficacy, based on the identification of optinum sintering conditions. All three
glass ceramics, namely BTllO, BTllI and BT112 >ere found to be fully crystalline,
with BTlll and BT112 comprising of biocompatibe crystalline phases. The biaxial
flexural strengths of the three glass ceramics ranged frcn 70-149MPa, and were shown to
be superior to those of clinically established ceramic in dry conditions and following
incubation in simulated physiological conditions. The bacteriostatic effect for each glass
ceramic was also established, where BTl 12 showed a inhibitory effect against three of
the most common bacteria found at implantation sites, amely, E.faecalis, MRSA and P.
aeruginosa. The results of the evaluation suggest that the materials studied offer
advantages over current clinical materials and indicre the potential suitability of the
glass ceramics as therapeutic bone grafts.
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4.1

Introduction

Bone is limited in the size of fracture or defect it can restore to healthy tissue.
Furthermore, bone can suffer from pathological conditions, {e.g. cancer) and is subject to
degeneration as a result of age and disease (i.e. osteoporosis). In certain cases, patient
comfort and bone function may often be restored by surgical reconstruction [1]. The
requirement for bone replacement material is demonstrated several ways, including the
fact that delayed healing, or non-union occurs in 5 per cent of all fractures, and 20 per
cent of high-impact fractures [2]; such defects may exceed the body’s regenerative
capabilities unless surgeons intervene to bridge the skeletal defect [3]. Despite the fact
that autograft bone is the gold standard for bone grafting procedures this approach is
associated with several inherent drawbacks, including; the requirement for a second
surgery (to harvest graft tissue), increased surgical times, procurement morbidity, and
limited availability [4-9]. On the other hand, allograft tissue is beset with intrinsic
limitations, including; increased risk of disease transmission, the potential provocation of
immunogenic responses, as well as compromised supplies [9, 10]. An alternative is
required in order to satisfy an ever-increasing demand for bone graft material [11].
Synthetic bone graft substitutes may provide an alternative to autograft and allograft
bone, and would intrinsically ameliorate the primary complications associated with such
materials. Synthetic bone grafts offer many advantages over natural bone grafts options,
including: a reduced risk of disease transmission, no requirement for a second surgery to
harvest material and reduced morbidity, and provision of a limitless supply of material in
various forms, sizes and shapes. In addition to such features, synthetic materials may also
help to control implant infection, via the inclusion of antibacterial agents within the
material {e.g. the inclusion of antibiotics or the release of antibacterial ions from the
material).
Implant-associated infections are the result of bacterial adhesion to an implant surface
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and subsequent biofilm formation at the implantation site [12]; causing 45% of all
nosocomial infections [13]. In a recent Swiss study it was found that revision surgeries
were required for 66% of patient who contracted MRSA (Methicillin-resistant
Staphylococcus aureus), 79% for MSSA (Methicillin-sensitive Staphylococcus aureus)
and 75% for those patients who contracted various CoNS {Staphylococcus epidermidis.
Staphylococcus

lugdunertsis,

Staphylococcus

capitis,

Staphylococcus

homiuis,

Staphylococcus intermedius, Staphylococcus simulans, Staphylococcus xylosus and
Staphylococcus schleiferi) [14]. Furthermore, it is known that the presence of an implant
decreases the minimal infecting dose of Staphylococcus aureus (S. aureus) [15]. Should
bacterial adhesion occur prior to tissue regeneration, host defences may not prevent
surface colonisation for certain bacterial species which are capable of forming a biofilm.
Therefore, inhibiting bacterial adhesion is essential to prevent implant-associated
infection. The possibility of partial biofilm detachment leading to infection of
surrounding tissues and the circulatory system is also of concern [16]. Pathogenic
microorganisms, particularly gram-positive S. aureus are found at the site of
approximately 90% of all implants [17], Enterococci faecalis is also a clinically
significant species of gram positive bacteria,

[18] which, along with gram-negative

Pseudomonas aeruginosa, have also been implicated in implant-associated infections
[19]. Clearly a significant issue, with rates of infection ranging from 0.8-1.2% in
orthopaedic surgery (total hip arthroplasty), and 3.6-8.1% (closed fractures) to
17.5-21.2% (open fractures) in trauma surgery [20], a local method of infection control is
required at implant sites. Recently, calcium-strontium-zinc-silicate glasses, which are
based on the Ca0-Zn0-Si02 ternary phase diagram [21], coupled with ionic substitution,
have been shown to release controlled amounts of therapeutic Zn

and Sr

ions when

placed in normal and extreme physiological conditions. The levels of synergistic ion
release from these materials correlates well with the levels of Sr^^ and Zn^^ions typically
associated with clinical benefits [22, 23]. Additionally these materials have also
demonstrated antibacterial efficacy along with enhanced cell viability; indicating that
such compositions may be ideally suited to utilize as a bone replacement material [22].
Boyd et al, previously demonstrated that grafts from the glass system comprising of
Calcium-Strontium-Zinc-Silicate,

exhibited

superior in

vitro cell

viability over
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Novabone® (Novabone products, FL, USA) [24], and demonstrated the ability of the
glass grafts to integrate into host bone tissue and induce bone growth in close apposition
to the implanted particles in vivo [25]. However the Sr-doped zinc-silicate glasses, which
have demonstrated exceptional potential as bioactive bone substitutes, have limitations.
In particular, the research work to date has emphasised the use of glass particles (90710pm). Particulates in this range are suitable for numerous indications but are
contraindicated where the implant may be required to bear loads. Current synthetic bone
grafts available to surgeons are not indicated for load bearing applications, due to their
inherent mechanical properties and fabrication forms [26-28]. Where grafts are implanted
at load bearing sites, external or internal fixation is required, which leads to increased risk
of infection plus increased surgical time and costs [29]. The availability of a bone graft
which is suitable to bear loads in vivo as well as possessing antibacterial properties would
be extremely advantageous. To this end, three glass ceramics, based on the established
BTl 10, BTl 11 and BTl 12 glass compositions [22] were characterised in terms of their
optimum sintering temperatures in order to maximise the mechanical strength of each
material, the subsequent crystalline structures which evolved were identified and the
antibacterial efficacy as a function of time investigated against bacteria frequently
associated with the site of implantation.
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4.2

Materials and Methods

4.2.1 Glass Synthesis

Three glass formulations (Table 1) were synthesised. Glasses werepared by weighing
out the appropriate amounts of analytical grade reagents (SigiAldrich, Wicklow,
Ireland); silicon dioxide, zinc oxide, calcium carbonate, strontiumbonate and sodium
carbonate into a plastic container. Each formulation was thorough!ixed in the closed
container for 30min. Compositions were then fired (1480°C for Ih platinum crucibles
and the glass melts shock quenched into water. The resulting frit \dried in an oven at
120T for 1 day.

Table 1: Glass compositions (mol. fraction).

Glass

Si02

ZnO
'(12 “

BTlio^

CaO
-----

SrO

NaiO

0.2

0.1

BTlll

0.4

0.1

0.1

0.2

0.2

BT112

0.4

0

0.1

0.2

0.3

4.2.2 Attrition Milling

The dried frit was ground in an attrition mill (NETZSCH, Letchauerschmierung,
Germany), using iso-propanol and zirconia beads. The frit was proied in 15g batches,
which were placed in a ceramic crucible, zirconia beads with a diaer ranging 2-4 mm
were placed in the crucible, and iso-propanol was added to the leve the beads. The frit
was milled by means of two shaft mounted blades rotating at a spetf 1500 rpm for one
hour. The resulting ground powder was placed in a sieve and washeith iso-propanol in
order to separate it from the Zirconia beads and to capture any glaarticles attached to
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the beads. The resulting slurry was placed in a round bottomed lask, dried in a water
bath at 100°C, and stored in a dessicator for subsequent use.

4.2.3 Particle Size

A MALVERN MS 2000 LF particle size analyzer, with the abilif to detect particles in
the range of 0.02pm - 2000pm, equipped with a Hydro 2000 wet (ispersion module was
used to determine the particle size distribution using the I SO 1320-1 protocol (fixed
wavelength >t=0.63, result accuracy ± 1%). The glass was prejared for particle size
analysis as follows; the attrition milled glass powder (0.5g ) wa placed into a 40 ml
beaker and 30 ml of a 0.1% Sodium Pyrophosphate, which act: as a dispersant, was
added, as the MALVERN MS 2000 LF uses a wet technique. The leaker was placed on a
magnetic stirrer and stirred for a minimum of 1 minute to ensur that the powder and
dispersant formed a suspension. Following a debubbling step, 2Cml of the suspension
was taken, by means of a pipette, from between the middle of the 'ortex and edge of the
glass at half the depth of the liquid. The suspension was placed ii the MS2000 sample
tank and ultrasonic vibrations applied for two minutes.

4.2.4 Dilatometry

The optimum sintering temperature for each glass composition vas determined using
dilatometry. Cylindrical pellets (5mm diameter) of various leigths (BTl 10-5.5mm,
BTl 11-4.2 mm and BTl 12-2.7 mm) were obtained by uniaxial pressing. A Netzsch
pushrod dilatometer model 402C was used to measure the shriikage of the samples
during heating up to 1280° C with a heating rate of 5° C/min in a hdium atmosphere. The
relative variation of the sample’s length (AL/Lq) during heating wa measured directly by
the instrument, where Lo is the initial length of the cylindrical ample and AL is the
variation of the sample’s length at a given temperature. A thermocouple in direct
proximity to the sample yields reproducible temperature measurerrent. This also allowed
use of the c-DTA® Software for calculation of endothermic and exithermic effects in the
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sample as well as determination of all the characteristic esion values. The
temperature which gave the highest degree of shrinkage was idention the dilatometry
trace as the highest AL/Lo% value [30] The values determined atoptimum sintering
condition are contained in Table 3.

4.2.5 Glass ceramic disc fabrication

For each BT glass, 1.5 grams (g) of attrition milled glass was wei out and manually
pressed (Specac 25 tonne press) in a 20mm diameter mould at 15ie pressure for 90
seconds. The resulting green bodies were 2mm (± 0.2 mm) thicte discs were then
subjected to a heat treatment programme as outlined in Figu, where the hold
temperature was equal to the temperature of maximum densificaobtained from the
dilatometry analysis; each disc was heated at 5°C per minute up tooptimum sintering
temperature identified and held for three hours. The sintered bodiere oven cooled to
room temperature and stored in a dessicator prior to subsequent ana.

Fig. 1 : Heat treatment program designed to optimise sintering condition (R.T)om Temperature)
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4.2.6 X-ray Diffraction

X-ray diffraction (XRD) analysis was performed using a Ps X’pert MPD Pro
3040/60 -ray Diffraction (XRD) Unit (Philips, Netherlands). » background nickel
coated sample holders were used for analysis of the attrition rr glass particles with
Cu ka radiation (at 40 kV and 35 mA). Diffractograms werllected in the range
5°<0<8O°, at a scan step size 0.0083° and a step time of 10s. Whignificant crystalline
activity occurred above the glass transition temperature, tlhases present were
identified using JCPDS (Joint Committee for Powder Diffrn Studies) standard
diffraction patterns using X’pert Highscore Plus software (P/ytical) and graphed
using Origin lab 8 version 8.1.

4.2.7 Biaxial Flexural Strength

The biaxial flexural strength of each glass ceramics were detero in a similar fashion
to that used by Williams et al., using three support bearings on 3st jig [31]. Sintered
discs of each glass ceramic (n=5) were incubated in 20 ml of dsed (DI) water [32,
33] at 37°C and agitated at 2Hz for 1,7 and 30 days in order to sate the physiological
environment. Dry samples, which were not incubated in DI watere also subjected to
testing (n=5). Following each incubation period, the discs wereoved for immediate
mechanical testing on an Instron 3345 (Instron Ltd., High WycoiBucks, U. K.) using
a 5kN load cell at a crosshead speed of Imm/min. Biaxial fle> strength (BFS) was
calculated according to Equation 1.
BF5(W/’a) = '^^^^^[(l+wX0.485ln(a/r) + 0.52} + 0.48]

uation l

Where
t = sample thickness (mm), v = Poisson’s ratio, a = specific raof support diameter
(mm).
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4.2.8 Antibacterial efficacy

The antibacterial properties were examined using the popuar ‘zone of inhibition’ test
[34] using Enterococcus faecalis (E. faecalis) (ATCC (American Type Culture
Collection) 29212) and Pseudomonas aeruginosa (P. aruginosa) (ATCC 27853)
standard stocks along with a clinical methicillin resistant Stapylococcus aureus (MRSA)
isolate. The E. faecalis and MRSA strains were maintained a Brain Heart infusion agar
and the Pseudomonas strain on Nutrient agar. A standard '.5 Me Farland (containing
approximately (l-2)x 108 CFU/ml) solution was prepared by iissolving selected bacterial
colonies in a physiological solution (turbidity was eMluated using an optical
instrument—Phoenix Spec BD McFarland) and then an aliaot of this suspension was
spread on Mueller Hinton agar plates, using a swab according to the CLSI (Clinical and
Laboratory Standards Institute) guidelines. Discs were then asptically placed on the agar
plates, which were incubated for 24 h at 35° C, and the zone o'inhibition is observed and
measured using a vernier callipers. Tests were completed as trplicates of triplicates. Zone
sizes were calculated as follows:

Size of inhibition zone (mm) = (halo 0-disc 0)/2

Equation 2
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4.3

Results

4.3.1 Attrition milling and Particle Size analysis

The particle size analysis carried out shows that attrition milling the glass powders
produced a multimodal particle size distribution, including sub micron particles (Table 2).
Particle size distribution ranges from a d90 of 5.53pm to 18.23 pm. The inclusion of
particle sizes in the sub micron range and larger is advantageous for material sintering
[35].

Table 2; Particle size distribution for each glass (post-attrition milling)

Particle Size Distribution (^m)
“Glass

dlO ^^0

BTllO

0.35

0.61

5.48

BTlll

0.42

6.71

7.41

BT112

2.98 5.59

18.23

4.3.2 Sintering study

The relative variation of the sample length (AL/Lq) and rate of length change versus
temperature during heating up to 1200°C for glass ceramic BTl 10 is plotted in Figure 2.
The plot demonstrates an expansion of approximately 0.7% up to 460°C. Between 580°C
and 650°C (extrapolated onset temperature 597°C) the first shrinkage step measuring
15% approximately takes place, this is followed by another step between 950°C and
1050°C approximately, with a third step taking place at 1140°C with extrapolated onset
temperatures of 1002°C and 1124°C. The corresponding peak temperatures in the rate
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of length change curve are 625°C, 1030°C and 1155°C, respectively. The shrinkage seen
at 1200°C is most likely due to total melting of the material. Based on the visual
examination (disc deformation/melting) of discs processed between 900°C and 1100°C
(10-50°C increments) a temperature of 1000°C was chosen as the optimum sintering
temperature. Processing at 1000°C corresponds to approximately 15% change in sample
length.

dL/Lo /%

dL/dt*10'/C%Anin)

0.0

0.20

-

-0.40

-0.60

-0.80

-1 .00

Fig. 2 :

Relative length change (solid line) and rate of length change (dashed line) of sample BTl 10.

The thermal behaviour of sample BTl 11 is depicted in Figure 3. Unlike BTl 10 the
sample appears to shrink from the beginning of the measurement, with a 1.25% decrease
in sample length occurring by 500°C.
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dL/Lo /%

dL/dt*10'A:%Anin)
0.0
-0 50

-1 .00
-1 .50

2.00

-

2.50

-

3.00

-

^.50
4.00

Fig. 3;

Relative length change (solid line) and rate of length change (dashed line) of sample BTl 11

During heating to 1100°C two major steps occur. Between 500°C and 550°C, shrinkage
again is seen to occur, the amount being relatively small at 4% approximately. No
significant shrinkage appears to occur until the temperature reaches 940°C where 17%
(approx.) shrinkage occurs up to 1000°C (970°C extrapolated onset temperature). There is
an absence of a plateau between 1000°C and the next visible shrinkage range of between
1000°C and 1020°C, where shrinkage is now measured at 20%. Above 1020°C the
material appears to melt with a sharp increase in material shrinkage to 48% and a large
increase in the rate of length change. Based on the visual examination (disc
deformation/melting) of discs processed

between 900°C and

1000°C (10-50°C

increments) a temperature of 970°C was chosen as the optimum sintering temperature.
Processing at 970°C corresponds to approximately 10% change in sample length.
The results for the thermal expansion and the length change rate of sample BTl 12 are
shown in Figure 4. The sample length appears to decrease continuously, beginning with a
relatively small step at 131°C.
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dDLo /%

dL/dt*10'/(%Anin)

0.0
0.20

-

-0.40
-0.60
-0.80
-1 .00
1.20

-

-1.40

Fig. 4 : Relative length change (solid line) and rate of length change (dashed line) of sample BTI12

The rate of shrinkage continues to be low until 720°C approximately, where the rate
increases and a decrease in sample volume is noted which ceases at 850 °C approx. The
percentage shrinkage up top this point is given as 17% approx. Between 850°C and 950°C
there is littler change in the sample shrinkage, however at ~950°C there appears to be a
small increase in sample volume for about 25°s. This may be due to partial melting or
mass change. The shrinkage of the material begins again at 1000°C approx., and drops
rapidly at 1100°C at which point total melting is believed to begin with a length change of
more than 60%. Based on the visual examination (disc deformation/melting) of discs
processed between 900°C and 1000°C (10-50°C increments) a temperature of 900°C was
chosen as the optimum sintering temperature. Processing at 900°C corresponds to
approximately 18% change in sample length. Table 3 summarizes the Temperature (°C)
at which maximum shrinkage occurred for each glass.
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Table 3: Temperature (°C) at which maximum shrinkage occurred for each glass.

Glass

Temp.

BYrrd

"lood

BTlll

970

BT112

900

4.3.3 X-ray diffraction

The diffraction pattern evident on Figure 5 illustrates the phase for each glass-ceramic at
the respective sintering temperatures. Table 4, which precedes Figure 5, identifies
diffraction peak positions for each of the crystal systems identified during analysis. Table
4 is designed to guide the interpretation of Figure 5.

Table 4; Details of peaks shown in Figure 5.

Peak
Identifier
A
B
C
D
E
F
G

JCPDS card
no.
00-037-0407
00-039-0235
00-037-0406
00-039-1425
00-031-0299
00-016-0818
00-043-1460

Sodium Zinc Silicate
Strontium Zinc Silicate
Sodium Zinc silicate

Chemical
Composition
Na2ZnSi04
Sr2ZnSi207
Na2ZnSi04

Cristobalite
Calcium Silicate
Sodium Silicate
Wollastonite-2A/

Si02
Ca2Si04
Na2Si03
CaSi03

Phase IdentiHer.

Crystal
structure
Orthorhombic
Tetragonal
Orthorhombic
Tetragonal
Orthorhombic
Hexagonal
Monoclinic
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“2 Theta

Figure 5: XRD trace for BTl 10-BTl 1 lat optimum sintering temperatures. See Table 4 for details of peaks
A-G

4.3.4 Biaxial flexural strength

The biaxial and flexural strength (BPS) of each glass ceramic (GC) is shown in Figure 6.
The results are grouped by incubation period under simulated physiological conditions,
and where significant differences occurred within time groupings or within each material,
this has been highlighted. A significant difference was noted between BTl 11 and BTl 12
one day samples, where the average BPS results were 149 and 80 MPa respectively.
Significant differences are noted with these 7 and 30 day incubation periods. Specifically,
an extremely significant difference is noted between BTl 12 7 day and BTl 10 and BTl 11
seven day samples where BTl 12 had insufficient strength to allow testing be carried out.
Similarly BTl 12 thirty day samples showed an extremely significant difference with
BTl 10 and BTl 11 30 day samples again where BTl 12 had insufficient strength to allow
testing be carried out. Within the BTl 12 group seven and thirty day samples showed an
extremely significant difference with both the non incubated and one day incubation
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samples.

BT110
BT111
BT112

Incubation Time (Days)

Figure 6: Biaxial flexural strength of BTl 10, BTl 11 and BTl 12 as a function of incubation time

4.3.5 Antibacterial efficacy

The antibacterial efficacy of glass ceramics derived from BTl 10, BTl 11 and BTl 12 was
demonstrated using the zone of inhibition protocol. The zones of inhibition for each
material are as seen in Figure 7.

162

Figure 7: The bacteriostatic effects of
BTl 10, BTl 11 and BTl 12 against, E.
faecalis (A), MRSA (B) and P.
aeruginosa (C)

BTl 12 exhibits a zone of inhibition for all three bacteria used. The radii of the zones of
inhibition were as follows- E. faecalis 13 mm ±0.2 mm, MRSA 6.5 mm ±0.2 mm and P.
aeruginosa 16 mm±0.2 mm. Also shown in Figure 7(C), BTl 10 demonstrates an
inhibitory effect on P. aeruginosa with a halo of inhibition present whose radius was
measured at 3.8 mm±0.2 mm. BTl 11 did not show bacteriostatic inhibition against the
bacteria examined.
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4.4

Discussion

During the sintering of a glass powder compact with a wide grain size distribution, small
particles are sintered first, thus, sintering kinetics at the first shrinkage are dominated by
the necking between the smallest particles. Maximum shrinkage is reached when larger
pores (pores formed from cavities among larger particles) have disappeared due to
viscous flow which reduces their radii with time [36]. In the present study the range of
particle size produced by attrition milling indicated a multimodal particle size
distribution, including sub micron particles (Table 2). Particle size distribution ranges
from a d90 of 5.53pm to 18.23 pm. The inclusion of particle sizes in the sub micron
range leads to higher packing densities and may lead to sintering occurring at lower
temperatures than those with a larger particle size distribution [37]. The shrinkage profile
for each of the materials studied are shown in Figures 3, 4 and 5, where each material
shows a distinct densification profile. BTllO shows a profile where at 580°C approx,
shrinkage begins. A previous study of these glass compositions by Looney et ai, [38]
indicated that BTl 10 has a Tg (glass transition temperature) close to this temperature at
600°C, which also corresponds well with the maximum rate of shrinkage occurring at
625°C. Following this initial shrinkage step significant crystallization of the glass is
known to occur [38], subsequently the amount of shrinkage drops to 4% approximately
up to 1000°C. It is noted that the presence of crystal structures can inhibit the sinterability
of glass materials [39] and this may impact on subsequent densification. The
densification of BTl 11 and BTl 12 appear to transpire at a consistent rate up to 940°C
and 720°C approx respectively. BTl 11 is noted to have a

Tpi (first crystallization

temperature) of 577, and a Tg of 546°C, BTl 12 has a Tg of 522°C and Tpi of 525°C which
may inhibit sintering, but also both contain a residual glass phase up to Tpi [38].
Investigation have not been carried out to indicate at what temperature the residual glass
is converted to a crystalline structure, this transformation may explain some of the
increase in densification observed, or may indicate that the amount of residual glass
present was not large enough to become evident in the dilatometry study, however these
hypotheses cannot be confirmed with the results generated. It is noted that at Tg no
corresponding increase in densification occurs. Following the examination of
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densification, processing temperatures were chosen for each glass (Table 3). The
mechanical strength of materials is directly influenced by their structure and the XRD
revealed three fully crystalline glass-ceramics containing distinct crystalline phases.
BTllO is shown to consist of three crystalline materials which occur at 1000°C,
interestingly these phases are also present at Tpi [38], indicating a very stable material
structure over the temperature range. The crystalline phases identified comprise sodium
zinc silicate (Na2ZnSi04) and strontium zinc silicate (Sr2ZnSi207); phases shown to
release therapeutic quantities of zinc and

strontium

respectively

in

simulated

physiological conditions [11]. BTlll comprises three crystalline phases following
processing at 970°C. The three phases identified in this paper have not been identified in
previous literature for BTlll [38]. Heating at 970°C also appears to eliminate the
presence of the previously reported residual glass phase for this material [38]. Two of the
crystalline species identified in BTlll have demonstrated biocompatibility namely
Cristobalite (Si02) [40] and calcium silicate (Ca2Si04) [41] indicating the potential
biocompatibility of the GC. BTl 12 like BTl 11 consists of a three phase system, where
two of the crystal structures are also identifiable at Tpi [38]. Both calcium silicate
(Ca2Si04) and sodium silicate (Na2Si03) found at Tpi and at 900®C have demonstrated
biocompatibility [40, 42]. The third crystalline structure is also a calcium silicate known
as Wollastonite 2M or pseudo Wollastonite (CaSiOs) whose biocompatibility is also well
known [43]. As a consequence of all three identified crystalline phases in BTl 12 being
biocompatible there is a strong indication of the potential biocompatibility of the GC,
though the blending of such phases has only had limited examination in the literature.
Knowledge of the mechanical properties is a crucial requirement for evaluating the
possibility of using materials in biomedical applications. Not only are the mechanical
properties of the processed material important but how that material may perform if
placed in vivo is even more important particularly if the material is designed to degrade as
a function of time and environment. In order to examine the suitability of these three
GC’s to perform in an aqueous environment, the materials were incubated (under
simulate physiological conditions) at various time intervals and compared to samples,
which were not incubated. Figure 6 outlines the biaxial flexural strength for each GC as a
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function of time. Consistently BTlll appears to have the highest mean BPS at each
timepoint. Following one day incubation there appears to be no reduction in BPS when
compared to the dry control specimens. At day seven the mean BPS does drop but is
unchanged by day 30. Whilst it appears that for BTl 10 the mean BPS of this GC appears
to increase slightly following one day of incubation and subsequently drops, this
observation is not statistically significant. BTl 12 shows dramatic changes in strength
over time when exposed to simulated physiological conditions. At 7 and 30 days BTl 12
samples degraded to such a degree which prohibited further mechanical evaluation. A
remarkable feature about the BPS for all three materials is that at only one time point
(one day incubation), was a statistically significant difference identified (notwithstanding
the inability to test BTl 12 at later time points). BTl 11 showed significant difference with
BTl 12, where the mean BPS was 149 MPa and 80 Mpa respectively. No statistically
significant differences were identified within GC’s again with the exception of BTl 12
seven and thirty days which showed an extremely significant difference with the other
equivalent timepoints and the tested BTl 12 samples. These results indicate that for GC’s
BTl 10 and BTl 11 the level of degradation experienced in an aqueous environment at
37°C does not negatively affect the mechanical strength of the materials and a controlled
strength-loss rate during biodegradation may be possible. The BPS of the GC’s is very
comparable to other state of the art materials currently being used as bioactive bone
grafts. For example pure P-TCP has a BPS in the region of 9l±33Mpa [44] in non
incubated conditions suggesting that all three BT GC’s exhibit more favourable BPS for
in vivo conditions. Studies by Kothapalli et al., [45] and Lorenzo et al., [46] indicated
that the maximum BPS on optimally sintered HA synthesised by wet precipitation
method to prepare nano-sized HA particles was 57.4 MPa and 74 MPa respectively (non
incubated) also indicating that at each timepoint BT GC’s exhibit superior BPS.
Regarding the potential antibacterial efficacy of the three BT GC’s, this was
demonstrated by a zone of inhibition test. It can clearly be seen in Figure 7 that a clear
zone of inhibition is present with regard to BTl 12 and all three bacteria. This is a very
interesting result as BTl 12 unlike the other GC’s does not contain zinc a known
antibacterial element. From the mechanical testing carried out it is clear that BTl 12 is the
most rapidly degrading GC, and that the degradation products particularly sodium ions
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can buffer the local environment towards an alkaline pH, neutralizing the effects of the
acidic environment created by macrophages involved in wound healing and bone repair
[47, 48]. This increase in local pH may inhibit the bacteria, however further analysis is
required in order to ascertain the specific method of bacterial growth inhibition. Glass
ceramics BTl 10 and BTl 11 showed poorer bacterial growth inhibition in comparison to
BT112. Both GC’s are doped with zinc however the slower degradation rates in
comparison to BTl 12 may be a contributing factor in the results that BTl 10 was the only
other GC to show antibacterial efficacy against P. aeruginosa. The zone of inhibition is a
qualitative test that demonstrates the bacteriostatic behaviour of materials, by indication
their ability to inhibit bacterial growth.

4.4.1 Limitations of the Study

The identification of crystal phases is challenging, especially where multiple phases
occur together and their Bragg Diffraction lines overlap and, in particular, where residual
stresses in a glass-ceramic can impose significant changes to the lattice parameters.
Whilst this work has leveraged JCPDS standards, strontium and calcium ions have
similar ionic sizes and identical charges and can form solid solution crystal phases
readily. As such an examination of solid solution substitutions would be of additional
benefit. Whilst the current study utilised dilatometry in order to assess the optimum
densification temperature, the degree of porosity and hence sintering was not established.
Additional studies including porosity analysis are required in order to establish the
sintering behaviour of the GC’s. Further analysis on the pertaining bacteriostatic effect of
BTl 12 is required as to access the modality of such inhibitory actions.
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4.5

Conclusions

The objective of this work was to establish processing conditions which would lead to
optimising the mechanical properties of three glass ceramic calcium silicate materials. It
has been shown that the glass ceramics formed in this paper possess unique blends of
crystal phases. These materials exhibit biaxial flexural strengths (BPS), which surpass
those of clinically established ceramics such as HA, and pure (3-TCP, in both dry and wet
incubation states. The BPS values established ranged from ranged from 70-149MPa. The
bacteriostatic effect for each GC was also established where BTl 12 showed an inhibitory
effect against three of the most common bacteria found at implantation sites namely E.
faecalis, MRSA and P. aeruginosa. On the basis of this work it is clear that BT glass
ceramics may be suitable for indication in in vivo implantation where currently HA and
p-TCP are used, further investigation into the cytocompatibility and bioactivity of these
materials is warranted.
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5. Conclusion

Based on the results of this research the following points can be concluded:
1. It is possible to convert all studied glasses, namely, BTl 10, BTl 11, BTl 12, BTl 13
and BTl 14 to glass ceramic materials through thermal treatment, where surface
nucleation appears to be the method of crystal formation. The corresponding glass
ceramics of BTl 11 and BTl 12 were shown to comprise of a residual glass phase believed
to be strontium enriched with respect to the glass ceramic. The presence of a residual
glass phase being Sr enriched with respect to the glass-ceramic may enhance the release
of Sr^^, which may be important for the regulation of osteoblastic and osteoclastic
activity by stimulating bone formation and reducing bone resorption.

2. It has been established, that, following thermal treatment at the first temperature of
crystallisation (Tpl) glass ceramics BTl 10, BTl 11 and BTl 12 comprise of known
biocompatible crystalline phases namely, sodium calcium silicate in the case of BTl 10,
calcium silicate in BTl 11 and calcium silicate and sodium silicate in BTl 12.

3. It is possible to fabricate fully integrated porous Sr-doped zinc-silicate glass-ceramic
scaffolds, based on glasses BT110-BT114, whose structure is permissive for osseous
integration with an average porosity of 94%.

4. The level of ion release detected in degradable porous glass ceramic foams, from all
five compositions, indicates that, in the case of Zn^^ at physiological pH 7.4, and Sr^^ in
both pH 7.4 and pH 3.0, the glass ceramics may have potential as therapeutic bone grafts.

5. The identification of the optimum sintering temperature and subsequent thermal
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treatment for each glass ceramic, BTI10, BTl 11 and BTl 12, showed substantial volume
shrinkage in each material and imparts a level of biaxial flexural strength on each
material, which is superior to current clinically used ceramics used in bone augmentation.

6.

The resulting crystalline phases following thermal treatment at the optimum sintering

temperature were, in the case of BTl 12, identified as biocompatible, which is an
indication of the potential biocompatibility of the glass ceramic.

7.

Glass ceramic BTl 12 demonstrated an inhibitory effect against three of the most

common bacteria found at implantation sites, namely, E. faecalis, MRSA and P.
aeruginosa, whilst BTl 10 was shown to have an inhibitory effect against P. aeruginosa.
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6. Future work
This research to date has established the excellent potential of the examined glass ceramic
compositions to function as load bearing therapeutic bone grafts. However, additional
work is recommended in order to further physical and biological evaluation:

1. Optimisation of processing of porous glass ceramic scaffolds and evaluation of
biaxial flexural strengths and modulus.

2. Cytotoxicity tests employing cell culture techniques to determine the lysis of cells
(cell death), the inhibition of cell growth, colony formation, and other effects on cells
caused by the class ceramics, and/or their extracts (ISO 10993-5).

3. Evaluation of hypersensitivity according to ISO 10993-10, to estimate the potential
for contact sensitisation by the glass ceramics and/or their extracts, using an appropriate
animal model. These tests are important because exposure or contact to even minute
amounts of potential leachables can result in allergic or sensitisation reactions.

4. Evaluation of genotoxicity according to ISO 10993-3 protocols as international
standards stipulate that any implantable material in contact with tissue for more than 30
days must undergo such testing.

5. In vitro evaluation of genetic up and down regulation of osteoblasts and osteoclasts
exposed to the ionic dissolution products of the experimental glass compositions in order
to assess the ability of the experimental compositions to genetically steer the tissue

175

towards regeneration and repair.
6.

Evaluation of the haemocompatibility of the glass ceramics according to ISO 10993-

4 in order to evaluate the effects of blood-contacting the materials and to determine the
degree of red cell lysis and the release of haemoglobin caused by materials.

7.

In vivo animal trials involving implantation of experimental glass ceramic

compositions into a critical size defect using a normal and osteoporotic model.
Implantation tests shall be used to assess the local pathological effects on living tissue, at
both the gross level and microscopic level.
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INTRODUCTION

Particulate Calcium-Strontium-Zinc-Silicate glasses demonstrate excellent potential as
bone graft substitutes [1], particularly in terms of antibacterial efficacy and therapeutic
release of strontium. However the synthesis of reticulated constructs (for enhanced bone
regeneration) based on the heat treatment of such materials is limited in the literature. The
objective of this work is to fabricate 3D glass-ceramic constructs (which share a similar
morphology to trabecular bone) by heat treating selected compositions from a popular
Calcium-Strontium-Zinc-Silicate system and to correlate phase transformations with the
mineralization potential using conventional analysis techniques.
EXPERIMENTAL METHODS

Glass Synthesis: Three glass compositions were prepared (Table 1).

Table 1: Glass composition (mol. fraction) with first crystallization temperature (Tpi)

Glass

Si02

ZnO

CaO

SrO

NaiO

Tpl CQ

BTllO

0.40

0.20

0.10

0.20

0.10

713

BTlll

0.40

0.10

0.10

0.20

0.20

577

BT112

0.40

0

0.10

0.20

0.30

525

Appropriate amounts of analytical grade reagents were weighed out and mixed to
homogeneity. Compositions were then fired (1480°C for Ihr) in platinum crucibles and
the glass melts shock quenched into water. The resulting frit was dried in an oven at
120°C for 1 day. The dried frit was attrition milled (1500 rpm Ihr) in iso-propanol with 24 mm zirconia beads and dried in a water bath at 100°C. Ceramic foams were synthesized
using a modified replication technique [2], with sacrificial polyurethane foam
characterized by a porosity of 60ppi. Heat treatments allowed for polymer burnout

(400°C, Ih) and crystallization (Tpl, 2h). Subsequent to processing, foam compositions
were then characterized using X-ray diffraction (XRD), to evaluate the crystalline phases
formed at Tpl. X-Ray tomography (XRT) was performed to examine foam morphology
morphological and porosity. Finally, compositions and contingent crystalline structures
were examined for mineralization potential using simulated body fluid (SBF) where the
materials surfaces were examined using scanning and transmission electron microscopy
(SEM and TEM). For reasons of clarity the glass materials (BTXXX) will be prefixed
with GC (CGXXX) to signify conversion to glass-ceramic in subsequent sections.

RESULTS AND DISCUSSION

Table 2: Results of XRD analysis on glass-ceramics

GlassCeramic
GCllO

GClll

GC112

JCPDS

Phase

Chemical

Crystalline

card no.

Identified.

Composition

structure

00-039-0235/

Strontium-zinc-silicate/

Sr2ZnSi207/

Tetragonal/

00-037-0407

Sodium zinc silicate

00-037-0407/

Sodium zinc silicate/

Na2ZnSi04/

Orthorhombic/

00-033-0302

Lamite

Ca2Si04

Monoclinic

00-.31-0299/

Calcium silicate/

Ca2Si04/

Orthorhombic/

00-039-1256/

Strontium silicate/

Sr2Si04/

Orthorhombic/

00-016-0818

Sodium silicate

Na2Si03

Hexagonal

Na2ZnSi04

Orthorhombic
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Fig. 3 : XRT image of BT glass ceramic foam

Table 2 highlights the crystalline structures derived from each glass composition at Tpl.
The phases arising from the heat treatment of BTlll and BT112 are associated with
varying levels of biocompatibility. The compatibility of the crystalline phases found as a
result of heat treating BTl 10 are, as yet, unknown. The XRT image as seen in figure 1
shows a three dimensional fully reticulated foam with a porosity level of >90%,
indicating excellent potential for the regeneration of osseous tissue. None of the glass
ceramic phases formed allowed for precipitation of an apatite layer in vivo, as examined
using EDX, SEM and TEM; an interesting finding, since it has also been shown that
certain glasses in this system behave in a similar fashion in SBF yet facilitate excellent
bone bonding and regeneration in vivo [1] .

CONCLUSION:
The materials synthesized exhibit morphology similar to that of trabecular bone, and
crystalline structures with varying degrees of biocompatibility. Whilst in vitro
mineralization potential is limited, further investigation is warranted given the discovery
of polymorphs with unknown compatibility.
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Appendix B- Biodegradable polymers for bone grafting
Both synthetic polymers and biologically derived (or natural) polymers have been
extensively investigated as biodegradable polymeric biomaterials. Biodegradation of
polymeric biomaterials involves cleavage of hydrolytically or enzymatically sensitive
bonds in the polymer leading to polymer erosion [1]. Depending on the mode of
degradation, polymeric biomaterials can be further classified into hydrolytically
degradable polymers and enzymatically degradable polymers. Most of the naturally
occurring polymers undergo enzymatic degradation. The rate of in vivo degradation of
enzymatically degradable polymers however, varies significantly with the site of
implantation depending on the availability and concentration of the enzymes. Chemical
modification of these polymers also can significantly affect their rate of degradation.
Natural polymers possess several inherent advantages such as bioactivity, the ability to
present receptor-binding ligands to cells, susceptibility to cell-triggered proteolytic
degradation and natural remodelling. The inherent bioactivity of these natural polymers
has its own downsides. These include a strong immunogenic response associated with
most of the polymers, the complexities associated with their purification and the
possibility of disease transmission. Synthetic biomaterials on the other hand are generally
biologically inert, they have more predictable properties and batch-to-batch uniformity
and they have the unique advantage having tailored property profiles for specific
applications, devoid of many of the disadvantages of natural polymers. Hydrolytically
degradable polymers are generally preferred as implants due to their minimal site to-site
and patient-to-patient variations compared to enzymatically degradable polymers [1].

1.1

Hydrolytically degradable polymers as biomaterials

Hydrolytically degradable polymers are polymers that have hydrolytically labile chemical
bonds in their back bone. The functional groups susceptible to hydrolysis include esters,
orthoesters, anhydrides, carbonates, amides, urethanes, ureas, etc. [2]. Two general routes
are used to develop hydrolytically sensitive polymers for biomedical applications. They
are step (condensation) polymerization and addition (chain) polymerization including
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ring opening polymerization. Step process is used to prepare a variety of hydrolytically
sensitive polymer classes, such as polyanhydrides, poly(ortho esters) and polyurethanes.
Ring opening polymerization (ROP) is an extensively investigated polymerization route
to develop hydrolytically sensitive polymers,

including the poly(a-esters) and

polyphosphazenes [3].
The most often utilized biodegradable synthetic polymers in tissue engineering are
saturated poly-a-hydroxy esters, including poly(lactic acid) (PLA) and poly(glycolic acid)
(PGA), as well as poly(lactic-coglycolide) (PLGA) copolymers. PLA exists in three
forms: L-PLA (PLLA), D-PLA (PDLA), and racemic mixture of D,L-PLA (PDLLA) [4].

1.1.2

Polyglycolide

Polyglycolide can be considered as one of the first biodegradable synthetic polymer
investigated for biomedical applications (Figure 1.1). Polyglycolide is a highly crystalline
polymer (45-55% crystallinity) and therefore exhibits a high tensile modulus with very
low solubility in organic solvents. The glass transition temperature of the polymer ranges
from 35 to 40°C and the melting point is greater than 200°C. In spite of its low solubility,
this polymer has been fabricated into a variety of forms and structures. Extrusion,
injection and compression molding as well as particulate leaching and solvent casting, are
some of the techniques used to develop polyglycolide-based structures for biomedical
applications [5]. Due to its excellent fiber forming ability, polyglycolide was initially
investigated for developing resorbable sutures. The first biodegradable synthetic suture
called DEXON that was approved by the United States Food and Drug Administration
in 1969 was based on polyglycolide. Non-woven polyglycolide fabrics have been
extensively used as scaffolding matrices for tissue regeneration due to its excellent
degradability, good initial mechanical properties and cell viability on the matrices.
Polyglycolide shows excellent mechanical properties due to its high crystallinity. A self
reinforced form composed of polyglycolide is stiffer than any other degradable polymeric
system used clinically [6] and has been shown to exhibit a modulus of approximately
12.5 GPa [7]. Due to its good initial mechanical properties, polyglycolides have been
investigated as bone internal fixation devices (Biofix®). Polyglycolide is a bulk degrading
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polymer, degrades by the non-specific scission of the ester backbone. The polymer is
known to lose its strength in 1-2 months when hydrolyzed and losses mass within 6-12
months. In the body, polyglycolides are broken down into glycine which can be excreted
in the urine or converted into carbon dioxide and water via the citric acid cycle [7]. The
high rate of degradation, acidic degradation products, which have been implicated in
adverse tissue reactions and low solubility however, limit the biomedical applications for
polyglycolide [3, 4].

Figure 1.1: Polyglycolide foam OsteoCure® f8].

1.1.3

Polylactide

Unlike glycolide, lactide is a chiral molecule and exist in two optically active forms; Llactide and D-lactide. The polymerization of these monomers leads to the formation of
semi-crystalline polymers. The polymerization of racemic (D,L)-lactide and mesolactide
however, results in the formation of amorphous polymers. Among these monomers, Llactide is the naturally occurring isomer. Similar to polyglycolide, poly(L-lactide)
(PLLA) is also a crystalline polymer (~37% crystallinity) and the degree of crystallinity
depends on the molecular weight and polymer processing parameters. It has a glass
transition temperature of 60-65°C and a melting temperature of approximately 175°C
[15]. Poly(L-lactide) is a slow-degrading polymer compared to polyglycolide, has good
tensile strength, low extension and a high modulus (approximately 4.8 GPa) and hence,
has been considered an ideal biomaterial for load bearing applications, such as
orthopaedic fixation devices. Figure 1.2 shows Plexur P® graft in various forms and
shapes Some of the PLLA-based orthopaedic products include: the Phantom Soft Thread
Soft Tissue Fixation Screws, Phantom Suture Anchors® (DePuy), Full Thread Bio
Interference Screws® (Arthrex), BioScrew® PLLA can also form high strength fibres and
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was FDA approved in 1971 for the development of an improved suture over DEXON®.
Due to the high strength of PLEA fiber, it has been investigated as scaffolding material
for developing ligament replacement or augmentation devices to replace non degradable
fibres, such as Dacron [9, 10]. Some PLEA fiber-based devices are currently under
investigation as long-term blood vessel conduits [3]. An injectable form of PEEA
(Sculptra®) has recently been approved by the FDA for the restoration or correction of
facial fat loss or lipoatrophy in people with the human immunodeficiency virus.
However, being more hydrophobic than polyglycolide, the degradation rate of PEEA is
very low. It has been reported that high molecular weight PEEA can take between 2 and
5.6 years for total resorption in vivo [3]. The rate of degradation however, depends on the
degree of polymer crystallinity as well as the porosity of the matrix. Even though the
polymer is known to lose its strength in approximately 6 months when hydrolyzed, no
significant changes in mass will occur for a very long time. PoIy(DE-lactide) (PDEEA) is
an amorphous polymer due to the random distribution of E- and D-lactide units and has a
glass transition temperature of 55-60°C. Due to its amorphous nature the polymer shows
much lower strength (-1.9 GPa) compared to poIy(E-lactide). This polymer loses its
strength within 1-2 months when hydrolyzed and undergoes a loss in mass within 12-16
months [7]. Being a low strength polymer with faster degradation rate compared to
poly(E-lactide), it is a preferred candidate for developing drug delivery vehicles and as
low strength scaffolding material for tissue regeneration. Polylactides e.g. polyglycolides
undergo hydrolytic degradation via the bulk erosion mechanism by the random scission
of the ester backbone. It degrades into lactic acid a normal human metabolic by-product,
which is broken down into water and carbon dioxide via the citric acid cycle [3].

Figure 1.2: Plexur P® graft in various forms and shapes [11].
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1.1.4

Poly(lactide-co-glycolide)

Among the co-polyesters investigated, extensive research has been performed in
developing a full range of poly(lactide-co-glycolide) polymers (PLGA). Both L- and DLlactides have been used for co-polymerization. In the composition range of 25-75%,
poly(L-lactide-co-glycolide) forms amorphous polymers. Miller et al. have shown that
the 50/50 poly(lactide-co-glycolide) is very hydrolytically unstable and the resistance to
hydrolytic degradation was found to be more pronounced at either end of the co-polymer
composition range [5, 12]. Different ratios of poly(lactide-co-glycolides) have been
commercially developed and are being investigated for a wide range of biomedical
applications. PuraSorb®PLG is a semi crystalline bioresorbable co-polymer of L-lactide
and glycolide with a monomer ratio of 80L:20G [13]. PLGA has been shown to under go
bulk erosion through hydrolysis of the ester bonds and the rate of degradation depends on
a variety of parameters including the LA/GA ratio, molecular weight, and the shape and
structure of the matrix. PLGA demonstrates good cell adhesion and proliferation making
it a potential candidate for tissue engineering applications. However, PLGA alone has not
demonstrated efficacy in the regeneration of healthy bone in osteopenic states, only with
the incorporation of drugs such as Ipriflavone has PLGA demonstrated limited
therapeutic efficacy [14]. Various studies have been performed so far using micro- and
nanofabrication techniques to form three-dimensional scaffolds based on PLGA [3].

1.1.5

Polycaprolactone

Polycaprolactone (PCL) is a semi-crystalline polyester, where its crystallinity tends to
decrease with increasing molecular weight, can be prepared by either ring-opening
polymerization of i -caprolactone using a variety of anionic, cationic and co-ordination
catalysts or via free radical ring-opening polymerization of 2-methylene-1-3-dioxepane
[15]. PCL is highly processible as it is soluble in a wide range of organic solvents, has a
low melting point (55-60°C) and glass transition temperature (~60°C) while having the
ability to form miscible blends with wide range of polymers [3]. The polymer undergoes
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hydrolytic degradation due to the presence of hydrolytically labile aliphatic ester
linkages; however, the rate of degradation is rather slow at up to 36 months [3, 15]. Due
to the slow degradation, high permeability to many drugs and non-toxicity, PCL was
initially investigated as a long-term drug/vaccine delivery vehicle. The long-term
contraceptive device Capronor® is composed of this polymer and has been developed for
the long-term zero order release of levonorgestrel [16]. PCL has low tensile strength
(approximately 23MPa) but an extremely high elongation at breakage (>700%) [5]. PCL
has been surface modified to possess a bone-like apatite layer bound to its surface as a
scaffold for tissue-engineering application [17]. The surface of PCL was treated with
aqueous NaOH to introduce carboxylate groups onto the surface and was subsequently
dipped in aqueous CaCL and K2HP04-3H20 to deposit apatite nuclei on the surface. The
surface-modified material successfully formed a dense and uniform bone-like surface
apatite layer after incubation for 24 h in simulated body fluid with ion concentrations
approximately equal to those of human blood plasma [17]. PCL cylindrical scaffolds with
gradually increasing pore size along the longitudinal direction were fabricated by a novel
centrifugation method to investigate pore size effect on cell and tissue interactions. The
scaffold was fabricated by the centrifugation of a cylindrical mould containing fibril-like
PCL, with a following fibril bonding by heat treatment [18]. The scaffold showed
gradually increasing pore size (from ^88 to .^405 pm and porosity (from ^80% to
94%) along the cylindrical axis under a centrifugal speed of 3000 rpm. The scaffold
sections were examined for their in vitro cell interactions using different kinds of cells
(chondrocytes, osteoblasts, and fibroblasts) and in vivo tissue interactions using a rabbit
model (skull bone defects) in terms of scaffold pore sizes. It was observed that different
kinds of cells and bone tissue were shown to have different pore size ranges in the
scaffold for effective cell growth and tissue regeneration. The scaffold section with 380405 pm pore size showed better cell growth for chondrocytes and osteoblasts, while the
scaffold section with 186-200 pm pore size was better for fibroblasts growth [18]. A
bioactive and bioresorbable scaffold fabricated from medical grade PCL (mPCL) and
incorporating 20% beta-tricalcium phosphate (mPCL-TCP), has been developed for bone
regeneration at load bearing sites by Abbah et al.[19]. Bone in-growth into mPCL-TCP
in a large animal model of lumbar interbody fusion was evaluated using six pigs, each
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undergoing a two-level (L3/4; L5/6) anterior lumbar interbody fusion and implanted with
mPCL-TCP scaffolds +0.6 mg rhBMP-2 as treatment group while four other pigs
implanted with autogenous bone graft, which served as control. pCT scanning and
histology revealed complete defect bridging in all (100%) specimens from the treatment
group as early as 3 months. Histological evidence of continuing bone remodelling and
maturation was observed at 6 months. In the control group, only partial bridging was
observed at 3 months and only 50% of segments in this group showed complete defect
bridging at 6 months. Furthermore, 25% of segments in the control group showed
evidence

of graft

fracture,

resorption

and

pseudoarthrosis.

Other

researchers

demonstrated that L-PLA fibers embedded in a porous PCL matrix promoted the in vitro
proliferation of human marrow stromal cells and osteoblasts [20]. PCL/TCP composites
have been successfully used in combination with platelet rich plasma in the treatment of
critical-size defects of the mandible in dogs [21]. Currently on the market as a
monofilament suture are co-polymers of e-caprolactone with glycolide known as
MONACRYL®.

Another bioresorbable multiblock co-polymer composed of e-

caprolactone, glycolide, lactide and poly(ethylene glycol) units has been developed as a
drug delivery vehicle for small and medium sized biologically active molecules
(SynBiosys®) [3].

1.2

Enzymatically degradable polymers for bone grafting

Proteins, the major structural components of many tissues are essentially amino acid
polymers arranged in a three-dimensional folded structure and are one of the most
important classes of biomolecules identified. Being a major component of the natural
tissues, proteins and other amino acid-derived polymers have been a preferred
biomaterial for sutures, haemostatic agents, scaffolds for tissue engineering and drug
delivery vehicles. Furthermore, protein based biomaterials are known to under go
naturally-controlled degradation processes [22]. The human body is capable of
synthesizing a wide range of proteins in which the precursor molecules pass through four
major stages in becoming functional proteins. The first step involves the formation of the
primary structure where, a linear sequence of various amino acids is held together by
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peptide bonds. The constituent amino acids then participate in hydrogen bonding to form
the secondary structure of protein. The linear primary structure arranges itself in the most
stable structures—a-helices or p-pleated sheets. These secondary structures then join
together to form three-dimensional tertiary structures which in turn interact with other
protein chains to form the more refined three-dimensional quaternary structure of a multi
unit protein [3].

1.2.1

Collagen

Collagen comprises 90% of the organic matrix of bone and, together with the mineral,
governs the biomechanical properties and functional integrity of this tissue [23]. Collagen
is a rodtype polymer nearly 300 nm long with a molecular weight of 300,000. There have
been more than twenty two different types of collagen identified so far in the human
body, with the most common being Type 1-lV. Type I collagen is the single most
abundant protein present in mammals and is the most thoroughly studied protein. The
Type I collagen is composed of three polypeptide subunits with similar amino acid
compositions. Each polypeptide is composed of about 1050 amino acids, containing
approximately 33% glycine, 25% proline and 25% hydroxyproline with a relative
abundance of lysine [3, 24]. The subunit chains of collagen are synthesized from free
amino acids in the body and undergo transcription, translation and post-translation
modification processes in appropriate cells such as fibroblasts and osteoblasts [3].
Collagen has a unique structure, size and amino acid sequence. The collagen molecule
consists of three polypeptide chains twined around one another as in a three-stranded
rope. Each chain has an individual twist in the opposite directions. The principal feature
that affects a helix formation is a high content of glycine and amino acid residues. The
strands are held together primarily by hydrogen bonds between adjacent —CO and —NH
groups, but also by covalent bonds. The basic collagen molecule is rod-shaped with a
length and a width of about 3000 and 15

A,

respectively, and has an approximate

molecular weight of 300 kDa [24]. Collagen undergoes enzymatic degradation within the
body via enzymes, such as collagenases and metalloproteinases, to yield the
corresponding amino acids. Due to their enzymatic degradability, unique physico
chemical,

mechanical

and

biological

properties collagen

has been

extensively
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investigated for biomedical applications. However, some disadvantages of collagen-based
systems arose from the difficulty of assuring adequate supplies, their poor mechanical
strength, and ineffectiveness in the management of infected sites. Collagen is mostly
soluble in acidic aqueous solutions and can be processed into different forms such as
sheets, tubes, sponges, foams, nanofibrous matrices, powders, fleeces, injectable viscous
solutions and dispersions. Collagen itself has been used as bone substitutes due to its
osteoinductive activity. Studies have also shown that the degradation rate of collagen
used for biomedical applications can be significantly altered by enzymatic pre-treatment
or cross-linking using various cross-linking agents [3, 24, 25]. Collagen in combination
with other polymers or chemicals was also used for orthopaedic defects. Demineralised
bone collagen was used as a bone graft material for the treatment of acquired and
congenital orthopaedic defects either by itself or in combination with hydroxyapatite
[26]. The result of this study showed that grafted demineralised bone collagen in
combination with hydroxyapatite was an excellent osteoinductive material and could be
used as a bone substitute. A recent study showed that addition of 500 lU of retinoic acid
to collagen at a site of a bone defect enhanced regeneration of new bone, achieving union
across the defect and leading to its complete repair [27]. Collagraft® (Zimmer, US) is a
composite of suspended fibrillar bovine derived collagen and a porous tricalcium
phosphate and hydroxyapatite ceramic, has been FDA approved for use as a
biodegradable synthetic bone graft substitute [3, 28]. In a rabbit femoral defect model,
Collagraft® demonstrated significantly enhanced bony ingrowth, compared to other bone
graft substitutes [29]. Similarly, clinical trials have indicated that when Collagraft® is
mixed with autogenous bone marrow it functions effectively in the treatment of acute
long bone fractures [30]. Healos® (Orquest, US) is a HA mineralized Type 1 collagen
sponge (Figure 1.3) [28] and is mainly used as an osteoconductive matrix. Cross-linked
absorbable collagen sponges have undergone clinical trials as protein carrier vehicles [3].
Bioactive proteins, such as recombinant human bone morphogenic protein (rhBMP-2),
were incorporated in collagen matrices to achieve sustained release of the protein due to
favourable interactions of the collagen matrix with the protein [31]. This combination
product is recently approved by the US FDA to be used in conjunction with a titanium
interbody spine fusion cage for anterior lumbar spinal fusion (InFUSE® Bone graft/LT-
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CAGE® Lumbar Tapered Fusion Device) and is approved in Europe (InductOs®) for the
treatment of acute tibia fractures in adults [3]. The major sources of collagen currently
used for biomedical applications are bovine or porcine skin or bovine or equine Achilles
tendons. One disadvantage of these collagen-based biomaterials which is a limiting factor
for the wide-spread clinical application is their mild immunogenicity imparted by the
composition of the terminal region and the antigenic sites in the central helix. The
immune response has been found to vary depending on the species from which collagen
has been isolated, processing techniques and the site of implantation. Other concerns
include the high cost of pure collagen, variable physico-chemical and degradation
properties and the risk of infectious diseases transmission due to the allogenic or
xenogenic origin of the material. Several recombinant systems are currently under
development to produce human sequence collagen to overcome some of the limitations of
using animal-derived collagen [32].

Figure 1.3; Heleos® in sponge form [33]

1.2.2

Chitosan

In respect of hard tissue engineering, a popular polysaccharide is the cationic polymer
Chitosan, which originates from crustacean skeletons, and the anionic polymer alginic
acid, derived from brown algae, both of which have been used as drug delivery vehicles
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[34]. Structurally chitosan is a linear polysaccharide consisting of p (1-4) linked Dglucosamine with randomly located N-acetylglucosamine groups depending upon the
degree of deacetylation of the polymer. Chitosan is derived from chitin, 2-acetamido-2deoxy-p-d-glucose through a p (1—^4) linkage, which is a fully acetylated polymer and
forms the exoskeleton of arthropod [3, 35]. Chitosan is obtained by (partial) deacetylation
of chitin in the solid state under alkaline conditions (concentrated NaOH) or by
enzymatic hydrolysis in the presence of chitin deacetylase. Because of the semicrystalline
morphology of chitin, chitosan obtained by solid-state reaction has a heterogeneous
distribution of acetyl groups along the chains. Chitin and chitosan are biocompatible,
biodegradable and non-toxic polymers [36]. Enzymes, such as chitosanase, lysozyme and
papain are known to degrade chitosan in vitro [37]. The in vivo degradation of chitosan is
primarily due to lysozyme and takes place through the hydrolysis of the acetylated
residues. The rate of degradation of chitosan inversely depends on the degree of
acetylation and crystallinity of the polymer [38]. The highly deacetylated form exhibits
the lowest degradation rates and may last several months in vivo. Apart from this,
chemical modification of chitosan can significantly affect its solubility and degradation
rate. In a study that compared the in vivo degradation of 85% deacetylated chitosan with
isobutyl substituted chitosan (degree of substitution, approximately 40%) after
implantation in the muscle pouch of mice demonstrated the faster degradation rate of
substituted chitosan [39]. The faster degradation rate has been attributed to the
deformation of strong hydrogen bonds present in chitosan. Chitosan is a natural polymers
thus possesses excellent properties such as biocompatibility, biodegradability, non
toxicity, adsorption properties [35]. Chitin and chitosan inherently have poor mechanical
properties. Therefore chitin can be used as bone substitute for bone repair and
reconstruction only if its mechanical property can be improved with addition of
biomaterials like hydroxyapatite (HAp), bioactive glass ceramic (BGC), etc. BGC Chitin
or chitosan/nBGC composite scaffolds were developed by lyophilization technique. The
composite scaffolds showed adequate porosity when the nBGC were homogenously
distributed on the pore walls. The developed nanocomposite scaffolds showed adequate
swelling and degradation properties aside of its ability to become bioactive.
Cytocompatability of the chitin/nBGC and chitosan/nBGC scaffolds was assessed using
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MTT assay, direct contact test and cell attachment studies. Results indicated no signs of
toxicity and cells were found to be attached to the pore walls offered by the scaffolds.
[36]. Similar composites demonstrated apatite formation when immersed in simulated
body fluid indicating their bioactivity [40]. Chitosan/HA composites have significantly
stimulated bone forming ability in vitro as demonstrated by induced proliferation of
human fetal osteoblast cells and mineral deposition [41].
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Appendix C- Glass formation and Nucieation
Various definitions of glass have been proposed such as “glass is an inorganic product of
fusion which has cooled to a rigid condition without crystallising”, however this
definition excludes organic substances which can form supercooled materials without
crystallising and also amorphous materials prepared by methods other than cooling.
Another definition states that “an amorphous substance is one that in which, long range
order in the atomic arrangement does not exist over distances greater than that of lOnm”
which does not take into account polycrystalline materials with a long range order less
than 10 nm [1]. The current accepted definition of a glass is “an amorphous solid
completely lacking in long range, periodic atomic structure, and exhibiting a region of
glass transformation behaviour”, therefore any material, inorganic, organic or metallic,
formed by any technique, which exhibits glass transformation behaviour is a glass [2].
As our understanding of glass technology progressed over time so too did the theories to
explain how or why glasses formed. Classical nucieation theory was developed where the
theory consists of two parts: 1) a thermodynamic expression for the free energy of
formation of a liquid droplet, and 2) a kinetic part which governs the size evolution of a
droplet. The first part leads to concept of critical radius and the definition of the nucleus,
while the second leads to an expression for the nucieation rate. The first part of this
theory been named as the “Structural theories of glass formation” and the other as the
“Kinetic theory of glass formation” [2].

1.1

Structural theories of glass formation

Some oxides can readily vitrify when cooled from the molten state whereas others
crystallise. Among the several theories initially proposed for glass formation, the
statements by Zachariasen have become the basis for the models for glass structures
termed the “random network theory”. Zachariasen developed his theory following work
by Goldschmidt and deduced that atoms are linked in the form of a three dimensional
(3D) network in glass as in crystals exhibiting isotropic properties. The network in the
glass could not be periodic as glasses do not exhibit sharp X-ray diffraction patterns
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similar to those found in crystalline materials. He also proposed that the energy content of
a substance in the glassy state must not be greatly different from that of the corresponding
crystal structure, and that the co-ordination number in a glass forming cation is close in
value in the glass and crystal. In the glass the structural units, which are the same as those
found in the crystal, are arranged in a non periodic fashion giving a random network due
to the distortion of bond angles. The structural units in the crystals are arranged in regular
lattices [1]. The 2-dimensional representation in Figure 1.1 illustrates these concepts for
M02, in its crystalline and glass form. Zachariasen proposed certain conditions for oxide
glass formation. Firstly, the material must contain a high proportion of cations, which are
surrounded by either oxygen triangles or oxygen tetrahedra, meaning that the co
ordination number of the network-forming cation must be 4 or less. Secondly, the oxygen
(anion) must be linked to no more than 2 cations and the oxygen polyhedra must share
only corners and not edges or faces, meaning that the network is an open structure.
Thirdly, at least 3 corners of each oxygen polyhedron must be shared in order to form a
continuous 3-dimensional network structure [2].
(a) Crystalline MOj

(b) Amorphous MOj

•

M ion

•

Oxygen ion

Figure 1.1: 2-dimensional schematic of MO2 in its (a) crystalline form and (b) amorphous form [3]

The oxides M2O and MO cannot meet the conditions proposed by Zachariasen
and thus cannot form glass in isolation, however the oxides M2O3 can if the oxygen forms
triangles around each M atom and in MO2 and M2O5, if the oxygen form tetrahedra
around each M atom [1]. Vitreous silica (Si02) is an example of a glass built up of
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tetrahedra units, the tetrahedra Si04 found in the crystalline state [1, 2]. Oxides which
form glasses upon cooling from melt are known as network forming oxides; they possess
the ability to construct 3D random networks. There are also two other types of functional
oxides when it comes to glass structure, namely, network modifying and intermediate
oxides. Network modifying oxides is one which in not capable of building a continuous
network. The effect of such oxides is usually to weaken the glass network. Taking
sodium oxide as an example, if introduced into a silica glass network, structural changes
occur where instead of the bridging oxygen ions which formed the link between the two
Si04 tetrahedra there now is found two non-bridging oxygen’s one of which had been
contributed by the sodium oxide. The effect of which is to disrupt the continuous network
structure. The introduction of a modifying oxide results in changes of the glass properties
including reduction in glass viscosity, melting temperature, glass transition temperature
and a more reactive and degradable material than that of a glass without the modified
network [1,2, 4]. Other oxides such as AI2O3 are termed network intermediates. They are
unable to form a glass by themselves but can isomorphically substitute for silicon in the
vitreous network [3, 5]. For example the tetrahedral group AIO4 can replace Si04
tetrahedra in silicate lattices. Since each aluminium ion has a charge of +3 as compared
with a unit charge of +4 for each silicon ion, an additional unit positive charge must be
present to ensure electoneutrality [1].

It is clear that the nature of the bonds formed

between cation and oxygen plays a critical role in type of network formed. Oxides which
form highly covalent bonds to oxygen are more likely to assume the role of network
formers than oxides in which ionic bonding is dominant [3]. The connectivity of a glass
network is determined by the ratio of bridging to non-bridging oxygen contained therein
[3]. The network connectivity of a glass can be calculated using molar composition by
equation 1 [6].

NC =

No. BOs - No. NBOs

Equation 1.1

Total No. Bridging species

Where, BO=Bridging Oxygen’s and NBO=Non-Bridging Oxygen’s.
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Glasses with NC significantly below 2 are termed invert glasses, where the amount of
network modifier (e.g. Na, K, Ca, and Sr) in the glass is greater than the amount of glass
former (e.g. Si). However, low NC glasses tend to be thermally unstable and devitrify
quite easily when heated above Tg due to the depolymerisation of the glass network.
Dissolution of very low NC glasses would also be rapid and not be practical in a
biological system. The initial burst of alkali ions would likely be cytotoxic and result in
cell death and fibrous encapsulation of the material [7], however a study by Boyd et ai,
[8]

on

a

series of zinc-calcium-strontium-silicate

glasses demonstrated

good

biocompatibility for glasses with NC of less than two which demonstrates not only is the
NC of the glass important regarding dissolution behaviour but also the interaction of ions
released once placed in vivo. The ability to detennine the role of an oxide in a glass
network can be determined by the ionic field strength of the ion and can be calculated by
the following equationF=Z/r"

Equation 1.2

Where Z is the valency and r the ionic radius [1]. The values of F allow a classification of
oxides according to their role in glass structure. Using such classification, cations with
high field strength (>1.3) such as silicon tend to play the role of network formers. Those
with lower field strengths (<0.4), such as sodium, are classified as network modifiers and
those ranging between 0.4-1.3, such as zinc are network intermediates [3, 9, 10] If we
take calcium as an example and substitute the appropriate values into equation 1.1 where
Z=4 and r=0.99, we can classify Ca

1.2

as a network modifying ion.

Kinetic theories of glass formation

When dealing with structural theories of glass formation the ability of an oxide to form a
glass has been related to the crystal structure of that oxide, however it is the structure and
properties of the melt which determine its ability to form a glass [1]. The structural theory
deals with the relative ease of glass formation only and more recent theories have
proposed that any substance will forma glass, if cooled rapidly enough not allowing the
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reorganisation of the structure into long range order and hence avoid crystallisation. This
theory is termed the Kinetic theory of glass formation. In order for a glass to crystallise
there must first occur the formation of nuclei on which the crystals can grow to detectable
size [3, 11]. Two possibilities arise which can prevent a supercooled melt from
crystallising, either the nucleation rate is very small or the rate of growth of crystals upon
the nuclei is negligible at all temperatures [1]. Nucleation can be either homogeneous or
heterogeneous, which means forming within the melt or at a pre-existing surface such as
an impurity, respectively [11]. If however no nuclei are formed, crystallisation cannot
occur and a glass will be formed, and as stated previously if the nuclei formed are not
detectable the solid is still considered a glass [3, 12]. Two barriers exist to the formation
of a nucleus, firstly the thermodynamic barrier. This barrier involves the free energy
change in a system when a nucleus if formed. Secondly the kinetic barrier which is
determined by the mass to be moved or rearranged , to allow the growth of a crystal from
a disordered liquid [3]. The overall process is determined by the following equation:

/=Aexp[-(W*+AGD)/kT]

Equation 1.3

Where A is a constant, W* and AGd are the thennodynamic and kinetic free energy
barriers to nucleation, respectively, k is the Boltzmann constant, and T is the absolute
temperature (K) [3]. As stated earlier a nucleus must not re-dissolve back into the melt
and must reach a critical size, this is designated as W* in the above equation. Formation
of a nucleus actually involves two changes in the energy of the thermodynamic barrier.
The first is achieved by the formation of a crystalline arrangement which lowers the
volume free energy, since the crystalline state has a lower free energy than the melt. The
second is an increase in surface energy due to the formation of a new interface between
regions of different structures. Figures 1.2 and 1.3 demonstrate the free energy difference
between a glass and crystal and the energy requirement to form a new nucleating surface
respectively. The net change in energy, W, for a sphere radius, r, is given by the
following equation-

W=4/37ir^AGv+47cr^7

Equation 1.4
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where the first term represents the change in the volume free energy, and the second in
surface energy [3].

Figure 1.2; The free energy difference (per volume) between a glass and crystal (or nucleus) is AGV [13]

Figure 1.3: Graphical representation of Nucleation opposed by energy needed to create a new surface [13]

Since AGv is negative for temperatures below the melting point of the crystal, the terms
have opposite signs. Thermodynamically stable nuclei can be formed when r reaches a
critical size, r*, known as a critical radius thus forming critical size nuclei. R* is given
by203

r*= -2y/AGv

Equation 1.5

If we now substitute r* into equation 1.4 we can define the value of W for the critical
nucleus, W* by the expression

W*= 167iy73AG

Equation 1.6

A number of approximations can be made for the value of AGv or AG, since AG =VniAGx
expressions can be written on either molar or volume basis-

AG= -AHf<Tm-T)/VmTr

Equation 1.7

Where AHf is the heat of fusion or as

AGv = -AHt<Tm-T)/VmTr

Equation 1.8

It becomes apparent from the above equations that the further below Tm the greater the
driving force for nucleation [14]. However, it is known that all melts do not crystallize
upon cooling, and the reason for this is that for nucleation to occur there is also a kinetic
barrier to overcome. Determination of the kinetic barrier for nucleation can be deduced
by the effective diffusion coefficient, D, which is given by

D = (kTX7h)exp(-AGD/kT)

Equation 1.9

Where X is the atomic jump distance, h is planks constant and k is Boltzmann’s constant.
In many cases, it has been assumed that D is related to the viscosity, q, of the melt via the
Stokes-Einstein relation-

D = kT/3>.q

Equation 1.10
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Using the relations given by equations 1.9 and 1.10, and substituting into the original
equation for nucleation rate, Eq 1.3, the following expression can be obtained -

(Ah/37iX^q)exp(-W*/kT)

Equation 1.11

The above expressions relate to the situation of homogenous nucleation. An expression
similar to Eq. 1.3 can be used for heterogeneous nucleation on a flat substrate

Equation 1.12

//;er=Ahctexp[-(W;,er*+AGD)/kT]

Where the subscript “het” refers to values for heterogeneous nucleation and Whet* is a
function of the angle of contact between the crystal nucleus and the substrate. A graphical
representation of equations 1.11 and 1.12 are given in Figures 1.4 and 1.5.
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• y'
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nucleus
Figure 1.4: Representation of the energy changes needed in a system in order for nucleation in
homogeneous and heterogeneous conditions [13]

Whilst the temperature of the melt is held above Tm (melting point) no nuclei tend to
form, however as the temperature drops to less than or equal Tm the change in the free
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energy of the system is such that a nucleus can become stable. If the temperature is very
near Tm the value of AG is very small, thus the critical radius for a stable nucleus, as per
Eq. 1.5 will be large and the probability of such a size nucleus is low [3]. As the
temperature decreases further the critical radius will become smaller so that the
probability of formation of a nucleus large enough to exceed the critical radius will
become significant and nuclei will begin to form in detectable quantities. Since a
significant degree of undercooling which may be as little as a fraction of a degree must
occur before the critical radius decreases to the point where detectable nuclei exist in the
melt, a metastable zone of undercooling exists. Once the temperature of the cooling melt
passes below the lower limit of the metastable zone, the thermodynamic barrier will
decrease with decreasing temperature, allowing nuclei to form at an increasing rate.

ti
oc
o

Z
♦-Temperature
Figure 1.5: Graphical representation of the thermodynamic and kinetic considerations relating to
nucleation rate as a function of temperature [13].

The controlled crystallisation of a glass involves crystal growth as well as nucleation [1].
Crystal growth depends on the rate at which the irregular glass structure can be re
arranged into the periodic lattice of the growing crystal and the rate at which energy
released in the phase transformation process can be eliminated, i.e. the rate of heat flow
away from the crystal glass interface. Considering the process of structural
transformation an atom in the crystal structure comprises a lower free energy than a
corresponding atom in the glass phase by an amount AG. For an atom to cross the
interface between the glass and the crystal phase it must overcome an energy barrier
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corresponding to a free energy of activation. An expression for the crystal growth rate can
be derived-

U = aovexp(-AE/kT)[l-exp(AG/kT)]

Equation 1.13

where ao is the interatomic separation distance, v is the vibrational frequency and AE and
AG are the kinetic and thermodynamic barriers to crystal growth [1, 3]. Equation 1.11
describes what is known as normal growth. It is based on the assumption that the
probability of an atom being added or removed from a given site is the same for all sites
on the crystal-liquid interface and this requires the interface to be rough on the atomic
scale. In general this is not true, generally growth takes place by a mechanism in which it
is energetically favourable for atoms to be added to step sites provided by screw
dislocations intersecting the interface. Thus only a fraction of the total number of sites
will be available for growth: this fraction is given by [1]-

J^ls\J2nYr

Equation 1.14

It is necessary for the right hand side of equation 1.13 to be multiplied by this factor, for
small undercoolings,/is small but increases for large undercoolings [1]. If we take the
same approach to nucleation rate as taken for nucleation growth rate, and introduce
equations 1.9 and 1.10 to describe diffusion, we obtain the expression [3]

U = (kT/37ia^oTl)[l-exp(AG/kT)]

Equation 1.15

The nucleation and crystal growth in glasses occurs simultaneously during cooling of the
melt, with rates apportioned to the change in temperature. Therefore it is prudent to
approach glass formation in the same way. Under these conditions, we can describe the
volume fraction of crystals in a sample VJV, where Vx is the volume of crystals and V is
the sample volume, by the expression
1/

Equation 1.16

207

Where ly is the nucleation rate per unit volume and U is the linear crystal growth rate.
During cooling both ly and U will be time dependant. If Uand U are known at a given
temperature it is possible to calculate the time required to form a specific volume fraction
of crystals, it is also possible to calculate the curve in temperature/time space that is a
time-temperature-transition curve if the quantities are known as a function of temperature
[3J, Figure 1.6 being an example. As a result of the competition between thermodynamic
and kinetic factors for both the nucleation and growth rates, the curve will have the
general shape as shown in Figure 1.6. Since ly and U approach zero as the temperature
approaches Tm, the time required to form the specified volume fraction of crystals will
approach infinity. The least favourable condition for glass formation occur at the
temperature, Tn, corresponding to the nose of the curve, where the time to reach the curve
tn is the least [3].

Figure 1.6: Time-temperature-transformation curve for a glass forming melt [13].

1.3

Primary Nucleation

1.3.1

Homogeneous Nucleation

Exactly how stable nuclei and crystals are formed within a homogeneous fluid is not
known with any degree of certainty [15]. In order for homogeneous nucleation to occur
all foreign nuclei must be excluded [1], the formation of the nuclei requires the formation
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of an interface between the two phases [16]. The classical theory of nucleation is based
on a condensation of a vapour to liquid, and can be extended to crystallization from melts
and solutions, it stemmed from work by Gibbs (1948), Volmer (1939), Becker and
Doring (1935) amongst others [1, 15]. The formation of nuclei depends on constituent
molecules coagulating, resisting the tendency to redissolve and also become orientated
into a fixed lattice. The formation of very small particles usually requires an increase in
the free energy of the system [16]. The classical theories of nucleation suppose that the
clusters are formed by an addition mechanism until the critical size is reached.

A +A=A2

Equation 1.17

A2 +A=A3
An-i+A=An

(critical cluster)

Further molecular additions to the critical cluster would result in nucleation and
subsequent growth of the nucleus. Similarly ions or molecules in a solution can interact to
form short lived clusters, short chains may be formed and eventually a crystalline lattice
structure built up [15]. The construction process which occurs very rapidly can only
continue in local regions of very high supersaturation, and many sub-nuclei redissolve as
they are too unstable. When the nucleus grows beyond a critical size it become stable
under the average conditions of supersaturation obtaining in the bulk of the fluid [15]. At
this stage, once the particle has reached a critical size the interface energy is small
compared with the volume energy decrease so that the overall change in free energy on
forming the new phase becomes negative [16]. The change of the free energies associated
with the process of homogeneous nucleation may be considered as follows:

AO = AOs + AG, = 4m-^cr + -w^AG,
^

Equation 1.18

where AGS is the excess free energy between the surface of the particle and the bulk.
AGV is excess free energy between a very large particle and the solute in solution. For
homogeneous nucleation the volume free energy for supercooling can be expressed by:
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AG, =
Equation 1.19

The two terms on the right- hand side of equation (1.2) have an opposite effect on the
system and they depend differently on the radius of the nucleus r. Therefore the free
energy of formation AG passes through a maximum value AGcryt, which corresponds, to
the nucleus critical size. From Fig. 1.2 it can be seen that AGs is a positive quantity,
proportional to r^. AGv is a negative quantity proportional to r^ [15]. If we take equation
1.2 and let it equal 0 the critical size for a spherical nucleus can be identified by equation
1.4
dAG

= 8;rrcr + Anr AG. = 0

dr

Equation 1.20

Therefore-

r =

1(7

-

AG,

Equation 1.21

where AGv is a negative quantity. From equations 1.2 and 1.5 we get

16;rCT^
CTJft

4;rcr

3(AG,)^
Equation 1.22

The rc represents the minimal size of a nucleus which needs to be gained before the new
phase is formed. If the cluster size is smaller than the critical size they can easily re
dissolve back in the liquid [3, 15]. As stated earlier and demonstrated in Figure 1.8 it can
be seen that nuclei with sizes larger rc will reduce the energy necessary to get a stable
nucleus which can continuously grow into crystals [15].
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SIz* of nuclout, r

Figure 1.8: Free energy diagram for nucleation explaining the existence of a critical nucleus [17].

The rate of nucleation, can be written as follows [15]

J = A exp

..2
-16;rcr 3u

ik^TH^nSy
Equation 1.23

Where S is the degree of supersaturation, u is the molecular volume and a is the
interfacial tension, and it is these three main variables that govern the rate of nucleation
[15].

1.3.2

Spinodal decomposition

Spinodal decomposition occurs during glass in glass phase separation [1]. It has been
observed for many glass forming systems that subjection to thermal treatment can cause
separation into two non crystalline phases. If this phase separation takes place in the melt
at a temperature above the liquidus temperature, it is described as stable immiscibility,
whereas phase separation occurring below the liquidus is described as metastable
immiscibility, or glass in glass phase separation. If a phase separated microstructure
develops in the glass prior to nucleation and crystal growth it is likely that the kinetics of
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these processes will be significantly affected [1]. Two types of phase separations are
possible in glass-ceramic systems, nucleation and growth and spinodal decomposition [1,
15, 16]. The theory of the former parallels closely to that of crystal nucleation and
growth. Figure 1.9 illustrates the free energy versus composition curve for a mixture of
components A and Bat temperature T. The presence of two minima in this curve creates a
situation in which the mixture will separate into two phases for composition lying
between U and V.

Cornposjftort

Figure 1.9: Free energy versus composition relationship and the resultant phase diagram showing the
regions of phase separation by spinodal decomposition and by nucleation and growth (shaded) [1].

The free energy of the mixture given by a point lying on the common tangent to points U
and V on the free energy curve will be reduced if the mixture undergoes phase separation.
As the temperature increases the two free energy minima move closer together, this leads
to the loci of the minima to trace out an immiscibility dome as shown in the bottom half
of Figure 1.9. Ultimately, the two minima coincide at a temperature Tc, known as the
upper consulate temperature. Within the immiscibility dome two distinct regions arise.
Point X and y represent inflections in the free energy curve such that between x and y
5 F/5C (the second differential of the free energy versus composition relationship) is
212

negative [1]. The basic principal of spinodal decomposition is based on Gibbs derivation
for the limit of stability of a fluid phase with respect to continuous change of phase
represented by

{5^G/8c^}t,p =0

Equation 1.24

where G is Gibbs free energy per mole of solution and c is the solution concentration. For
spinodal decomposition to occur a spontaneous phase transition is necessary and the
condition equation 1.9 should apply [15].

(8^G/8c^)</= 0

Equation 1.25

In the negative region of Figure 1.9 small fluctuation in composition are associated with a
reduction of the free energy. Phase separation within this region, which does not require a
nucleation process, is referred to as spinodal decomposition. As the temperature is raised
the points of inflection, x and y, will move closer together and again will coincide at the
consulate temperature. Thus the loci of these points will trace out an inner dome as
shown in the bottom half of Figure 1.9, the region within this is known as the spinodal
because of its spine like form. Looking at the upper half of Figure 1.9, in the region
between U and x and between V and y 5^F/5C^ is positive and here a small composition
fluctuation will be associated with an increase of free energy. Such fluctuations will
therefore be unstable and tend to redissolve. They will only continue to grow if they
attain a critical size, hence separation within the region outside the spinodal curve will be
a nucleation and growth process [1].

1.3.3

Heterogeneous nucleation

The nucleation of most phase transformations takes place heterogeneously, on container
walls, impurity particles or structural imperfections (Fig 1.10). The general action of such
nucleating substrates is to reduce the barrier to nucleation represented by surface energy
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[16]. Many reported cases of homogeneous nucleation are found on careful examination
to have been induced, it is generally accepted that true homogeneous nucleation is
uncommon [15].

Fig 1.10: Heterogeneous nucleation occurs on foreign surfaces or interfaces [17].

As the presence of a suitable foreign body can induce nucleation at degrees of
supercooling lower than those required for spontaneous nucleation, the overall free
energy change associated with the formation of a critical nucleus under heterogeneous
conditions AG’cnt, must be less than the corresponding free energy change Accrit
associated with homogeneous nucleation, i.e.

AG‘crit ~ OAG cnt

Equation 1.26

where the factor O is less than unity.
Previously in equation 1.23 it is stated that the interfacial tension, is one of the most
important factors in controlling the nucleation process. Figure 1.11 shows an interfacial
energy diagram for three phases in contact. The interfacial tensions are denoted, yd.
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between crystalline phase c and liquid 1, ysi, between another solid and liquid, and

jcs,

between solid crystalline and a solid foreign solid surface.

ret

Figure 1.11: Interfacial tensions at the boundaries between three phases [1]

Resolving these forces in a horizontal direction

Cos0 = YsI-Ycs/YcI

Equation 1.27

The angle 0, the angle of contact between the crystalline deposit and the foreign solid
surface, corresponds to the angle of wetting in liquid-solid systems [15]. In the case of
complete non affinity between the crystalline solid and the foreign solid surface, the
overall free energy of nucleation is the same as that required for homogeneous
nucleation. In the case of partial affinity, heterogeneous nucleation is easier to achieve as
the overall excess free energy required is less than that of homogeneous nucleation. For
the case of complete affinity, this case corresponds to the seeding of a supersaturated
solution with crystals of the required crystalline product (no nuclei have been formed)
[15]. Figure 1.11 indicates the relationship between O and 0. When some glass-forming
materials are cooled into a glassy state and then reheated to a temperature T between the
glass transition temperature and the melting point, a high volume of crystallisation is
frequently observed. In contrast when a sample of the same material is cooled directly to
T from a temperature above the melting point, the sample may remain free of visible
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crystallisation for an extended period. The origin of this difference in behaviour can be
associated with nuclei which form during cooling and reheating in the first type of heat
treatment. The ability to produce large densities of internal nuclei in glass forming liquids
by the addition of selected nucleating agents to the melt has important implications in
forming glass ceramic materials [15].

Fig 1.12: Ratio of free energies of homogeneous and heterogeneous nucleation as a function of contact
angle [18].

The crystallization process can occur within the bulk glass or on its surface, referred to as
bulk and surface crystallization, respectively. If crystallization occurs from nuclei
dispersed throughout the bulk of the base glass, then it is termed bulk crystallization.
Both homogeneous and heterogeneous nucleation may occur during bulk crystallization.
Figure 1.12 give a graphical representation of both nucleation types as a function of
contact angle and ratio of free energy. If the crystallization process is initiated on the
surface of the glass sample through heterogeneous nucleation, it is called surface
crystallization. The crystals grow from the surface towards the centre of the glass sample.
Bulk and surface phases are clearly distinct: a surface phase transition only affects the
surface—it does not reach into the bulk. Homogeneous nucleation does not lead to
surface crystallization [1, 15, 16, 19, 20].
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1.3.4

Secondary nucieation

A supersaturated solution nucleates more readily, i.e. at a lower supersaturation, when
crystals of the solute are already present or deliberately assed. The term secondary
nucieation is used in order to differentiate form primary nucieation where no crystals are
involved [15]. Arguably the best method for inducing crystallisation is to inoculate or
seed a supersaturated solution with small particles of the material to be crystallised [15].
Seed crystals, however do not necessarily have to consist of the material being
crystallised in order to be effective: isomorphous substances will frequently induce
crystallisation. Phosphates for example will often nucleate solutions of arsenates. The
success of silver iodide, as an artificial rain inducer is generally attributed to the striking
similarity of the Agl and ice crystal lattices. Melia and Moffitt (1964) studied secondary
nucieation in aqueous solutions of KCl and reported that the nucieation rate was
independent of the number of seeds added, Cayey and Estrin (1967) reported a strange
effect with the quantities of seeds added. One seed (~1 mm, <2mg) was more effective in
inducing nucieation than 50 mg but less so than 500mg. A critical size of seed of 200pm
was suggested in order to induce new nuclei to form [15]. There are several reasons why
the seed crystal size may influence secondary nucieation. Large seeds generate more
secondary nuclei in agitated systems than smaller ones due to their greater contact
probabilities and collision energies. Smaller crystals can follow the streamlines within the
turbulence eddies in vigorously agitated solutions behaving essentially as if they were
suspended in a stagnant fluid, rarely coming into contact with the agitator or other
crystals. Another factor are that crystals smaller than about 10pm probably grow much
more slowly than macrocrystals, and some damaged crystals may not be capable of
growth [15].
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Appendix D- Solid state and Liquid phase sintering

1.1

Solid state sintering

As formed a powder compact before it has been fired is composed of individual grains
separated by between 25 and 60% porosity, depending on the material and processing
method [1]. With extended heating it is possible to reduce the pore volume, leading to
compact shrinkage [2]. Neck growth between contacting particles is an important aspect
of sintering. Figure 1.1 illustrates the neck profile for two spheres initially in point
contact at various levels of densification. Volume conversion and surface energy
minimization dictate a final geometry of one sphere with a diameter 1.26 times the initial
diameter. As the neck grows the compact becomes stronger as a bonded network emerges
as shown in Figure 1.2. There are many sintering contacts on each particle, where each
contact grows and merges with its neighbour to form isolated pores [2].
Two Sphere Sintering Model

late
stage
neck
growth
(long time)

terminal
condition
fully
coalesced
spheres
(infinite time)

Figure 1.1: Two sphere sintering model with the development of an interparticle bond during sintering
starting with a contact point. Neck growth creates a new grain boundary at the particle contact [2].
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Fig 1.2 : Particles before (left) and after (right) sintering [2].

For a crystalline material a grain boundary grows in each contact to replace the initial
solid vapour interface. For the two sphere geometry, during prolonged sintering the grain
boundaries migrate an the particles coalesce into a single sphere with a final diameter
equal to 2.33 that of the original diameter [2]. Although there is considerable neck
growth, the actual volume of the neck is small therefore takes a small mass to form. This
neck possesses a small radius of curvature and a vapour pressure an order of magnitude
lower than that for the particle itself. The pressure difference between the neck area and
the particle surface tends to transfer material into the neck area [1]. The is only minor
densification during the early stage of sintering [2]. The intermediate stage is most
important for densification and determining the properties of the sintered compact. It is
characterized by simultaneous pore rounding, densification and grain growth. The driving
force is the elimination of the remaining surface energy since the curvature gradients
have largely been smoothened prior to the intermediate stage. The growing neck which
was the focus of the initial sintering stage looses identity and attention shifts to the pore
structure surrounding the necks [1, 2]. Grain growth becomes increasingly active as the
pore structure collapses. The pinning effect of the pores diminishes as they shrink and
occupy less grain boundary area. Consequently, the normal tendency for grain size
enlargement initiates rapid grain growth towards the end of the intermediate stage and the
beginning of the final stage [2]. Densification in the intermediate stage is accomplished
by volume and grain boundary diffusion. Pores located on grain boundaries disappear
more rapidly than isolated pores, in part due to the efficiency of grain boundaries as
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vacancy annihilation sites, therefore pores located on grain boundaries should shrink
substantially faster than pores located at the interior of a grain [2, 3]. Figure 1.4 illustrates
various grain pores along with their locations. Compared to initial and intermediate stage
sintering final stage sintering is much slower. There are simultaneous coarsening events
that impede densification. Initially the pores attach to grain corners, giving the idealised
final stage structure as illustrated in Figure 1.3.

Figure 1.3: Tetrakaidecahedron grain shape with spherical pores at grain corners [2]

A pore and a grain boundary have a binding energy as the pore reduces the total grain
boundary area. This binding energy increases with the porosity and the pore size,
meaning that the binding energy decreases during densification. Grain growth forces the
grain boundary to be curved, leading to a progressive increase in grain boundary area as
the grain boundary bows to sustain contact with a slower-moving pore. A critical
condition is arrived at where it is favourable from the boundary to break away from the
pore [2]. Separation leads to elimination of grain boundary bowing and the drag force on
the boundary form the pore, giving increased grain boundary mobility. In the
intermediate stage of sintering with a high porosity there is a large energy penalty for
pore boundary separation, densification reduces this penalty and as a consequence the
grain boundary mobility must be manipulated to sustain a microstructure conductive to
final stage densification [2].
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Figure 1.4: Pore geometries encountered in sintering are represented by the isolated
internal spherical pores inside the grains, while pores on the grain edges and faces are
lenticular, and pores on grain corners are rounded tetrahedrons [2].

1.2

Liquid phase sintering

The formation of a liquid phase during sintering usually increases the sintering rate [3].
Surface tension from the liquid phase is a significant factor in determining the sintering
rate. In cases where liquid sintering takes place the three main concerns are solid
solubility in the liquid, wetting of the liquid on the solid grains and solid phase diffusion
in the liquid [2, 3]. In most cases the liquid wets the solid particles and also has solubility
for the solid. The capillary forces from the liquid acts on the solid particles to eliminate
porosity and reduce interfacial area. Further diffusion rates in liquids are relatively high,
resulting in faster bonding and densification compared to equivalent solid state sintering
[2, 3]. In many systems the liquid persists through the high temperature portion of the
sintering cycle, producing the desired densification but with concomitant coarsening [2].
The initial stage of liquid phase sintering is often referred to as the rearrangement stage
due to the significant densification resulting from particle repacking concurrent with
liquid formation. In spite of the short duration the changes induced in the initial stage are
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often most significant [3]. Dramatic microstructural changes occur, including solid state
sintering, coalescence, liquid spreading, capillary attraction, particle sliding, diffusional
homogenisation and particle fragmentation. The liquid formation and associated capillary
force cause rearrangement and clustering in the microstructure, rearrangement occurs
both between particles and between clusters of particles [3]. Penetration refers to the flow
of liquid through the pore and grain structure by a combination of reaction and capillarity.
A by product of penetration is fragmentation of the solid particles. In most systems the
liquid initially is not at an equilibrium composition, therefore surface energy is not.
Additionally the initial liquid has a high curvature which aids solubility and penetration.
As a consequence the spreading liquid can penetrate the solid-solid interfaces.
Penetration occurs within a few minutes of liquid formation. The actual rate depends on
the liquid reactivity, viscosity and contact angle [3]. As stated earlier with liquid
formation there is a densification due to the capillary force exerted by the liquid on the
solid particles. These grains shrink as the solids dissolve into the liquid. Rapidly, the solid
grains pack to a higher density, releasing liquid to fill the pores between the grains. For
wetting liquids, the solid-liquid surface energy is lower than the soli-vapour surface
energy, resulting in reduced system energy. During rearrangement the compact exhibits
viscous response to the capillary action. The elimination of porosity increases the
compact viscosity. As a consequence the densification rate decreases continuously. Full
density is possible by rearrangement if sufficient liquid is formed. Since monosized
spheres pack to 74% density in theory, at least 26 vol. % liquid is required to obtain full
density by rearrangement. Rearrangement is inhibited by particle contacts formed through
compaction or solid-state sintering during heating [1-3]. As densification by arrangement
slows, solubility and diffusivity effect begin to dominate. This second stage is termed
solution-reprecipitation. The solubility of a grain in its surrounding liquid varies inversely
with the grain size, with small grains having a higher energy and solubility. This
difference establishes a concentration gradient in the liquid. Material is transported from
the small grains to the larger ones by diffusion through the liquid with larger grains
growing at the expense of smaller ones. This is termed Oswald ripening [2], and leads to
the establishment of less grains. Solution reprecipitation not only contributes to grain
coarsening but also to densification via grain shape accommodation, allowing a
224

customised fitting together of the growing grains to optimally fill space. The amount of
liquid determines the diffusion distance and the necessary degree of grain shape
accommodation [2]. The final stage of liquid phase sintering is controlled by
densification of the solid structure by solid phase sintering. Densification is slow due to
the rigid skeleton of contacting solid grains. Microstructural coarsening continues and the
residual pores enlarge if they contain trapped gas, giving compact swelling. In general
properties of most liquid phase sintered materials are degraded by prolonged final stage
sintering; hence shorter sintering times are preferred [2, 3].

1.

W. David Kingery, H.K.B., Donald R. Uhlmann, ed. Introduction to Cermaics. 2
ed. Vol. Wiley. 1976: Cambridge.
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A glass ceramic biomaterial

Introduction

5

This invention relates to a glass ceramic biomaterial.

Statements of Invention

10

According to the invention there is provided a glass ceramic biomaterial having a
crystalline atomic structure, at least part of the biomaterial being degradable for
release of bioactive ions.

The stmcture of the biomaterial enables the biomaterial to be employed in load
15

bearing applications without an additional binding agent and/or cement and/or binding
gel being required. The biomaterial may also be employed in non load bearing
applications.

By releasing bioactive ions, the biomaterial may assist in promoting a therapeutic
20

response in a body tissue and/or in a body bone and/or in a body part.

In one embodiment of the invention the biomaterial comprises strontium (Sr).
Strontium is particularly effective in promoting bone regeneration in bone tissue.
Preferably the biomaterial comprises SrO. Ideally the molar percentage of SrO is
25

between 10% and 40%. Most preferably the biomaterial is degradable for release of
Sr^" ions. The biomaterial may be degradable for release of Sr" * ions with a level of
greater than 5 parts per million. Preferably the biomaterial is degradable for release of
Sr^ ions with a level of greater than 50 parts per million. Ideally the biomaterial is
degradable for release of Sr^^ ions with a level of greater than 100 parts per million.

30
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In another embodiment the biomaterial comprises zinc (Zn). Zinc is particularly
effective as an anti-bacterial agent to minimise infection. Preferably the biomaterial
comprises ZnO. Ideally the molar percentage of ZnO is between 0.1% and 30%.
Most preferably the biomaterial is degradable for release of Zn^^ ions. The
5

biomaterial may be degradable for release of Zn^^ ions with a level of greater than 1.4
parts per million. Preferably the biomaterial is degradable for release of Zn^" ions with
a level of greater than 5 parts per million. Ideally the biomaterial is degradable for
release of Zn^^ ions with a level of greater than 100 parts per million.

10

In one case the biomaterial comprises calcium (Ca). Preferably the biomaterial
comprises CaO. Ideally the molar percentage of CaO is between 0.1% and 20%.

In another case the biomaterial comprises silicon (Si). Preferably the biomaterial
comprises Si02. Ideally the molar percentage of Si02 is between 33% and 60%.
15
In one embodiment the biomaterial comprises sodium (Na). Preferably the
biomaterial comprises Na20. Ideally the molar percentage of Na20 is between 0.1%
and 40%.

20

The biomaterial may comprise crystalline strontium zinc silicate. The biomaterial may
comprise crystalline sodium calcium silicate. In one case the biomaterial comprises a
blend of crystalline strontium zinc silicate and crystalline sodium calcium silicate.

The biomaterial may comprise crystalline sodium zinc silicate. The biomaterial may
25

comprise crystalline calcium silicate. In one case the biomaterial comprises a blend of
crystalline sodium zinc silicate and crystalline calcium silicate.

The biomaterial may comprise crystalline strontium silicate. The biomaterial may
comprise crystalline sodium silicate. In one case biomaterial comprises a blend of

30

crystalline calcium silicate and crystalline strontium silicate and crystalline sodium

P055WO

silicate. In another case the biomaterial comprises a blend of crystalline strontium
zinc silicate and crystalline strontium silicate and crystalline sodium zinc silicate. In a
further case the biomaterial comprises a blend of crystalline strontium silicate and
crystalline sodium zinc silicate.
5
The biomaterial may comprise crystalline zinc silicate.

The biomaterial may comprise crystalline strontium silicon.

10

In another embodiment the crystallisation temperature is between 400° C and 900° C.
Preferably the crystallisation temperature is between 500° C and 800° C. Ideally the
glass transition temperature is between 400° C and 750° C. Most preferably the glass
transition temperature is between 500° C and 650° C.

15

In one case the biomaterial comprises a foam. Preferably at least part of the
biomaterial is porous. The porous biomaterial may assist in promoting tissue in
growth. Ideally the porosity of at least part of the bio material is greater than 90%.

The invention also provides in another aspect the use of a glass ceramic biornaterial of
20

the invention for prophylactic treatment at a bone tissue fracture site.

In a further aspect of the invention there is provided the use of a glass ceramic
biomaterial of the invention as a bone tissue autograft extender.

25

The invention also provides in another aspect the use of a glass ceramic biomaterial of
the invention as a radiopacifier and/or as a coating for a heart tissue.

In another aspect of the invention there is provided a method of manufacturing a glass
ceramic biomaterial.
30
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In one embodiment of the invention the method comprises the step of sintering a glass
powder. Preferably the sintering step is performed prior to crystallisation. The
sintering step may comprise the step of performing dilatometry. Preferably the
dilatometry step comprises the step of heating at a rate of approximately 5°C per
5

minute. Ideally the dilatometry step comprises the step of heating to approximately
1280“C. The sintering step may comprise the step of performing hot stage
microscopy.

The invention provides in another embodiment a method of manufacturing a glass
10

ceramic biomaterial of the invention.

Brief Description of the Drawings

15

The invention will be more clearly understood from the following description of some
embodiments thereof, given by way of example only, with reference to the
accompanying drawings, in which:

Fig. 1 is an X-ray tomography image of a glass ceramic biomaterial according to the
20

invention.

Fig. 2 is a graph illustrating the phase transformation of the glass ceramic bio material
of Fig. 1,

25

Fig. 3 is an X-ray tomography image of four cross sections of the glass ceramic
bio material of Fig. 1,

Figs. 3(a) to 3(d) are graphs illustrating the phase transformation of four other glass
ceramic biomaterials according to the invention,
30
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Fig. 4 is a graph illustrating ion release for the glass ceramic biomaterial of Fig. 1 and
three of the glass ceramic biomaterials of Figs. 3(a) to 3(d),

Fig. 5 is an image of the glass ceramic biomaterial of Fig. 1 with a precipitate apatite
5

bioactive coating,

Fig. 6 is a graph illustrating a heat treatment program designed for burning-out the
polyurethane templates and ciystallizing BT glass at Tpi,

10

Fig. 7 is a graph illustrating a XRD trace for BTl 10-BTl 14 at Tpi,

Fig. 8 illustrates a XRT linage of a fully porous glass-ceramic scaffold.

Fig. 9 are graphs illustrating Zinc release at pH3 over 1, 7 and 30 days with significant
15

differences for (a), BTl 10, (b) BTl 11, (c) BTl 13 and (d) BTl 14,

Fig. 10 are graphs illustrating Zinc release at pH7.4 over 1, 7 and 30 days with
significant differences for (a), BTl 10, (b) BTl 11, (c) BTl 13 and (d) BTl 14,

20

Fig. 11 are graphs illustrating Strontium release at pH3 over 1,7 and 30 days with
significant differences for (a), BT 110, (b) BT 111, (c) BT 112, (d) BT 113 and (e)
BTl 14,

Fig. 12 are graphs illustrating Strontium release at pH7.4 over 1, 7 and 30 days with
25

significant differences for (a), BT 110, (b) BT 111, (c) BT 112, (d) BT 113 and (e)
BTl 14,

Fig. 13 are graphs illustrating BTl 10-BTl 14 showing zinc release at pH3 (a), pFI7.4
(b), and strontium release at pH3 (c), pH7.4 (d) over 1, 7 and 30 days with significant
30

differences.
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Fig. 14 is a graph illustrating the relative length change and rate of length change of
sample BT 112,

5

Fig. 15 is a graph illustrating the relative length change curve, rate of length
change curve, DSC curve, TG curve and 1

st

derivation of the TG curve of

sample BT 112,

Fig. 16 is a graph illustrating the relative length change and rate of length change
10

of sample BT 110,

Fig. 17 is a graph illustrating the relative length change and rate of length change of
sample BT 111,

15

Fig. 18 is a graph illustrating the relative length change and rate of length change of
sample BT 113,

Fig. 19 is a graph illustrating the relative length change and rate of length change of
sample BT 114, and
20
Fig. 20 is a graph illustrating the comparison of the thermal expansion/shrinkage
behaviour of the various glass powders.

25

Detailed Description

Referring to the drawings, and initially to Figs. 1 to 3 thereof, there is illustrated a
glass ceramic biomaterial 1 according to the invention.

7
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The biomaterial 1 comprises strontium (Sr), zinc (Zn), calcium (Ca), silicon (Si), and
sodium (Na). In particular the biomaterial 1 comprises SrO, ZnO, CaO, Si02 and
NaiO. In this case the biomaterial 1 consists of SrO, ZnO, CaO, Si02 and Na20 and
is free of any further binding agents and/or cements and/or binding gels. The molar
percentage of SrO may be between 10% and 40%. The molar percentage of ZnO
may be between 0.1% and 30%. The molar percentage of CaO may be between 0.1%
and 20%. The molar percentage of Si02 may be between 33% and 60%. The molar
percentage of Na20 may be between 0.1% and 40%. In this case the molar
percentage of SrO is 20%, the molar percentage of ZnO is 20%, the molar percentage
10

of CaO is 10%, the molar percentage of Si02 is 40%, and the molar percentage of
Na.O is 10%.

The biomaterial 1 has a crystalline atomic stmcture. In this case the biomaterial 1
comprises a blend of crystalline strontium zinc silicate and crystalline sodium calcium
15

silicate. The biomaterial 1 is provided in the form of a porous foam.

The crystallisation temperature of the biomaterial 1 may be between 400” C and 900”
C, and preferably is between 500” C and 800” C. In this case the crystallisation
temperature of the biomaterial 1 is 713” C.
20
Fig. 2 illustrates the phase transformation of the basic glass composition into the
biomaterial 1 at the first crystallization point (Tpi). During processing, the basic glass
composition converts from an amorphous glass into the blend of crystalline strontium
zinc silicate and crystalline sodium calcium silicate at the first crystallization point
25

(Tpi), as illustrated in Fig. 2. This conversion radically alters the structural
characteristics and properties of the biomaterial 1 in comparison to the basic glass
composition. The temperatures referred to in Fig. 2 are the first crystallization point
(Tpi).

P055WO

Surprisingly the biomaterial 1 with the crystalline atomic structure is degradable for
release of bioactive ions. In this case the biomaterial 1 is degradable for release of
Sr^^ ions and for release of Zn^"^ ions. Fig. 4 illustrates the Zn^"^ ion release at 7 days
and at 30 days maturation under Ph3 and Ph7. It would have been expected that the
5

processing of the basic glass composition would have resulted in a stable inert glass
ceramic, and it would have been expected that the resulting atomic structure would
not have enabled any ion release. Contrary to what would have been conventionally
expected, it has been found unexpectedly that the processing of the basic glass
composition results in the biomaterial 1 with the crystalline atomic structure which

10

provides for degradation and release of constituent ions, as illustrated in Fig. 4.

The glass based biomaterial 1 releases ions which may lead to a therapeutic response
for example in a bone prosthesis in a human body. The Sr^^ ions may assist with bone
regeneration, and the Zn^^ ions may provide an anti-bacterial function. The
15

biomaterial 1 olfers the controlled release of ions which are known to inhibit bacterial
colonisation of implants and synergistically release ions which promote osteoblastic
bone formation at the expense of osteoclastic bone resorption. The biomaterial 1
offers a synergy of antibacterial and regenerative ion release. In the biomaterial 1, the
Zn^ ions are released at levels appropriate to inhibit infection in vivo.

20
The bioactive glass of the invention comprises Calcium-Strontium-Zinc-Silicate. The
glass releases controlled amounts of therapeutic Zn^^ and Sr^^ ions when placed in
normal and extreme physiological conditions. The bioactive glass is suited to utilize
as a bone replacement material. The level of Zn^^ and Sr^^ ions released from the
25

bioactive glass material achieve clinical benefits and therapeutic effects including bone
formation in the range of 2.45 to 6.5 parts per million (ppm), and antibacterial efficacy
of 3-7 ppm respectively.

The crystalline atomic structure of the biomaterial I is a function of the composition
30

of the biomaterial 1, the processing temperature to produce the biomaterial 1, and the
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length of time which the biomaterial 1 is processed at this temperature. The invention
provides a glass ceramics construct with a synergistic composition of Sr^^ and Zn^^ in
which the crystalline atomic structure may be chosen to alter the material properties
of the biomaterial 1.
5
The glass-ceramic 1 is a polycrystalline solid prepared by controlled crystallization of
glass. Crystallization is accomplished by subjecting suitable glasses to heat treatments
which result in the nucleation and growth of crystal phases within the glass.
Depending on the heat treatment applied, for example time and temperature, the
10

crystallization process may be taken almost to completion, however it is also possible
that a residual glass phase will remain. The properties of the glass ceramic 1 are
controlled by the material microstmcture and composition. It would not have been
possible to predict the evolution of crystalline phases or at what temperatures they
occur as a result of processing. No phase diagrams exist for the parent glass systems.

15

It would not have been possible to qualify or quantify which crystalline materials may
form under processing. The crystalline phase evolution of the glass 1 is determined by
processing of the glass material. Many different parameters may be varied to create
crystalline phases for example varying heating rates, holding temperatures and time
parameters. Following processing the materials are analysed qualitatively and

20

quantitatively to determine the phases present.

The biomaterial 1 is provided in the form of a solid, load-bearing structure. No
further binding agents and/or cements and/or binding gels are required with the
biomaterial 1. The biomaterial 1 has the ability to bear loads normal to physiological
25

loading in the skeleton. The biomaterial 1 may also be deployed as a non load-bearing
element.

Fig. 1 illustrates an X-ray tomography (XRT) image of the foam biomaterial 1. The
porous nature of the biomaterial 1 facilitates tissue in-growth.
30
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The glass ceramic biomaterial 1 may be deployed as a fully reticulated foam, a bulk
biomaterial or a coating. The biomaterial 1 is suitable for the following fields of use:
load-bearing and non load-bearing dental, craniofacial, maxillofacial and/or
orthopaedic applications.
5
Infection may be an ongoing clinical concern, both immediate to introduction of
biomaterials in the body and for the long term viability of the in vivo construct. The
biomaterial 1 offers an antibacterial solution to reduce infection at the post-operative
stage, whilst also offering fiill porosity for bone in-growth, and load bearing
10

capabilities for increased scope of applications. In respect of patients who suffer from
metabolic bone diseases such as osteoporosis, the invention provides for controlled
release of therapeutic agents, such as Sr"^, from a load bearing construct either foam,
bulk or coating. The inclusion of Sr'”' in synergy with Zn^^ also offers significant
advantages in bone regeneration as a function of controlled ion release to mediate

15

specific regenerative responses in bone tissue in a material capable of forming a direct
bond with bone while retaining bone bonding capabilities, as illustrated in Fig. 5. Fig.
5 illustrates a surface image of the biomaterial 1 immerged in simulated body fluid
(SBF) for 7 days showing a precipitate apatite bioactive coating.

20

The biomaterial 1 has numerous advantages from a material and surgical applications
standpoint, for example the capability to release ions, applicability to non load-bearing
applications as well as applicability to load-bearing applications, capability of being
deployed as a reticulated foam, and being a fully crystalline material.

25

The biomaterial 1 may be employed in a variety of applications, for example for
controlled drug delivery, and/or for drug delivery in combination with a hydrogel,
and/or for stem cell tissue engineering, and/or as a component in a toothpaste for
sensitivity control, and/or as a component in a bone cement for improved radiopacity,
and/or as a component in a bone cement for improved biocompatibility and/or

11
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antibacterial efficacy, and/or as a component of a composite biomaterial for tissue
engineering, and/or as a coating on a medical device.

The biomaterial 1 may be used for prophylactic treatment at a bone tissue fracture
5

site, such as the neck of a femur or a vertebra. The biomaterial 1 may be used as a
bone tissue autograft extender. The biomaterial 1 may be used as a radiopacifier
and/or as a coating for a heart tissue.

The biomaterial 1 may be provided in a variety of shapes, for example as a rod, and/or
10

a plate, and/or a prosthetic bone shape.

Fig. 3 illustrates the XRT montage of the biomaterial 1 of the invention illustrating the
interconnected pore stmcture through multiple cross sections of the biomaterial 1.

15

In a second embodiment of the invention, the biomaterial comprises SrO, ZnO, CaO,
Si02 and NaiO. In this case the molar percentage of SrO is 20%, the molar
percentage of ZnO is 10%, the molar percentage of CaO is 10%, the molar
percentage of Si02 is 40%, and the molar percentage ofNa20 is 20%.

20

In this case the bio material comprises a blend of crystalline sodium zinc silicate and
crystalline calcium silicate.

In this case the crystallisation temperature of the biomaterial is 577° C.

25

In a third embodiment of the invention, the biomaterial comprises SrO, CaO, Si02 and
Na20. In this case the molar percentage of SrO is 20%, the molar percentage of ZnO
is 0%, the molar percentage of CaO is 10%, the molar percentage of Si02 is 40%, and
the molar percentage of Na20 is 30%.

12
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In this case the biomaterial comprises a blend of crystalline calcium silicate and
crystalline strontium silicate and crystalline sodium silicate.

In this case the crystallisation temperature of the biomaterial is 525° C.

In a fourth embodiment of the invention, the biomaterial comprises SrO, ZnO, Si02
and NaaO. In this case the molar percentage of SrO is 30%, the molar percentage of
ZnO is 20%, the molar percentage of CaO is 0%, the molar percentage of SiOa is
40%, and the molar percentage ofNaaO is 10%.
10
In this case the biomaterial comprises a blend of crystalline strontium zinc silicate and
crystalline strontium silicate and crystalline sodium zinc silicate.

In this case the crystallisation temperature of the biomaterial is 668° C.
15
In a fifth embodiment of the invention, the biomaterial comprises SrO, ZnO, Si02 and
Na20. In this case the molar percentage of SiO is 30%, the molar percentage of ZnO
is 10%, the molar percentage of CaO is 0%, the molar percentage of Si02 is 40%, and
the molar percentage of Na20 is 20%.
20
In this case the biomaterial comprises a blend of crystalline strontium silicate and
crystalline sodium zinc silicate.

In this case the crystallisation temperature of the biomaterial is 567° C.
25
The following table lists the glass compositions in mol. fractions.

Glass designation

Si02

ZnO

CaO

SrO

Na20

First embodiment

0.4

0.2

0.1

0.2

0.1

Second embodiment

0.4

0.1

0.1

0.2

0.2

13
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Third embodiment

0.4

0

0.1

0.2

0.3

Fourth embodiment

0.4

0.2

0

0.3

0.1

Fifth embodiment

0.4

0.1

0

0.3

0.2

The following table lists the glass compositions with the crystalline compounds
formed at Tpi. Tpi is the first crystallization point, which is the temperature at which
the glass converts fully to a crystalline ceramic.

Glass-Ceramic Designate

Tp.(°C)

Crystalline Compound
Formed at Tpi

First embodiment

713

Strontium Zinc Silicate
Sodium Calcium Silicate

10

Second embodiment

577

Sodium Zinc Silicate
Calcium Silicate

Third embodiment

525

Calcium Silicate
Strontium Silicate
Sodium Silicate

15

Fourth embodiment

668

Strontium Zinc Silicate
Strontium Silicate
Sodium Zinc Silicate

Fifth embodiment

567

Strontium Silicate
Sodium Zinc Silicate

20

Figs. 3(a) to 3(d) illustrate an XRD trace for each biomaterial 2, 3, 4, 5 after
processing at the respective Tpi.

25
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Third embodiment

0.4

0

0.1

0.2

0.3

Fourth embodiment

0.4

0.2

0

0.3

0.1

Fifth embodiment

0.4

0.1

0

0.3

0.2

The following table lists the glass compositions with the crystalline compounds
formed at Tpi. Tpi is the first crystallization point, which is the temperature at which
the glass converts folly to a crystalline ceramic.

Glass-Ceramic Designate

Tp,(°C)

Crystalline Compound
Formed at Tpi

First embodiment

713

Strontium Zinc Silicate
Sodium Calcium Silicate

10

Second embodiment

577

Sodium Zinc Silicate
Calcium Silicate

Third embodiment

525

Calcium Silicate
Strontium Silicate
Sodium Silicate

15

Fourth embodiment

668

Strontium Zinc Silicate
Strontium Silicate
Sodium Zinc Silicate

Fifth embodiment

567

Strontium Silicate
Sodium Zinc Silicate

20

Figs. 3(a) to 3(d) illustrate an XRD trace for each biomaterial 2, 3, 4, 5 after
processing at the respective Tpi.

25

Example 1

Glass Synthesis
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Five glass formulations as listed in Table 1 were synthesised. Glasses were prepared
by weighing out the appropriate amounts of analytical grade reagents obtained from
Sigma Aldrich, Wicklow, Ireland; silicon dioxide, zinc oxide, calcium carbonate,
strontium carbonate and sodium carbonate into a plastic container. Each formulation
was thoroughly mixed in the closed container for 30 mins. Compositions were then
fired at 1480°C for 1 hour in platinum crucibles and the glass melts shock quenched
into water. The resulting frit was dried in an oven at 120‘'C for 1 day.

ZnO

CaO

SrO NajO

BTllO 0.4

0.2

0.1

0.2

0.1

BTlll

0.4

0.1

0.1

0.2

0.2

BT112

0.4

0

0.1

0.2

0.3

BTl 13

0.4

0.2

0

0.3

0.1

BT114

0.4

0.1

0

0.3

0.2

Glass

10

Si02

Table 1: Glass composition (mol. fraction).

Attrition Milling
The dried frit was ground in an attrition mill obtained from NETZSCH,
Lebenschauerschmierung, Germany using iso-propanol and Zirconia beads. The frit
15

was processed in 15 g batches, which were placed in a ceramic crucible, zirconia
beads with a diameter ranging 2-4 mm were placed in the cmcible, and iso-propanol
was added to the level of the beads. The frit was milled by means of two shaft
mounted blades rotating at a speed of 1500 rpm for one hour. The resulting ground
powder was placed in a sieve and washed with iso-propanol in order to separate it

20

from the Zirconia beads and to capture any glass particles attached to the beads. The
resulting slurry was placed in a round bottomed flask, dried in a water bath at 100°C,
and stored in a dessicator for subsequent use.

Particle Size

15
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A MALVERN MS 2000 LF particle size analyzer, with the ability to detect particles
in the range of 0.02pm - 2000pm, equipped with a Hydro 2000 wet dispersion
module was used to determine the particle size distribution using the ISO13320-1
protocol with a fixed wavelength X=0.63, and result accuracy ± 1%. The glass was
prepared for particle size analysis by the following means. 0.5g of the attrition milled
glass powder was placed into a 40ml beaker and 30 ml of a 0.1% Sodium
Pyrophosphate, which acts as a dispersant was added, as the MALVERN MS 2000
LF uses a wet technique. The beaker was placed on a magnetic stirrer and stirred for a
minimum of 1 minute to ensure that the powder and dispersant fonned a suspension.
10

Following a debubbling step, 20 ml of the suspension was taken, by means of a
pipette, from between the middle of the vortex and edge of the glass at half the depth
of the liquid. The suspension was placed in the MS2000 sample tank and ultrasonic
vibrations applied for two minutes.

15

Differential Scanning calorimetry
The identification of glass transition temperatures (Tg) and first the crystallization
temperatures (Tpj) for each glass using differential scanning calorimetry (DSC) was
performed using a Labsys 1600 obtained from SET ARAM Instruments, Caluire,
France. The results will be used herein and are presented in Table 3.

20

Scaffold fabrication
The slurry for the impregnation of the polyurethane foam was prepared using the
following recipe. Polyvinyl alcohol (PVA) having 87-89% hydrolyzed, and Average
Mw 13,000-23,000, was dissolved in water, the ratio being 0.01 moFL. Then BT
25

glass powder was added to 100 ml PVA-water solution up to concentration of 40
wt%. Each procedure was carried out under vigorous stirring using a magnetic stirrer
for 1 hour. The polyurethane foams cut to shape, with dimensions 5 x 5mm, were
immersed in the above prepared slurry and remained in it for 15 minutes. The foams
were manually retrieved from the suspension as quickly as possible, and the extra

30

slurry was completely squeezed out. The samples called green bodies were then
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placed on a smooth surface and dried at ambient temperature for at least 12 hours.
Post-forming heat treatments for the burnout of the polymer template structure were
programmed, as shown in Fig. 6. The burning condition of the polymer template was
identical for all samples. The polyurethane foam exhibits both thermoplastic and
5

thermoset characteristics and when heated partial decomposition occurs resulting in
vaporization and the formation of a melt, which occurs at approximately 260°C. All
foams were subsequently heated to their respective Tpi values and held for 2 hours.

Fig. 6 illustrates a heat treatment program designed for buming-out the polyurethane
10

templates and crystallizing BT glass at Tpi.

X-ray Diiffaction
X-ray diffraction (XRD) analysis was performed using a Philips X’pert MPD Pro
3040/60 -ray Diffraction (XRD) Unit obtained from Philips, Netherlands. Zero
15

background nickel coated sample holders were used for analysis of the 90-710 Im
glass particles with Cu ka radiation at 40 kV and 35 mA. Diffractograms were
collected in the range 5"<0<8O'', at a scan step size 0.0083° and a step time of 10 s.
Where significant crystalline activity occurred above the glass transition temperature
the phases present were identified using Joint Committee for Powder Diffraction

20

Studies (JCPDS) standard diffraction patterns using X’pert Highscore Plus software
obtained from PANalytical and graphed using Origin lab 8 version 8.1.

X-Ray Tomography
The X-ray tomography examination of the samples was carried out using a phoenix|x25

ray Nanotom obtained from General Electric Company with a tungsten transmission
target and a 2 megapixel high contrast flat panel digital detector. The maximum
accelerating voltage used was 50 kV. 1440 projections in 360° views were obtained.
A voxel resolution of 1 Op was employed to obtain a 3D image of the glass ceramic
foam. Analysis of reconstructed 3D data sets was carried out using Volume Graphics

30

VGStudioMax Software.
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Dissolution experiments
In order to simulate physiological conditions of normal and extreme environments
within the body, as pH 7.4 is representative of the physiological environment and pH
3.0 representative of extreme physiological conditions and the acidic environment
produced by osteoclasts, TRIS-HCL buffer and Citric acid buffer solutions were
prepared to have a pH of 7.4 ± 0.1 and 3.0 ± 0.2, respectively at a temperature of
37“C ± rC, according to ISO 10993-14.

10

The TRIS-HCI buffer solution was freshly prepared as follows:
13.25 g of tris (hydroxymethyl) aminomethane were dissolved in 500 ml of water
(ISO 3696, grade 2). The pH was adjusted with an appropriate amount of 1 mol/1
hydrochloric acid to pH 7.4 ±0.1 at a temperature of (37 ±1) °C. The solution was
topped up to 1000 ml with water (ISO 3696, grade 2).

15
The buffered citric acid solution was freshly prepared as follows:
21 g of citric acid monohydrate were dissolved in 500 ml water (ISO 3696, grade 2)
in a 1000 ml volumetric flask. 200 ml of 1 mol/l sodium hydroxide solution were
added and diluted to the mark with water (ISO 3696, grade 2). 40.4 ml of this
20

solution were mixed with 59.6 ml of 0.1 mol/l hydrochloric acid yielding the buffered
citric acid solution. Each glass-ceramic foam was immersed in 10 ml of TRIS buffer
with a sample size = 5 for each designate, and citric acid buffer with a sample size = 5
for each designate, and maintained at 37°C in a thermally controlled oven. Specimens
were stored for 1, 7 and 30 days. After each storage period, specimens were removed

25

via filtration and filtrates retained for ionic content analysis. The Sr‘^ and Zn^^content
of each filtrate was analysed using a SpectrAA 220 Fast Sequential, using flame
atomic absorption spectroscopy in an acetylene-afr flame. Zn and Sr hollow cathode
lamps were used at wavelengths 213.9 and 460.7 nm, respectively. In order to
eliminate interferences when measuring strontium levels 0.5 g KCL was added to each

30

filtrate.

P055WO

Results are expressed as mean of the mean of triplicate determinations. Analysis of the
results was carried out using Students’s t-test, and then one way analysis of variance
followed by Bonferroni post-hoc test for multiple comparison between different
groups. Each experiment was performed in triplicate and analysed using Graphpad
prism 5 software obtained from Graphpad software Inc. with a significance level of
P<0.05.

Results
10
Attrition milling and Particle Size analysis
The particle size analysis carried out shows that attrition milling the glass powders
produced a multimodal particle size distribution including sub micron particles as
listed in Table 2. Particle size distribution ranges from a d90 of 5.53pm to 18.23 pm.
15

The inclusion of paificlc sizes in the sub micron range and larger is preferred for the
fabrication of reticulated glass-ceramic foams utilizing the replication technique.

Particle Size Distribution (pm)
Glass

dlO

d50

d90

BTllO

0.35

0.61

5.48

BTlll

0.42

6.71

7.41

BT112

2.98

5.59

18.23

BT113

0.32

0.47

5.53

BT114

0.40

3.09

17.68

Table 2: Particle size distribution for each glass (post-attrition milling).
20

Differential scanning calorimetry
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The results of the differential scanning calorimetry are shown in Table 3. The glass
transition temperatures recorded range from 522°C to 623°C, and the first
crystallization temperatures range from 525°C to 713 °C.

Glass;

Tg(°C):

Tp. (°C);

BTl 10

603

713

BTl 11

546

577

BT112

522

525

BTl 13

598

668

BTl 14

542

567

Table 3: Glass transition temperature (Tg) and first crystallization peak (Tpi) for each
glass.

Table 3 illustrates Tg and Tpi for each glass composition; it was observed, as one
10

would expect, that both Tg and Tpi decrease with increasing Na to Zn ratio. The
atomic radii of Zn^ *^ and of Na* are 74 pm and 95 pm respectively, thus as Na20
content increases, the glass network is expanded resulting in a reduction of both glass
density and glass oxygen density accounting for the reduction of Tpi as Na20 content
is increased. Another factor in the reduction of Tg is the Sr to Ca ratio. A substitution

15

of 0.1 mole fraction of strontium for calcium, where all calcium has been substituted
in BTl 13 and BTl 14 shows a marked reduction in Tg. Sr^*^ is slightly bigger that the
Ca^^cation, (113 and 99 pm respectively) again resulting in the expansion of the
network and a reduced glass density.

20

X-ray diffraction
The following diflfaction pattern. Fig. 7 illustrates the phase for each glass-ceramic at
Tpi. Table 4 identifies diffraction peak positions for each of the crystal systems
identified during analysis. Table 4 is intended to guide the interpretation of Fig. 7.
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Peak Identifier

JCPDS card no.

Phase Identifier.

Chemical Composition

A

00-037-0407

Sodium Zinc Silicate

Na2ZnSi04

B

00-039-0235

Strontium Zinc

Sr2ZnSi207

Silicate
C

00-033-0302

Lamite

Ca2Si04

(Calcium Silicate)
D

00-031-0299

Calcium Silicate

Ca2Si04

E

00-016-0818

Sodium Silicate

Na2Si03

F

00-039-1256

Strontium Silicate

Sr2Si04

G

00-037-1485

Zinc Silicate

Zn2Si04

H

00-038-0271

Strontium Silicate

Sr2Si04

I

00-038-1366

Strontium Silicon

SrSi2

Table 4; Detailed Legend for Fig. 7.

Fig. 7 illustrates a XRD trace for BTl 10-BTl 14 at Tpi.

X-ray tomography
Fig. 8 illustrates a XRT image of a fully porous glass-ceramic scaffold. An XRT
image of a glass-ceramic scaffold produced from the Sr-doped zinc-silicate glassceramic may be seen in Fig. 8. The XRT image obtained shows an integrated porous
network. The porosity of tfrree BTl 13 scaffolds was measured in a 250x250x250
voxel cube and was found to have an average porosity of 95%.

Dissolution experiments
15
Zinc Release
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The

release profiles at pH 3 (extreme physiological condition) are shown in Figs.

9 and 13. The Zn^^ release profiles at pH 7.4 (normal physiological condition) are
shown in Figs. 9 and 13.

Strontium Release
_2
The Sr"^"
release profiles at pH 3 are shown in Figs. 11 and 13. The Sr^^ release

profiles at pH 7.7 are shown in Figs. 12 and 13.

Fig. 9 illustrates Zinc release at pH3 over 1, 7 and 30 days with significant differences
10

for (a), BTl 10, (b) BTl 11, (c) BTl 13 and (d) BTl 14. Fig. 10 illustrates Zinc release
at pH7.4 over 1, 7 and 30 days with significant differences for (a), BTl 10, (b) BTl 11,
(c) BTl 13 and (d) BTl 14. Fig. 11 illustrates Strontium release at pH3 over 1,7 and
30 days with significant differences for (a), BTl 10, (b) BTl 11, (c) BTl 12, (d) BTl 13
and (e) BTl 14. Fig. 12 illustrates Strontium release at pH7.4 over 1, 7 and 30 days

15

with significant differences for (a), BTl 10, (b) BTl 11, (c) BTl 12, (d) BTl 13 and (e)
BTl 14. Fig. 13 illustrates BTl 10-BTl 14 showing zinc release at pH3 (a), pH7.4 (b),
and strontium release at pH3 (c), pH7.4 (d) over 1, 7 and 30 days with significant
differences.

20

Discussion

The aim of this example was to fabricate a fully integrated porous Sr-doped zincsilicate glass-ceramic scaffold, whose structure was permissive for osseous integration
and to investigate the ion release rate with respect to the divalent ions of zinc and
25

strontium. It is clear from the results that a flilly porous material, where the porosity is
between 93-96% has been created, hence providing a suitable scaffold to enhance
bone ingrowth, and to allow proper vascularisation. It is appropriate to examine the
XRD findings in corporation with the ion release results as these are intrinsically
linked, by the fact that the structure of the material governs its chemical properties.

30

Detailed analysis based on inter glass ceramics and the statistically significant
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differences that occur between glass ceramics at similar time timepoints, as outlined in
Fig. 13, is difficult to carry out as the relative percentages of each crystalline phase
have not been determined and therefore requires further investigation. There are four
materials that are designed to release zinc, namely BTl 10, BTl 11, BTl 13 and
5

BTl 14. Each glass ceramic as outlined in Fig. 7 and Table 4 comprise a unique
grouping of crystalline species. BTl 10 comprises two crystalline phases, sodium zinc
silicate (Na2ZnSi04) and strontium zinc silicate (Sr2ZnSi207). Both phases are noted
to contain zinc, where the level of zinc in the parent glass is 20 molar percent. The
range ofZn^^ released from the glass ceramic under pH3 conditions is between 74 and

10

142 ppm whilst at pH7.4 range from 2 to 6.2 ppm based on the mean released at each
timepoint, the mean released at each timepoint being the values that will be mentioned
throughout the discussion. No significant difference is found between the thi'ee
timepoints at either pH level indicating that the level ofZn^^ released is not time
dependant but is most noticeably dependant on its environment. BTl 11 contains one

15

crystalline phase containing zinc namely, sodium zinc silicate (Na2ZnSi04). The parent
glass for BTl 11 includes 10 molar percent zinc, which is half that of BTl 10. The
range of Zn^"^ released from the glass ceramic under pH3 conditions is between 140
and 300 ppm whilst at pH7.4 range from 10.2 to 18.6 ppm. The levels of zinc
detected plateaux at 7 days at pH 3 and at 30 days at pH7 clearly indicating from Fig.

20

10 that at a neutral pH, the release of zinc ions appears to be time dependant. BTl 13
contains 30 molar percent zinc. The crystalline phases observed include sodium zinc
silicate (Na2ZnSi04), strontium zinc silicate (Sr2ZnSi207) and zinc silicate (Zn2Si04).
The range of Zn‘" released from the glass ceramic has been detected at 154-600 ppm
and 8-14 ppm at pH3 and pH7.4 respectably. At pH3 the levels detected plateaux at 7

25

days and statistically significant differences occur between all timepoints. At pH7.4
the level of Zn^^ detected is greatest at day 30, indicating the release is linked to
incubation time. BTl 14 like BTl 10 and BTl 11 comprises one zinc containing
crystalline phase namely sodium zinc silicate (Na2ZnSi04). At pH 3 the highest level
of zinc ion released was detected at day 7, where the range at the extreme pH level

30

was 76-172 ppm. At pH 7 the levels detected were 1.4-5ppm where the highest level
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was detected at 30 days. There were no significant differences observed between the
timepoints at their respective pH levels.

The dissolution mechanism for many glass-ceramics has been shown to be an initial
5

attack on a residual glass phase followed by degradation of the ciystalline material.
However as we can see from the XRD analysis in Fig. 7, the glass-ceramics appear to
be fully crystalline with no residual glassy phase. In considering the durability of glassceramics, the materials must be viewed as multiphased composition dependant
systems, where each phase possesses individual corrosion characteristics. This

10

example is particularly interested in the degradation products Zn^ and Sr^' and
whether the levels released are within identified therapeutic ranges. Figs. 9(a&b) and
10(a&b) demonstrate the range of Zn^^ released from the zinc containing glass
ceramics where the levels were found to be in the range of 1.4 to 600 ppm (parts per
million) . Zn^^ levels associated with clinical benefits on bone formation range from

15

2.45 to 6.5 ppm. Zinc deficiency is associated with retardation and failure of bone
growth in animals and humans. Zinc is also associated with increasing osteoblast
proliferation, osteoclast inhibition, biomineralization and bone formation. A range of
3-7 ppm of Zn^^ has been associated with antibacterial efficacy against S. mutans and
A. viscosus both associated with infected hip joints. As is evident from the results

20

presented above, glass-ceramics BTl 10 and BTl 14 fall within the range known to be
of therapeutic benefit without exhibiting cytotoxic effects, with BTl 11 and BTl 13
being marginally outside the range at 10.2 and 8 ppm respectively. The Sr^^ released
from the glass ceramics BTl 10 to BTl 14 ranged from 0 to 583 ppm. Strontium
induces osteoblast activity in the range of 8.7 to 87.6 ppm and reduce bone resorption

25

by inhibiting osteoclast action from 8.7 to 2102.8 ppm. It is thus evident that the glass
ceramics BT110 to BT114 may indeed have the desired effect on bone turnover.

Example 2

30

Synthesis of materials
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In order to achieve a dense material, sintering of the glass powder compact takes
place prior to crystallization. Analysis of materials, for example utilising dilatometry
or hot stage microscopy, are employed to establish the optimal sintering temperatures.
The optimum sintering temperature of a material is controlled by the materials
chemical composition; it is not possible to predict such temperatures without
analytical evaluation. The processing parameters for dilatometry included heating the
BT glass at a rate of 5°C/min up to 1280”C. This heating regime produced optimum
sintering temperatures where the BT glass-ceramics are at their most dense. The
10

range can be found in Table 5.

Optimum sintering study

The results for the thermal expansion shown in a red solid line and the length
15

change rate shown in a red da.shed line, 1^^ derivation of the length change curve
of sample BT 112 are shown in Fig. 14. The sample length seems to decrease
continuously, starting with a small step at 131°C - the peak temperature of the
derivation, followed by bigger step at 806°C and a sharp drop down at
approx 1100°C - also peak temperatures of the derivation. The comparison with

20

an STA measurement illustrated in Fig. 15 reveals that there is a peiTnanent
mass change of approx 18% in total. Especially the two steps at 131 °C and
806°C are caused by mass changes, also reflected by corresponding DTG and
DSC peaks of 131°C/802°C and 145°C/805°C. The two further DSC peaks at
940°C and 1054°C do not have significant counterparts in the DTG curve, just

25

minor peaks are visible. Therefore perhaps melting is the reason. The increasing of
the length change signal as shown in the extra window in Fig. 14 may perhaps be a
consequence of partial melting at peak temperature of 940°C. If the big step with a
length change of more than 60% - the peak temperature of the derivation:
1100°C - is again caused by melting of material components or if sintering plays a

30

role, too, may not be decided. The length change data of sample BT 112 are
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summarized in Table 5.

The shape of the sample after finishing the measurement was not rod-like, as
expected; it was more like a molten lump of material.

Fig. 14 illustrates the relative length change (red, solid line) and rate of length
change (red, dashed line) of sample BT 112. Fig. 15 illustrates the relative length
change curve (red, solid line), rate of length change curve (red, dashed line),
DSC curve (blue), TG curve (green, solid line) and 1
10

derivation of the TG

curve (DTG curve, green, dashed line) of sample BT 112.

Fig. 16 illustrates the relative length change (violet, solid line) and rate of length
change (violet, dashed line) of sample BT 110. In contrast to sample BT 112,
sample BT 110 illustrated in Fig. 16 shows up to approx 460°C an expansion of
15

about 0.7%. At 597°C - the extrapolated onset temperature - a shrinkage step of
about 15% takes place, followed by two further steps between 950°C and 1200°C
with extrapolated onset temperatures of ]002°C and 1124°C. The corresponding
peak temperatures in the rate of length change curve are 625°C, 1030°C and
1155°C, respectively.

20
The length change data of sample BT 110 may be found in Table 5.

Fig. 17 illustrates the relative length change (blue, solid line) and rate of length change
(blue, dashed line) of sample BT 111. The thermal behaviour of sample BT 111 is
25

depicted in Fig. 17. The sample shrinks almost from the beginning of the
measurement. During heating up to 1100°C three major steps occur: at 508°C,
970°C and 1017°C - the extrapolated onset temperatures.

The corresponding length change data are listed in Table 5.
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Fig. 18 illustrates the relative length change (green, solid line) and rate of length
change (green, dashed line) of sample BT 113. The thermal length change profile of
sample BT 113 illustrated in Fig. 18 is more complex than the previous ones. There is
almost no change in length of the sample until 563°C - the extrapolated onset
temperature of the first step. But then several other steps are following, the biggest
ones are at 811°C, 961°C and 1143°C - the extrapolated onset temperatures.

The corresponding length change data are presented in Table 5.
10

Fig. 19 illustrates the relative length change (dark blue, solid line) and rate of length
change (dark blue, dashed line) of sample BT 114. Sample BT 114 illustrated in Fig.
19 starts to decrease in length at about 100°C. Up to 470°C a shrinkage of 0.9%
takes place. In the following three steps occur: at 492°C, at 942°C and at 1015°C 15

the extrapolated onset temperatures. The length change profile itself, except the
absolute temperature values, is similar to sample BT 111.

The corresponding length change data can be found in Table 5.

20

A comparison between the length change curves of the various samples is illustrated
in Fig. 20. Fig. 20 illustrates the comparison of the thermal expansion/shrinkage
behaviour of the various glass powders.

Temperature[°C]

Relative Length Change / [%]
BT

no

i

BT 111

BT112

BT113

BT 114

40

l,01E-02

-6,90E-03

-2,50E-02

l,10E-02

-4,25E-03

60

l,89E-02

: -3,46E-02

-4,63E-02

l,90E-02

-6,57E-03

80

2,46E-02

; -6,97E-02

-0,13903

2,56E-02

-l,29E-02

100

2,80E-02

-0,11892

: -0,33851

2,96E-02

-4,21E-02
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120

3,09E-02

-0,18663

-0,65796

' 2,98E-02

-0,10817

140

3,26E-02

-0,22898

-1,16986

1 2,25E-02

-0,16211

160

3,51E-02

-0,30527

-1,61234

l,80E-02

-0,20686

180

3,79E-02

-0,38947

-1,94222

l,63E-02

-0,2446

200

4,17E-02

-0,44373

-2,19813

l,56E-02

-0,27427

220

4,62E-02

-0,48051

-2,39412

l,51E-02

-0,29978

240

5,17E-02

-0,53155

-2,56394

l,64E-02

-0,32571

260

5,72E-02

-0,59387

-2,71445

l,86E-02

-0,352

280

6,16E-02

-0,67451

-2,86361

2,15E-02

-0,37853

300

6,59E-02

-0,71435

-3,00127

2,46E-02

-0,4068

320

6,88E-02

-0,75312

-3,11965

2,71E-02

-0,43695

340

7,18E-02

-0,78642

-3,23344

2,81E-02

-0,46784

360

7,45E-02

-0,8218

-3,35155

2,69E-02

-0,50458

380

7,67E-02

-0,86506

-3,48056

2,37E-02

-0,54828

400

7,71E-02

-0,91001

-3,5787

l,90E-02

-0,60186

420

7,80E-02

-0,96625

-3,65397

l,37E-02

-0,6716

440

7,79E-02

-1,03186

-3,71918

9,14E-03

-0,76524

460

7,40E-02

-1,11274

-3,78738

5,24E-03

-0,89094

6,38E-02

-1,21918

-3,86715

l,69E-03

-1,09132

500

3,64E-02

-1,45067

-3,96473

-2,13E-03 1 -1,52828

520

-7,28E-03

-2,2561

-4,09908

-8,76E-03

-2,42226

540

-8,88E-02

-3,72063

-4,22891

-2,80E-02

-3,22345

560

-0,29646

-4,17867

-4,28067

-0,1114

-3,45407

580

-0,86778

-4,45359

-4,30408

-0,54602

-3,58499

600

-2,93152

-4,53094

-4,32215

-0,91106

-3,68212

620

-8,25511

-4,53745

-4,34781

-0,97884

-3,83705

640

-14,39519

-4,52136

-4,38459

-1,20867

-3,97364

660

-14,99596

-4,47685

-4,41691

-1,43434

-4,09378

680

-15,19991

-4,43337

-4,44894

-1,45939

-4,20155

700

-15,23652

-4,42049

-4,53522

-1,45096

-4,29706

720

-15,24554

-4,43589

-4,80118

-1,43794

-4,37461

740

-15,24559

-4,46571

-5,3859

-1,41147

-4,429

480

- -JL

.......................
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760

-15,24303

-4,50765

-6,32112

-1,37102

-4,46924

780

-15,25196

-4,56827

-7,91001

-1,33174

-4,51377

800

-15,26971

-4,64214

-10,93097

-1,31476

-4,57508

820

-15,28346

-4,69394

-15,10089

-2,01961

-4,66838

840

-15,29506

-4,7492

-16,81478

-2,29775

-4,80601

860

-15,31357

-4,8163

-17,14723

-2,37057

-5,01101

880

-15,33942
-4,92039
-15,37613 1 -5,09407

-17,38711

-2,48721

-5,34515

-17,66452

-2,70263

-5,89204

920

-15,40417

-5,39527

-17,88799

-3,10525

940

-15,46667

-5,99954

-17,99463

-3,97514

-6,71378
^ -8,26935

960

-15,5795

-7,21685

-17,31957

-5,68263

-1 1,76761

980

-15,8102

-10,10159

-16,9358

-8,41035

-17,69876

1000

-16,34657

-16,79848

-17,52953

-12,27601

-18,53004

1020

-17,6415

-31,95371

-18,94075

-16,9128

-43,75716

1040

-19,61054

-48,36021

-21,47064

-18,52188

-45,83688

900

L,

Table 5: Length change values of the various glass powders.

Figs. 14 to 20 illustrate the shrinkage of each glass ceramic BT 110 to BT 114. Table
5

5 outlines the shrinkage levels found with the corresponding increase in temperature.

The invention is not limited to the embodiments hereinbefore described, with
reference to the accompanying drawings, which may be varied in construction and
detail.
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Claims

1.

A glass ceramic biomaterial having a crystalline atomic structure, at least part
of the biomaterial being degradable for release of bioactive ions.

2.

A biomaterial as claimed in claim 1 wherein the biomaterial comprises
strontium (Sr).

3.

A biomaterial as claimed in claim 2 wherein the biomaterial comprises SrO.

4.

A biomaterial as claimed in claim 3 wherein the molar percentage of SrO is

10

between 10% and 40%.

5.

A biomaterial as claimed in any of claims 2 to 4 wherein the biomaterial is
degradable for release of Sr^^ ions.

15

6.

A biomaterial as claimed in claim 5 wherein the biomaterial is degradable for
release of Sr^"" ions with a level of greater than 5 parts per million.

20

7.

A biomaterial as claimed in claim 6 wherein the biomaterial is degradable for
release of Sr"^ ions with a level of greater than 50 parts per million.

A biomaterial as claimed in claim 7 wherein the biomaterial is degradable for
release of Sr^" ions with a level of greater than 100 parts per million.
25
A biomaterial as claimed in any of claims 1 to 8 wherein the biomaterial
comprises zinc (Zn).

10.
30

A biomaterial as claimed in claim 9 wherein the biomaterial comprises ZnO.
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11.

A biomaterial as claimed in claim 10 wherein the molar percentage of ZnO is
between 0.1% and 30%.

12.

A biomaterial as claimed in any of claims 9 to 11 wherein the biomaterial is
degradable for release ofZn^^ ions.

13.

A biomaterial as claimed in claim 12 wherein the biomaterial is degradable for
release of Zn^^ ions with a level of greater than 1.4 parts per million.

10

14.

A biomaterial as claimed in claim 13 wherein the biomaterial is degradable for
release of Zn^^ ions with a level of greater than 5 parts per million.

15.

A biomaterial as claimed in claim 14 wherein the biomaterial is degradable for
release of Zn^^ ions with a level of greater than 100 parts per million.

15
16.

.A biomaterial as claimed in any of claims 1 to 15 wherein the biomaterial
comprises calcium (Ca).

17.

A biomaterial as claimed in claim 16 wherein the biomaterial comprises CaO.

18.

A biomaterial as claimed in claim 17 wherein the molar percentage of CaO is

20

between 0.1% and 20%.

19.
25

30

A biomaterial as claimed in any of claims 1 to 18 wherein the biomaterial
comprises silicon (Si).

20.

A biomaterial as claimed in claim 19 wherein the biomaterial comprises Si02.

21.

A biomaterial as claimed in claim 20 wherein the molar percentage of Si02 is
between 33% and 60%.
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22.

A biomaterial as claimed in any of claims 1 to 21 wherein the biomaterial
comprises sodium (Na).

5

23.

A biomaterial as claimed in claim 22 wherein the biomaterial comprises Na20.

24.

A biomaterial as claimed in claim 23 wherein the molar percentage of Na20 is
between 0.1% and 40%.

10

25.

A biomaterial as claimed in any of claims 1 to 24 wherein the biomaterial
comprises crystalline strontium zinc silicate.

26.

A biomaterial as claimed in any of claims 1 to 25 wherein the biomaterial
comprises crystalline sodium calcium silicate.

15
27.

A biomaterial as claimed in claims 25 and 26 wherein the biomaterial
comprises a blend of crystalline strontium zinc silicate and crystalline sodium
calcium silicate.

20

28.

A biomaterial as claimed in any of claims 1 to 27 wherein the biomaterial
comprises crystalline sodium zinc silicate.

29.

A biomaterial as claimed in any of claims 1 to 28 wherein the biomaterial
comprises crystalline calcium silicate.

25
30.

A biomaterial as claimed in claims 28 and 29 wherein the biomaterial
comprises a blend of crystalline sodium zinc silicate and crystalline calcium
silicate.
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31.

A biomaterial as claimed in any of claims 1 to 30 wherein the biomaterial
comprises crystalline strontium silicate.

32.
5

A biomaterial as claimed in any of claims 1 to 31 wherein the biomaterial
comprises ciystalline sodium silicate.

33.

A biomaterial as claimed in claims 29, 31 and 32 wherein the biomaterial
comprises a blend of crystalline calcium silicate and crystalline strontium
silicate and crystalline sodium silicate.

10

34.

A biomaterial as claimed in claims 25, 31 and 28 wherein the biomaterial
comprises a blend of crystalline strontium zinc silicate and crystalline
strontium silicate and crystalline sodium zinc silicate.

15

35.

A biomaterial as claimed in claims 31 and 28 wherein the biomaterial
comprises a blend of crystalline strontium silicate and crystalline sodium zinc
silicate.

36.
20

A biomaterial as claimed in any of claims 1 to 35 wherein the biomaterial
comprises crystalline zinc silicate.

37.

A biomaterial as claimed in any of claims 1 to 36 wherein the biomaterial
comprises crystalline strontium silicon.

25

38.

A biomaterial as claimed in any of claims 1 to 37 wherein the crystallisation
temperature is between 400" C and 900° C.

39.

A biomaterial as claimed in claim 38 wherein the crystallisation temperature is
between 500° C and 800° C.

30

33
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40.

A biomaterial as claimed in any of claims 1 to 39 wherein the glass transition
temperature is between 400“ C and 750“ C.

41.
5

A biomaterial as claimed in claim 40 wherein the glass transition temperature
is between 500“ C and 650“ C.

42.

A biomaterial as claimed in any of claims 1 to 41 wherein the biomaterial
comprises a foam.

10

43.

A bio material as claimed in any of claims 1 to 42 wherein at least part of the
biomaterial is porous.

44.

A biomaterial as claimed in claim 43 wherein the porosity of at least part of
the biomaterial is greater than 90%.

15
45.

A glass ceramic biomaterial substantially as hereinbefore described with
reference to the accompanying drawings.

46.
20

Use of a glass ceramic biomaterial as claimed in any of claims 1 to 45 for
prophylactic treatment at a bone tissue fracture site.

47.

Use of a glass ceramic biomaterial as claimed in any of claims 1 to 45 as a
bone tissue autograft extender.

25

48.

Use of a glass ceramic biomaterial as claimed in any of claims 1 to 45 as a
radiopacifier and/or as a coating for a heart tissue.

49.

A method of manufacturing a glass ceramic biomaterial.
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50.

A method as claimed in claim 49 wherein the method comprises the step of
sintering a glass powder.

51.
5

A method as claimed in claim 50 wherein the sintering step is performed prior
to ciystallisation.

52.

A method as claimed in claim 50 or 51 wherein the sintering step comprises
the step of performing dilatometry.

10

53.

A method as claimed in claim 52 wherein the dilatometry step comprises the
step of heating at a rate of approximately 5°C per minute.

54.

A method as claimed in claim 52 or 53 wherein the dilatometry step comprises
the step of heating to approximately 1280°C.

15
55.

A method as claimed in claim 50 or 51 wherein the sintering step comprises
the step of perfomiing hot stage microscopy.

56.
20

A method of manufacturing a glass ceramic biomaterial as claimed in any of
claims 1 to 45.

57.

A method of manufacturing a glass ceramic biomaterial substantially as
hereinbefore described with reference to the accompanying drawings.

25
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Abstract

A glass ceramic biomaterial

A glass ceramic biomaterial (1) comprises SrO, ZnO, CaO, Si02 and Na20. The
biomaterial (T) has a cr>'stalline atomic structure. The biomaterial (1) is provided in
the form of a porous foam. The biomaterial (1) with the crystalline atomic structure is
degradable for release of bioactive Sr^^ ions and for release of bioactive Zn^"^ ions.
The Sr“^ ions may assist with bone regeneration, and the Zn^^ ions may provide an
10

anti-bacterial function.
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